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Mycobacteria are associated with several human diseases. Disease-causing mycobacteria are 
usually classified into one of two groups, the Mycobacterium tuberculosis (M. tuberculosis) 
complex and the non-tuberculous mycobacteria (NTM). The M. tuberculosis complex 
comprises a small group of mycobacteria, amongst them M. tuberculosis and M. bovis. 
These two mycobacteria are the cause of tuberculosis in humans. Various NTM are found 
to be associated with mycobacterial disease, e.g. M. abscessus, M. avium and M. genavense. 
Besides these two groups M. leprae and M. lepromatosis have been identified as causative 
agents of leprosy. The latter are not discussed within the scope of this thesis.
M. tuberculosis is a small, non-motile Gram-positive bacterium, which divides at an 
extremely low rate of about once every 16 to 20h. The mycobacterium, highly adapted 
to the human host, is transmitted between humans through aerosols. Patients with active 
tuberculosis cough and sneeze and can transmit the mycobacteria to individuals in their 
surrounding. Upon transmission of M. tuberculosis, primary infection will lead to clinical 
symptoms in less than 10% of the infected. About another 10% of the infected eradicate 
the mycobacteria successfully, while the majority remain with a latent infection [1]. During 
latency the bacteria remain dormant but may reactivate months or years later and cause 
active tuberculosis. An active infection of M. tuberculosis results in most cases in pulmonary 
tuberculosis. M. tuberculosis causes severe tissue destruction and/or necrosis in the lung, a 
process which is balanced by wound healing and fibrosis, resulting in the formation of scars 
and/or cavities with necrotic tissue. Hematological spread of the bacteria to other organs, 
giving rise to extrapulmonary tuberculosis disease, occurs in up to 15% of the cases [1]. 
Extrapulmonary tuberculous lesions are often found in peripheral lymph nodes, kidney, brain 
and bones, but also other organs may be affected. If not treated with antibiotics tuberculosis 
is a deadly disease in approximately half of the cases. 
NTM infections are usually less severe than tuberculosis, because NTM infections 
often can be controlled and eradicated by the immune system. However, NTM can cause 
tuberculosis-like diseases, for example in COPD patients, and NTM may occasionally cause 
cutaneous diseases, lymphadenitis, soft tissue diseases or skeletal infections. The infections 
may remain local, may become manifest recurrently or may disseminate throughout the 
body. Dissemination of infection is a severe manifestation of the disease which may occur 
in individuals with a strongly impaired immune response. This may be due to nongenetic 
causes, for example the use of immunosuppressive medicines or an underlying disease (e.g. 
acquired immune deficiency, silicosis or diabetes). On the other hand the immunity may be 
impaired due to genetic defects [2-4], as for instance observed in patients with Mendelian 
susceptibility to mycobacterial disease (MSMD [MIM 209950]). Investigation of the causes 










































alternative or additional treatments. For example, children with an interleukin-12 receptor β1 
(IL-12Rβ1) deficiency or a partial interferon-γ receptor 1 (IFN-γR1) deficiency and a NTM 
infection may benefit from IFN-γ treatment in addition to antibiotic therapy. The antibiotic 
treatment regimen depends on the NTM species involved, on the sites of infection and on 
underlying diseases.
The M. bovis Bacillus Calmette-Guérin (BCG) strain is a live attenuated strain, derived 
from M. bovis, which is used as a vaccine and protects very well against developing 
tuberculosis in childhood. Incidentally, immunocompromised patients, for example MSMD 
patients, are at high risk for developing severe BCG infections after BCG vaccination (4). 
2. Immunity towards mycobacteria
The course of mycobacterial infections is dependent on the interactions of the mycobacterium 
and the defense system of the host. The human body is protected from invasion of pathogens 
by the skin and the mucosal membranes. Once pathogens, such as mycobacteria, pass this 
first line of defense the immune system is activated to fight the pathogens. Upon the first 
encounter with mycobacteria the innate arm of the immune system is rapidly activated 
(Figure 1). When the mycobacteria are not successfully eradicated by the innate immune 
system, the adaptive arm of the immune system is needed to combat the infection. In this 
process, granulomas may be formed to isolate infection sites from the rest of the body. 
2.1. Innate immune responses to mycobacteria
Upon encounter with bacteria the immune system is activated (Figure 1). Factors of the 
humoral complement system are activated as well as cellular-bound pattern recognition 
receptors (PRR). In response bacteria are opsonized and subsequently eradicated by the 
phagocytic cells: the granulocytes, monocytes, macrophages and dendritic cells. 
After mycobacteria break through the first line of defense the classical and alternative pathway 
of the complement system is activated via factors, such as C1q and C3 [5]. During the first 
innate immune response, the complement factor C3 is activated via the lectin pathway or the 
C2 pathway of the complement system [6, 7], resulting in the opsonization of mycobacteria 
(Figure 1A). The lectin pathway plays a pivotal role in the uptake (phagocytosis) of 
mycobacteria by phagocytes during the innate immune response after the first encounter with 
mycobacteria. This pathway of the complement system is initiated when mannose-binding 
lectin, present in plasma, binds to the mannose residues of mycobacterial glycoproteins. 
Subsequently, C3 is converted into C3a and C3b. Mycobacteria coated with C3b are 











































the mannose receptor expressed on macrophages and DC-SIGN expressed on dendritic cells 
play an important role in the uptake of mycobacteria by these phagocytic cells [8, 9]. In 
addition, C3b induces the formation of membrane attack complexes via the activation of C5, 
by cleaving C5 into C5a and active C5b. The presence of the membrane attack complexes 
on bacteria will lead to osmotic lysis of the bacteria. Meanwhile C3a and C5a influence B 
cell activation and the role of dendritic cells in T cell polarization [10]. The factors of the 
complement system are constitutively produced by various cell types. During an immune 
response the production can be enhanced by IL-1β, IFN-α, IFN-γ and endotoxins [11, 12].
Bacteria are opsonized and end up in an endosome-like vesicle, the phagosome, (Figure 
1B) a process called phagocytosis. Subsequently, the phagosome fuses with a lysosome 
into a phagolysosome, which further matures. In the early phagosome the bacteria are 
exposed to reactive oxygen radicals. In the mature phagolysosome the bacteria can be 
killed via a lowered pH and enzymatic hydrolysis of bacterial components (Figure 1B). The 
phagolysosome maturation is an important step in the eradication of mycobacteria. However, 
mycobacteria have evolved mechanisms to evade the phagolysosomal killing mechanisms. To 
counterweight immune evasion, IFN-γ is an important cytokine which remarkably enhances 
the innate intracellular bactericidal processes in the phago- and the phagolysosome [13]. 
Before and during phagocytosis, the cellular part of the innate immune system is activated 
by membrane-bound and intracellular PRRs. PRRs, expressed by phagocytes, recognize 
characteristic pathogen-associated molecular patterns (PAMPs) (Table 1). Upon PRR and 
PAMP interaction signals within the cells will regulate the formation of an immune response. 
In this way, various immune responses can be initiated depending on the pathogen-specific 
PAMPs. Several classes of PRRs are known: Toll-like receptors (TLRs), C-type lectin 
receptors, nucleotide binding oligomerization domain-like receptors (NLRs) and retinoic acid 
inducible gene-I-like helicases (RLHs). Thus, the immune response is differentially shaped 
via the interactions of specific PRRs with various pathogens. For example, in the event of 
viral infections anti-viral responses, to stop viral replication and assembly, are initiated 
after interaction of typical viral products with certain PRRs. Other PRRs are stimulated by 
mycobacterial PAMPs (Table 1). Upon PRR interactions with mycobacterial PAMPs, the 
production of type I cytokines and several anti-bacterial processes are induced [7] (Figure 
1A). 
PRRs differentially signal via the transcription factors Nuclear factor κb (NFκb) or the 
interferon regulatory factors (IRFs) [6, 7, 14] in order to induce the expression of inflammatory 
genes, amongst them various cytokine genes. TLR1, -2, -4, -5, -6, NLRs and RLHs mediated 
signaling via NFκb results in the production of the proinflammatory cytokines IL-12, tumor 
necrosis factor (TNF) and IL-1β, while the TLR3, -7, -8, -9 and RLH signaling via IRFs 













































































































































NKT Natural killer or NK-like T cell
CR Complement Receptor
PRR Pattern Recognition Receptor
APC antigen presentation cell
Light grey   cytosol
Dark grey   nucleus
Figure 1. Cellular immune responses against mycobacteria. Upon encountering mycobacteria 
phagocytes, such as monocytes, are stimulated by mycobacterial-associated molecular patterns, which 
interact with PRRs on the cell surface of the monocytes (A). The monocyte is stimulated to produce 
cytokines, bactericidal defensins, cathelicidin and complement factors. The complement factors can 
bind to the cell surface of mycobacteria and subsequently to the complement receptors. The complement 
receptors mediate the phagocytosis of mycobacteria (1B). By means of phagocytosis the mycobacteria 
are internalized in an endosome-like particle, the phagosome. Subsequently, the phagosome fuses with 
the lysosome, in order to lyse the mycobacteria. Concomitantly, the monocyte is stimulated via PRRs 
to produce cytokines, for example IL-23. IL-23 stimulates innate NK-like T cells to produce IFN-γ and 
GM-CSF (1C). In turn, IFN-γ enhances the microbicidal mechanisms, type I immune responses and 
antigen processing and presentation by monocytes. The monocytes, stimulated by GM-CSF, mature 
into dendritic antigen-presenting cells, which in turn may trigger the T cells from the adaptive immune 
system (1D). During the cellular interaction between the antigen-presenting cell and the T cell an 
immunological synapse is formed, wherein the HLA with mycobacterial antigens interacts with the 
TCR of specific T cells. After recognition of the antigen by the TCR the T cell is stimulated. CD8+ T 
cells employ cytotoxic functions, while CD4+ T cells react by producing cytokines.
Furthermore, PRR signaling results in the expression of other inflammatory effectors and 
chemokines and the production of the antibacterial defensins and cathelicidin. In addition, 
the phagocytosis and killing of the bacteria within phagolysosomes are also regulated via 
PRR signaling. The latter processes can be enhanced by IFN-γ.
During the innate immune response various leukocytes are recruited to the site of 
infection, including, neutrophils, phagocytes, Natural Killer (NK) and NK-like T cells. 
Infected macrophages produce IL-8 and attract neutrophils to the infection site. Neutrophils 
can produce neutrophil extracellular traps (NETs). NETs are structures of chromatin with 
proteins that can bind and kill bacteria. These NETs are capable of trapping mycobacteria 
but are unable to kill them [15]. In addition, the recruited neutrophils produce anti-bacterial 
peptides and cooperate with monocytes and macrophages in the modulation of the immune 
response [16]. Other cells are attracted and various cellular interactions further strengthen the 
immune response. For example, both monocytes and T cells play a role in the establishment 
of a strong type I immune response. Monocytes, activated by mycobacterial products, 










































response to IL-23 and IL-1β. In turn, IFN-γ strengthens the innate immune responses of 
monocytes to enhance anti-bacterial processes (Figure 1C) and the production of IL-12, while 
GM-CSF further directs the maturation of monocytes. IL-12 in turn, strongly enhances the 
production of IFN-γ [17]. These modulators of the innate immune response also orchestrate 
the development of an adaptive T cell response.
Table 1. Pattern recognition receptors (PRR) and their ligands, the pathogen-associated molecular 
patterns (PAMPs), which induce signals in the human phagocytes [6, 7]. 
Class of 
PRR
PRR cellular localization PAMPsa 
TLRs TLR1/2 cell surface Triacyl lipopeptides
TLR2 cell surface Phosphatidyl-myo-inositol mannoside
Lipoarabinomannan
Hemagglutinin
TLR3 endolysosomes Viral ssRNA from RSV
Viral dsRNA from CMV
TLR4 cell surface Mannan
Lipopolysaccharide from bacteria
TLR5 cell surface Flagellin from flagellated bacteria
TLR6/2 cell surface Diacyl lipopeptides from mycoplasma
TLR7 endolysosomes Viral ssRNA
RNA from Streptococcus
TLR8 endolysosomes Viral ssRNA
TLR9 endolysosomes Viral dsDNA from CMV
CpG motifs from bacteria and virusses
C-type lectins Mannose 
receptor
cell surface Mannose
DC-SIGN cell surface Mannosylated lipoarabinomannan 
gp120 from HIV virus
Dectin-1 cell surface β-glucans from fungi
Mincle cell surface Trehalose-dimycolate
RLHs RIG-I cytoplasm Viral ssRNA (negative strand)
polyIC (short)
MDA5 cytoplasm Viral ssRNA (positive strand)
polyIC (short)
NLRs NOD1 cytoplasm Diaminopimelic acids
NOD2 cytoplasm Muramyl dipeptide
NLRP1 cytoplasm Muramyl dipeptide
NLRP3 cytoplasm Viral and bacterial RNA
β-glucan from fungi
NLRC4 cytoplasm Flagellin from flagellated bacteria











































2.2. Adaptive immune responses to mycobacteria
When mycobacteria manage to evade the innate immune defense, the adaptive arm of the 
immune system is needed to control infections in a more specific, mycobacterial-antigen 
restricted manner. After the first encounter with a pathogen, antigen-specific T and B cells 
are selected in lymphoid organs and will expand and further differentiate. The differentiated 
B and T cells are released from the lymphoid organs carry out their tasks at the infection 
sites. The generation of a primary adaptive immune response takes several days and becomes 
effective about 5 to 7 days after the first infection. After successful eradication of the pathogen 
some of these T and B-cells become memory cells. Those cells remain circulating and can be 
recruited and expanded more rapidly upon a second infection.
Immature B cells with membrane-bound immunoglobulins that recognize mycobacterial 
(non-self) antigens are positively selected in lymphoid organs. These B-cells mature further, 
expand and are released from the lymphoid organ. Circulating B cells are activated after 
recognition of specific antigens and start to produce anti-mycobacterial antibodies. These 
antibodies circulate in the blood and tissue fluids in the body and play a pivotal role in the 
humoral defense. Antibodies bound to mycobacteria help in the uptake of the pathogen by 
phagocytes via the classical pathway of the complement system.
Antigen specific T cells within the pool of newly generated T cells can be selected and 
expanded in lymphoid organs. T cells in the lymphoid tissue are instructed by dendritic cells. 
The foreign peptides are processed and presented within the context of HLA molecules to 
lymphoid CD8+ and CD4+ T cells [18]. Upon interaction of a dendritic cell with a T cell, 
carrying an αβ T-cell receptor (αβ TCR) that recognises a specific mycobacterial antigen in 
the context of HLA, this T cell further develops, proliferates and differentiates. The expanded 
T cells will be released from the lymphoid organs to carry out their tasks in the infected 
tissues. The differentiated CD3+CD8+ T cells employ cytotoxic functions, while CD3+CD4+ 
T cells further shape the immune system by producing cytokines upon recognition of the 
mycobacterial antigen (Figure 1D). Three main subsets of CD4+ T cells are distinguished; 
Th0, Th1 and Th2 cells. Th0 or T helper 0 cells are naive cells which can differentiate 
(polarize) into typical Th1 or Th2 cells [19]. This T helper cell polarization is guided by 
professional antigen-presenting dendritic cells [20] or monocyte-derived dendritic cells.
Th1 or T helper 1 cells can produce IFN-γ and facilitate cell-mediated immune responses 
(Figure 1), for example, phagocytosis, the enhancement of cytotoxic NK and T cell responses. 
Th1 cells are important in the control of infections with viruses and intracellular bacteria, 
such as Mycobacteria and Salmonellae [21]. IL-12 is the main regulator of the polarization 
of naïve Th0 cells into Th1 cells. In addition, IL-12 strongly enhances the proliferation of 
Th1 cells and induces the production of IFN-γ, which is the main cytokine of the type I 










































act in concert with other type I cytokines: TNF, IL-1β and IL-18 [22, 23]. These cytokines 
determine the shape of the innate and adaptive immune responses against mycobacteria 
towards a type I immune response.
IL-4 regulates the polarization of Th0 cells into Th2 cells, while IFN-γ negatively 
interferes with the formation of a Th2 response [24]. This indicates that there is a certain 
balance between the generation of a Th1 and a Th2 response. When the Th1 immune response 
is impaired, relatively more T cells will be shaped into the Th2 type, as is observed in MSMD 
patients [25]. Thus, an impaired type I immune response correlates with a disturbed Th1/
Th2 balance. Activated Th2 cells produce IL-4, together with other type 2 cytokines, such 
as IL-5 and IL-13. IL-4 and IL-13 inhibit the enhancing effects of IFN-γ on the bactericidal 
processes of macrophages [26], which further illustrates the dichotomy between type I and 
type II immune responses.
Th2 cells support B cells in their development and function to establish a robust antibody 
response. Th2 cells are important in the control of infections of extracellular pathogens, such 
as helminths [27]. In addition, Th2 cells are involved in several auto-immune diseases, such 
as SLE [28] and atopic allergic diseases [29]. Hence, factors which play a role in the Th1/Th2 
balance of abovementioned diseases may also play a role in the susceptibility to or protection 
against to mycobacterial diseases.
Besides the Th0, Th1 and Th2 subsets, other subsets of T cells are described. For example, 
Th17 cells are IL-17-producing T cells, which are modulated by IL-23, IL-1β, IL-6 and/or 
TGF-β. These cells are not fully differentiated, but show plasticity in effector functions. To 
indicate the plasticity, these cells can regain the capacity to produce IFN-γ [30]. Since IL-
23 is an important cytokine in the maintenance of the IL-17-producing T cells, IL-12Rβ1 
deficient patients have in addition to an impaired IFN-γ-mediated immune response also 
an impaired IL-17-immune response [31]. A study of IL-17 deficient mice showed that IL-
17 plays a major role in chemokine production and neutrophil recruitment to cutaneous 
infections [32]. This is confirmed by a study with IL-17 overexpression in lung epithelium of 
mice, which caused local chemokine production and leukocyte infiltration [33]. In humans, 
an impaired development of IL-17-producing T cells results in susceptibility to mucosal 
candida infections [34]. These studies indicate an important role of antigen-specific IL-17-
producing T cells in neutrophil recruitment at mucosal sites, which is also important for lung 
infections with mycobacteria.
Fully differentiated CD8+ effector and CD4+ responder T cells may turn into memory T 
cells. While the selection of newly generated T cells is time-consuming, the memory T cells 
can be expanded and instructed rapidly after another encounter with the same pathogen. 
In this way the immune system responds more rapidly upon a second encounter with a 











































Other important classes of adaptive T cells are regulatory T-cells (Tregs) and CD1 
restricted T cells. In patients with active tuberculosis higher levels of circulating Tregs were 
found, compared to patients with latent tuberculosis [36]. Depletion of Tregs enhances the 
Th1 immune responses in patients with active disease [36]. Tregs suppress IFN-γ-mediated 
T cell responses via the production of TGF-β and IL-10 [37]. In this way, Tregs control 
the function of T-cells during homeostasis and during inflammatory conditions in order to 
prevent uncontrolled T cell reactions resulting in unnecessary tissue damage. 
CD1 restricted T cells recognize mycobacterial lipids within the context of CD1 molecules. 
Phagocytes can take up lipid antigens from the mycobacterial membranes and present them 
within CD1 molecules on the outer cell surface to special classes of T cells, for example 
the invariant NK-like T cells carrying an invariant TCR chain. These T cells are capable of 
producing IFN-γ and exhibit effector and memory functions [38] and thus are important in 
the control of mycobacterial infections [39]. 
2.3. Granuloma formation in the control of mycobacterial infections
Granulomas can be formed in the lung and other organs during M. tuberculosis infections, 
but also during NTM or BCG infections [40, 41]. A granuloma is formed by an interplay 
of different cell types to encapsulate infected macrophages [42]. In this way the sites of 
infection are walled off. Around the infected macrophages uninfected monocytes, neutrophils 
and lymphocytes are recruited. The infected macrophages become surrounded by other 
phagocytes and are enclosed by a fibrous cuff, consisting of collagens and other extracellular 
matrix molecules, while lymphocytes reside on this outer layer of the granuloma. In this way, 
mycobacteria are captured within granulomas, which are not vascularized, under hypoxic 
conditions. In this state the mycobacteria can remain dormant for many months or years. 
Genetic immunodeficiency, HIV infection or immunosuppression due to e.g. malnutrition 
results in impaired granuloma formation. The CD4+ T cells play a major role in the 
maintenance of the granuloma structure [43]. Impaired CD4+ T cell functions can result in 
a decay of granulomatous structures [44]. Due to the loss of these structures necrosis of 
the infected cells occurs within the granuloma resulting in the release of mycobacteria and 
subsequently the infection will reactivate.
In mycobacterial diseases Th1 cytokines play a major role in orchestrating granuloma 
formation and homeostasis. In studies of the course of mycobacterial infections in TNF-
deficient mice, it appeared that TNF is a crucial cytokine in the induction of cell recruitment 
and the formation of granulomas [45]. In humans, TNF blocking agents, used in the 
treatment of rheumatoid arthritis or Crohn’s disease, can result in the resuscitation of latent 
M. tuberculosis and subsequently in severe disseminated infections [46-48]. Granuloma 
formation is completely absent in patients with severe disseminated NTM or BCG infections, 










































IL-12Rβ1 deficiency the granuloma formation is often incomplete [49]. This indicates that 
IFN-γ also plays an important role in granuloma formation. Besides these host factors 
mycobacterial factors also influence granuloma formation.
3. Cytokines in the control of type I immune responses
IL-12 and IFN-γ are the main regulatory cytokines in a strong type I immune response. IL-
12, the best described cytokine of the IL-12 cytokine family, is a strong modulator of type 
I immune responses by NK cells and adaptive T cells. IL-23 is also a member of the IL-12 
cytokine family, which is structurally and functionally closely related to IL-12 [50]. IL-23 
may play a role in the activation of memory cells [51] and IL-17-producing T cells [52]. 
Both IL-12 and IL-23 can be produced by phagocytes and can enhance IFN-γ production and 
proliferation of various subsets of T-cells. IFN-γ is a pleiotropic cytokine that plays a central 
role in the type I immune responses important in the defense against intracellular bacteria. 
IFN-γ and IL-12/23 act in concert with other important type I cytokines: IL-1β, IL-18 and 
TNF [17, 53].
3.1. IL-12 and IL-23
IL-12 and IL-23 have similar and distinct structures and features (Figure 2). The IL-12p40 
subunit is the common subunit of IL-12 and IL-23. The IL-12p35 subunit and the IL-23p19 
subunits are the specific subunits of IL-12 and IL-23 respectively, which show structural 
similarity [54]. The cytokines bind and act on different receptor complexes (figure 2). The 
IL-12 and IL-23 receptors consist of a common receptor chain, IL-12Rβ1, and a specific 
receptor chain, the IL-12Rβ2 and the IL-23R, respectively. The IL-12R complex signals 
via STAT4 [55], while the IL-23R complex signals via STAT3 and STAT4 [50]. Dimeric 
STAT modules are transcription factors, for instance for the IFNG gene. IL-12, IL-23 and 
their receptors are expressed differentially and their receptors differ in signaling. These two 
cytokines display both common and distinct effects, probably due to differential binding 
capacities of the different STAT modules to the various STAT binding sites in promoters. 
IL-23 can be produced by monocytes and dendritic cells directly upon PRR stimulation 
by bacterial products [17, 56, 57]. For IL-12 production IFN-γ stimulation [58, 59] and/or 
cellular interaction with activated T cells is needed [60]. Costimulation by CD40-CD40L 
[61, 62] and/or CD28-CD80/86 interactions [63] is also important for a strong induction of 
IL-12. Several in vitro studies have shown that many other factors are also involved in the 
regulation of IL-12 and IL-23 production. Gram-positive bacteria seem to stimulate the IL-12 
production preferentially, while Gram-negative bacteria induce more IL-23 [64]. GM-CSF 











































dendritic cells can produce large amounts of IL-12. The anti-inflammatory cytokine IL-10 
effectively inhibits the IL-12 and IL-23 production [67]. Thus, in vivo, a complex interplay 




































Figure 2. The IL-12 and IL-23 cytokines, their receptors and signal transduction. IL-12 and IL-
23 both consist of two linked subunits. The IL-12p40 subunit is their common subunit. In IL-12 the 
p40 subunit is linked to the IL-12-specific p35 subunit, while in IL-23 the p40 subunit is linked to 
the IL-23-specific p19 subunit. Their receptors also have a common receptor chain: IL-12Rβ1. IL-12 
binds to a receptor complex which contains the IL-12Rβ2 receptor chain. IL-23 binds to a receptor 
complex containing the IL-23R chain. After IL-12 binding to its receptor, STAT4 is phosphorylated 
and dimerized to form a homodimer. The STAT4 homodimer translocates to the nucleus, binds to STAT 
binding sites in promoters and acts as a transcription factor, for example for the IFN-γ promoter. IL-
23 signals likewise, although next to STAT4, STAT3 is also phosphorylated and STAT3 and STAT4 
heterodimers are formed, though STAT3 and STAT4 can each also form homodimers. [50, 54, 68]
The IL-12R consists of an IL-12Rβ1 chain and an IL-12Rβ2 chain. The IL-12Rβ1 chain 
is present on nearly all lymphocytes. The IL-12Rβ2 chain is present on non-stimulated NK 
cells and can be induced on other lymphocytes. For example, T- cells express IL-12Rβ2 after 
TCR triggering [69]. Subsequent stimulation of these T cells with IL-12 results in type I 
immune responses. 
One of the main actions of IL-12 is the induction of IFN-γ production by T cells, which 










































capacity and proliferation of NK and T cells. Another important action of IL-12 is that IL-12 
drives T cell polarization of the adaptive CD4+ T cells towards Th1 cells [68, 70], via the 
induction of the Th1-specific transcription factor T-bet [71]. 
The expression pattern of the IL-23R is not as well understood, because of the lack of 
a good antibody to detect IL-23R expression on individual cells. Thus, it is not clear which 
cells are responsive to IL-23. Reported IL-23 effects on certain cell types may have been 
induced directly or indirectly via another cell type. 
Previously, IL-23 was reported to activate memory T cells and to induce IFN-γ production 
in humans and in mice [51, 54, 72]. Other studies with normal and IL-23p19-/- mice revealed 
that IL-23 plays an important role in the immune responses of IL-17-producing T cells [52]. 
IL-23 does not influence the IL-17 production directly, though IL-23 contributes to the 
survival and proliferation of IL-17-producing T cells [73], which are shaped by the cytokines 
IL-1β, IL-6, IL-21 and TGF-β [74]. Both IL-17 and IL-23 play an essential role in the mucosal 
immunity against M. tuberculosis [75, 76], Klebsiella pneumoniae [56, 77] and Candida 
albicans [78, 79]. In addition, IL-23 plays a role in the IFN-γ and IL-17-mediated immune 
responses, IL-23 may also regulate the production of the anti-inflammatory cytokine IL-10. 
Activated CD4+ and CD8+ T cells were also found to be able to produce IL-10 in response to 
IL-23 [80]. All these effects of IL-23 were found to be important in the control of infections 
and IL-23 plays a role in various auto-immune diseases, because IL-23R polymorphisms 
were found to be associated with immune diseases, such as inflammatory bowel disease [81], 
psoriasis [82], Graves’ disease [83] and ankylosing spondylitis [84]. Taken together, it is 
clear that IL-23 plays a crucial role in establishment of an immune response. Still, the direct 
biological effects of IL-23 at the cellular level remain to be elucidated.
3.2. Interferon-γ 
IFN-γ can be produced by various subsets of T cells; NK cells, iNKT cells, NK-like T cells, 
γδT cells and αβT cells. For instance, IL-12, IL-23 and IL-27 stimulate NK cells to produce 
IFN-γ, which is synergistically enhanced by IL-1β and IL-18. IFN-γ production by adaptive 
T cells requires TCR activation in addition to cytokine stimulation. 
IFN-γ is a homodimer which signals via the IFN-γR complex (Figure 3). The IFN-γR 
consists of two IFN-γR1 and two IFN-γR2 chains. After IFN-γ ligation to its receptor STAT1 
is phosphorylated and dimerized. STAT1 homodimers act as transcription factors on various 
genes, such as CD54, CD64 and genes for other transcription factors, such as IRF1 and 
CIITA [85]. Thus, IFN-γ stimulates gene transcription directly or via the induction of other 
transcription factors. In this way IFN-γ regulates immune responses with different kinetics. 
For instance, STAT1-mediated transcription occurs within minutes after IFN-γ exposure, 
while interferon regulatory factor 1 (IRF-1)-mediated transcription occurs with a few hours 
delay. Relatively late, more than 8 hours after IFN-γ stimulation, the protein inhibitor of 











































as a negative feedback loop [86]. PIAS1 suppresses STAT1 mediated transcription, but does 
not directly suppress IRF-1-induced transcription.
IFN-γ is a stable cytokine which has pleiotropic effects on various cell types. Nearly all 
cell types express the IFN-γR [87], though the response varies between cell types. IFN-γ 
alarms and activates the immune system, by means of a wide range of responses of infected 


















Figure 3. The signal transduction of IFN-γ and IFN-α/β. IFN-γ is a homodimer which signals via its 
own receptor complex, consisting of two IFN-γR1 and two IFN-γR2 chains. After ligation of IFN-γ to 
the IFN-γR, STAT1 is phosphorylated, dimerized and translocated to the nucleus. STAT1 homodimers 
bind to GAS sites and act as a transcription factor [85]. IFN-α and IFN-β are structurally related and 
signal via a common receptor, which consists of two chains, the IFN-αR1 en IFN-αR2. After IFN-α/β 
ligation to the receptor, STAT1 and STAT2 are phosphorylated and form heterodimers. Subsequently 
IRF-9 binds to the heterodimer to form the ISGF3 complex [88, 89]. This complex translocates to the 
nucleus and binds to the ISRE sites within various promoters. IFN inducible genes may have GAS sites 
or ISRE sites or both. IFN-α may activate PRMT1 [90], which was found to be associated with the IFN-
α/β receptor (in mice). In this way, IFN-α may influence PIAS1 and other PRMT1 protein substrates 
[91]. PIAS1 negatively interferes with the transcription activity of STAT1 [86]. 
IFN-γ increases phagocytosis of pathogens via the upregulation of receptors which 
mediate the opsonization of bacteria, for instance, the immunoglobulin-binding receptor 
CD64 [92, 93] and receptors of the complement system [94, 95]. To stimulate these processes 
IFN-γ also enhances the synthesis of immunoglobulins [96, 97] and complement factors [98, 
99], which bind to bacteria prior to opsonization. 
Furthermore, several anti-bacterial processes of phagocytes are stimulated by IFN-γ. 










































[100] and IFN-γ stimulates the phagolysosome fusion and maturation in order to lyse the 
pathogen [101-103]. IFN-γ reduces the serum iron concentration [104] and the intracellular 
iron content of phagocytes. In this way, the bacterial growth is restrained because iron is 
essential for replicating intracellular bacteria [105]. IFN-γ also induces the production and 
secretion of anti-microbial peptides, such as the defensins [106] and cathelicidin [107], in 
order to lyse extracellular bacteria.
IFN-γ influences also the immune responses of various T cell subsets in several ways. The 
antigen presentation of various cell types is stimulated by IFN-γ, via the enhancement of the 
processing of bacterial antigens and upregulation of HLA Class I and Class II on various cell 
types [85]. In this way, the antigen-specific T cells are activated and start to proliferate. IL-
12 and IFN-γ further regulate the differentiation of the activated T cells towards a Th1 type 
of cell and IFN-γ downregulates the formation of a Th2 response [24]. Furthermore, IFN-γ 
regulates the cytolytic activity of the innate NK cells [108].
The production of chemokines and cytokines by various cells is also induced by IFN-γ. 
The production of chemokines, such as MCP-1 and CXCL-10 can be enhanced by IFN-γ 
[109] as well as the TLR-ligand induced production of IL-12, IL-1β and TNF by monocytes, 
macrophages and dendritic cells [58, 110, 111]. These cytokines act in concert with IFN-γ to 
eradicate bacterial pathogens and to form granulomas [49].
Furthermore, IFN-γ competes with the anti-inflammatory cytokine IL-10 in the 
establishment of an effective immune response [112-114]. IFN-γ can suppress the activity 
of IL-10 by inhibiting STAT3 and even prime for IL-10-mediated STAT1 signaling, while 
IL-10 is able to reduce the IFN-γ responsiveness if IL-10 acts before IFN-γ and TLR-ligands. 
In this way IL-10 and IFN-γ control the extent of an immune response, in order to prevent 
exaggerated and/or auto-immune reactions.
3.3. The role of type I interferons in the immunity against intracellular bacteria
Type I interferons can be induced by various intracellular bacteria, such as Legionella 
pneumophila [115] and Listeria monocytogenes [116, 117]. Host immunity against 
intracellular bacteria may benefit from the production of type I IFNs, since these interferons 
can stimulate antibody production, proliferation of mature CD8+T cells and the function of 
mature dendritic cells [118]. On the other hand, both IFN-α and IFN-β were found to be able 
to inhibit immature immune cells. For example, the IL-12 production of antigen-presenting 
cells can be inhibited by IFN-α and IFN-β [119, 120]. Thus, intracellular pathogens may 
benefit from the induction of IFN-α/β by inhibiting the establishment of a Th1 immune 
response. To illustrate the latter, mice lacking the IFN-αR are resistant to L. monocytogenes 
infections [117]. M. tuberculosis may also result in the induction of type I interferons. The 
blood cells from pulmonary tuberculosis patients display a transcript signature like that of 











































with antibiotics, during recovery, the blood cells from the patients showed a decreased type 
I interferon signaling and an increased IFN-γ production [122]. Direct evidence that M. 
tuberculosis is able to induce one of the type I interferons in these patients has not yet been 
found. In mice, virulent M. tuberculosis species induce the production of IFN-α and these 
mice show a diminished Th1 immune response [123, 124].
While IFN-γ is the sole member of the type II interferons, the type I interferons group 
encompasses 8 subtypes: IFN-α, -β, -δ, -ε, -ω, -κ, -τ and –ζ. All type I interferons act on 
the same receptor complex, albeit with different efficacy. These interferons are selectively 
produced by almost all cell types in response to viral infections [89]. Special PRRs, such 
as MDA5, TLR3, TLR8, TLR9 and RIG-I can be triggered by viral RNA or DNA [125]. 
Subsequently, type I interferons are produced and secreted in order to accomplish local or 
systemic effects. In response to type I interferons various anti-viral proteins are expressed 
and activated, resulting in the inhibition of viral replication and viral assembly [126]. 
IFN-α and the other type I interferons signal in the same way via STAT1 and STAT2 
heterodimers. IRF-9 binds to this heterodimer to form the stable interferon-stimulated gene 
factor 3 (ISGF3) complex [88, 127]. The ISGF3 complex acts as a transcription factor on 
interferon-stimulated response element (ISRE) sites in the promoter of various immune genes 
(Figure 3), for example the promoter of IRF1 [128]. The effect of IFN-α signaling depends 
on the presence of IRF-9. In IRF-9 knockout mice the signaling of IFN-α occurs via dimers 
of STAT1 and STAT2 instead of the ISGF3 complex. As a consequence, IFN-α stimulation 
results in an IFN-γ-like gene expression pattern [129].
In addition to this signaling pathway, IFN-α regulates protein arginine methyl transferase1 
(PRMT1) activation in monocytes. In mice, it was found that PRMT1 associates with the 
IFN-αR and that IFN-α stimulation can result in PRMT1 activation [90]. PRMTs are able 
to methylate various kinds of proteins, amongst them PIAS1 [90]. PIAS1 is a negative 
regulator of STAT1 transcription. PIAS1 bound to STAT1 decreases the binding efficiency of 
STAT1 to certain but not all GAS sites, thereby selectively interfering with IFN-γ signaling 
[130]. Whether this or other PRMT pathways play a role in the immune responses of type I 
interferons in humans needs to be investigated. 
4. Mycobacterial immune evading strategies
Mycobacterial infections may persist because of a lack of IL-12 and IFN-γ mediated immune 
responses. On the other hand mycobacteria have evolved mechanisms to enhance their 
virulence and to evade host immunity. NTM species and BCG are poorly pathogenic and 
the low virulence of these species wins from the host only when the host is immunodeficient 










































Mycobacteria from the M. tuberculosis complex are more virulent and have additional 
features to evade host immune responses. 
The mycobacterium has a peculiar cell wall, which is rich in mycolic acid and other lipids. 
Binding of antibodies to these foreign lipids results in the activation of the complement 
system. The mycobacteria are easily opsonized or phagocytosed, and can reside within 
phagocytes, thereby escaping the attack by defensins and the complement system. Various 
mycobacterium species have evolved mechanisms to circumvent the hostile environment of 
macrophages and are able to survive in the host macrophages.
Mycobacteria are taken up by phagocytes in a phagosome. In the early phagosome most 
bacteria are killed directly by the superoxide burst, which is mediated via the NADPH complex 
[131]. IFN-γ is known to strengthen the oxidative burst [132]. Pathogenic mycobacteria 
express superoxide dismutase, an enzyme that reduces oxygen radicals, thereby protecting 
the bacteria from oxidative stress [133]. Also the cell wall lipoglycans protect mycobacteria 
from damage by scavenging the reactive oxygen species [134].
The phagosome fuses with a lysosome into a phagolysosome, a process which is actively 
accomplished by tethering molecules and a fusion machinery, consisting of SNARE proteins. 
The bacterium can subsequently be killed within a mature phagolysosome. Within the 
mature phagolysosome the pH drops, whereby several proteases are activated. However, 
mycobacteria are able to inhibit this process. The decrease in pH in the phagolysosome after 
phagocytosis is restrained and the mycobacterium inhibits host factors involved in bacterial 
killing and phagolysosome maturation [135]. For example, mycobacteria exclude H+ATPases 
from the phagosome, thereby preventing the decrease in pH and the subsequent activation of 
lysosomes, which only show activity at low pH. Mycobacteria also block the tethering and 
fusion of the phagosome with the lysosome, by inhibiting the tethering molecule EEA1 and 
the activation of SNARE proteins [135].
Dependent on the mycobacterial strain, the bacteria have additional evading strategies. 
For example, the more virulent M. tuberculosis confers high resistance to the killing of 
macrophages by reactive nitric oxide and reactive nitrogen intermediates [135]. However, 
M. avium is also able to prevent phagosome-lysosome fusion and is highly resistant to 
nitric oxide but is less pathogenic compared to M. tuberculosis [136]. Thus, the highly 
pathogenic M. tuberculosis has additional immune evading strategies. For example, virulent 
mycobacteria have the ESX-1 secretion system [137]. The ESX-1 system secretes ESAT-6 
and CFP10 into the cytoplasm of the host cell. Secretion of these molecules leads to the 
lysis of membranes in the host cell and to non-apoptotic, necrotic cell death. Mycobacteria 
benefit from this necrosis of the infected macrophages, while apoptotic cell death of infected 
macrophages is more beneficial for the host [138]. After necrosis of the infected macrophage 
the mycobacteria easily spread and infect other monocytes or macrophages. After apoptotic 











































antigen-presenting dendritic cells are able to phagocytose these vesicles and present 
mycobacterial antigens in HLA molecules to CD4+ and CD8+ T cells [139]. To evade this, the 
virulent M. tuberculosis produces a 19 kDa protein which negatively interferes with antigen 
presentation by HLA Class II molecules [140]. 
The presence and the efficiency of these immune-evading mechanisms differ between the 
various mycobacterial strains. In addition, host factors influence the interactions whereby the 
pathogen regulates the immune evasion. 
5. Risk factors in the susceptibility to mycobacterial infections
Various kinds of factors enhance the susceptibility to mycobacterial diseases. The role of 
genetic factors in the susceptibility to tuberculosis seems less important, while genetic 
mutations are often the cause of the susceptibility to severe disseminated NTM or BCG 
infections. 
Genetic deficiencies are often found in young children with severe disseminated NTM 
or BCG infections. Various genetic defects have been identified in several genes involved 
in the Th1 cytokine pathway. These patients are highly susceptible to infections with NTM 
species or BCG which are normally poorly pathogenic [21, 141, 142]. Some of these patients 
may also develop severe infections with other pathogens, such as Salmonellae and viruses. 
For example, IL-12p40 or IL-12Rβ1-deficient patients are also susceptible to Salmonellae 
infections, and signal transducer and activator of transcription 1 (STAT1)-deficient patients 
are also susceptible to various viral infections, while IFN-γR1 or IFN-γR2-deficient patients 
are relatively resistant to Salmonellae and viral infections [141].
Severe NTM or BCG infections are also found in patients with other genetic diseases such 
as chronic granulomatous disease (CGD) and severe combined immunodeficiency (SCID). 
For example, mutations in CYBB or NCF1 are a cause of CGD. Within the phagocytes of 
these patients the formation of superoxide radicals is greatly reduced. This leads to the 
susceptibility to mycobacterial infections, but also to infections with various other bacteria 
and fungi. SCID patients are also highly susceptible to mycobacterial infections, amongst 
others, as a result of an impaired B and T cell immunity.
Several environmental and host factors that increase susceptibility to tuberculosis have 
been described, such as other diseases, air pollution, malnutrition, smoking, alcoholism and 
genetic host factors. For example, having silicosis [143], having diabetes [144] or smoking 
[145] increases the risk of developing tuberculosis more than twofold. Co-infection with 
human immunodeficiency virus (HIV) increases the risk up to 37 times [1]. Furthermore, 
several host genetic factors were found to be weakly associated with tuberculosis. Associations 










































IFNG, VDR, TLR1, and TLR8 [144, 146-151]. However, tuberculosis disease usually does 
not follow a Mendelian inheritance pattern since the susceptibility is polygenic and multi-
factorial [148]. 
6. Genetic deficiencies and the susceptibility to NTM and BCG infections
Among MSMD patients with NTM or BCG infections various defects were found in the genes 
encoding for IL-12p40, IL-12Rβ1, IFN-γR1, IFN-γR2, STAT1, Nuclear-factor-κB-essential 
modulator (NEMO), tyrosine kinase 2 (TYK2), Interferon-stimulated gene 15 (ISG15) and 
IRF-8 [141, 152, 153]. These mutations lead to a lack of Th1 immune responses.
Each of the genetic deficiencies in the genes of the Th1 cytokine pathway, as found 
in humans, causes a similar susceptibility in mice. Knock out (KO) mice completely 
deficient in IFN-γ, IFN-γR1, IL-12p40 or IL-12Rβ1 develop normally. When challenged 
with mycobacteria these mice develop severe infections and show a lack of Th1 immune 
responses [154]. In comparison with wild type mice the KO mice were more susceptible 
to M. tuberculosis infections. In addition, the KO mice show no protective immunity to M. 
avium and BCG and fail to form mature granulomas. In humans, IL-12p40 and IL-12Rβ1 
deficiency lead to susceptibility to infections with poorly pathogenic Mycobacteria and/or 
Salmonellae and granuloma formation is impaired [21]. In patients with complete IFN-γR 
deficiency [4], granuloma formation is completely absent [49]. The enhanced susceptibility 
to infections with intracellular pathogens in humans and mice confirm that the IL-12/IFN-γ 
axis is essential for control of these infections and that a complete deficiency of one of the 
genes in the IL-12 and IFN-γ cytokine pathway is a major cause of MSMD.
STAT1, NEMO and TYK2 deficiency are not only the cause of susceptibility to 
mycobacterial diseases, but also lead to susceptibility to various other kinds of infections. 
STAT1-deficient patients are also susceptible to severe or lethal viral infections [155, 156]. 
This may be explained by the fact that STAT1 is not only involved in IFN-γ signaling, but also 
in the signaling of type I interferons. NEMO plays an essential role in the nuclear translocation 
of NFkB and is thus involved in the signaling of Th1 cytokines, such as IL-1, IL-18 and TNF 
[157]. Furthermore, NEMO plays a role in the CD40-mediated induction of IL-12 production 
by dendritic cells [156]. NEMO is also involved in other signaling pathways, such as TCR 
and B cell receptor signaling. The involvement in various immune processes explains why 











































TYK2 deficiency was found in two unrelated patients. One patient had besides a 
Salmonella and a BCG infection in addition to severe viral and fungal infections as well as 
elevated serum IgE levels [158]. The other patient had an herpes infection and a disseminated 
BCG infection, but normal IgE levels [159].The susceptibility to infections with various 
pathogens can be explained by the fact that TYK2 not only plays a role in IL-12 signaling but 
also in the signaling of other cytokines, such as IL-6 and IL-10. 
Recently, ISG15 and IRF-8 mutations were reported as MSMD causing mutations. 
ISG15 mutations were found in two unrelated patients with impaired IFN-γ immunity, who 
developed relatively mild mycobacterial diseases at the age of 12 and 15 year [152]. ISG15 
regulates the secretion of IFN-γ by NK cells and T cells and is abundantly produced by 
granulocytes and induces the secretion of IFN-γ by NK cells and T cells, alone or in synergy 
with IL-12 [152]. The latter emphasizes the important role of the ISG15-IFN-γ axis between 
granulocytes and NK cells in the innate immune response against mycobacteria. 
IRF-8 mutations were found in three unrelated patients who developed BCG infections 
after vaccination [153]. IRF-8 regulates the transcriptional response, for example the 
transcription of IL12B and NOS2, induced by interferons and TLR ligands [160]. A complete 
IRF-8 deficiency was found in one patient who presented with an absence of CD14+ and 
CD16+ myeloid cells in the blood. Two other patients with an autosomal dominant form 
of the disease showed a marked loss of CD1c+CD11+ dendritic cells and their capacity to 
produce IL-12. This illustrates the importance of IRF-8 in the generation of myeloid and 
dendritic cells and their capacity to modulate a type I immune response. 
6.1. Diagnosis 
Severe BCG or NTM infections are rare and develop with heterogeneous symptoms. The first 
infections become manifest in most cases in early childhood. Rapid diagnosis of the nature 
of the immunodeficiency is difficult, but mandatory for immunotherapeutic interventions, to 
help to combat the mycobacterial infections successfully. 
When a case with a severe NTM or BCG infection is presented, MSMD can be suspected. 
In first instance, underlying diseases such as HIV infections and chronic granulomatous 
disease should be excluded. The incidence of these diseases is higher and both diseases 
require other treatments. Whether patients with NTM or BCG infections had had severe 
infections with other pathogens may already give information about the nature of a defect in 
the immune system. Furthermore, parental consanguinity and family history may also indicate 
whether the disease is genetically inherited in an autosomal recessive, autosomal dominant 
or X-linked manner. When the patient is suspected to have MSMD, several immunological 
investigations are necessary to reach a clear diagnosis. Valuable information can be obtained 
by cellular analysis and functional assays using whole blood, PBMCs and/or cultured T cell 










































T-cells from IL-12Rβ1 and TYK2-deficient patients show poor IFN-γ production upon 
TCR triggering and additional IL-12 stimulation. FACS (fluorescence activated cell sorting) 
analysis of the IL-12Rβ1 protein on activated T cells will give an indication of a defect in 
the ability to express the receptor protein on the membrane. The PBMCs from a patient with 
IL-12p40 deficiency show impaired IL-12p40 production upon lipopolysaccharide (LPS) 
stimulation. Additional tests can be done to investigate a putative mutation in TYK2. The T 
cells of TYK2 patients are unresponsive to IL-12, but also to IFN-α [158].
To identify an IFN-γR deficiency the monocytes of the patient can be tested for IFN-γ 
responsiveness. CD14+ monocytes stimulated with IFN-γ upregulate the cell surface 
expression of CD54 and CD64 and the LPS induced IL-12p40 and TNF production. Failure in 
the response indicates a defect in the IFN-γR expression or IFN-γ signaling. The quantification 
of the IFN-γR expression level by FACS may also indicate a defect in the receptor. An absent 
or abnormally high expression of IFN-γR1 on the cell surface may indicate a complete defect 
or the inability to internalize the protein, respectively. An impaired IFN-γ responsiveness can 
also be due to a STAT1 deficiency. This deficiency results also in unresponsiveness to IFN-
α/β and can be further characterized by functional STAT assays, for example electrophoretic 
mobility shift assays to study the binding of STAT modules to DNA. 
Additional tests can be done to investigate a putative mutation in NEMO, ISG15 or IRF-
8. The T cells of these patients are unresponsive to IL-12, but are also unable to respond 
to IFN-α [158]. The monocytes of putative NEMO patients can be tested for the ability to 
produce cytokines after stimulation of the CD40 receptor. In NEMO patients, the CD40-
induced production of IL-12p40, TNF and IL-6 is markedly reduced, while the LPS-induced 
production of TNF and IL-1β is normal [156]. ISG15 deficiencies can be expected when 
whole blood leukocytes, which are stimulated with BCG or BCG with IL-12, produce 
reduced levels of IFN-γ. The IFN-γ production of ISG15-deficient cells can be restored with 
recombinant ISG15. IRF-8 deficiency can be assumed when there is a severe lack of CD14+ 
monocytes or a selective loss of CD1c+CD11c+ monocytes.
The ultimate diagnosis can be made when the genetic basis of the defect is revealed. 
Next to the functional assays, the DNA or mRNA coding for the protein of interest can be 
amplified by (RT-)PCR in order to be sequenced for mutations. Clear null mutations can be 
found, but also variations with unknown impact on protein function. The impact of gene 
deletions or early stop codons within the coding sequence on the features and functions of 
the gene product is clear. The impact of a subtle genetic variation is less clear. For example, 
in the IL-12Rβ1, IFN-γR1 and IFN-γR2 proteins various amino substitutions, with unknown 
impact on protein function were found. Those variants need to be functionally characterized 













































MSMD patients with NTM or BCG infections need antibiotics and additional measures to 
combat the infections [2, 4]. The choice of antibiotic treatment depends on the sensitivity of 
the mycobacterial species to antibiotics. Antibiotic treatment is often required permanently, 
because of the dissemination of the mycobacteria and the hampered immunity. Vaccination 
of a sibling from MSMD patients with the live BCG vaccine should be avoided, until it is 
proven that the sibling is not affected by the same genetic deficiency. IL-12Rβ1-deficient 
and partial IFN-γR1-deficient patients usually respond very well to antibiotic therapy, and 
additional treatment with high doses of IFN-γ is possible. Complete STAT1, IFN-γR1 or IFN-
γR2 deficiency usually leads to a more severe disease, for which antibiotic treatment alone 
may not be not successful. Full remission is not always achieved and relapse of the infection 
frequently occurs after withdrawal of the antibiotic therapy. 
Stem cell transplantation is suggested as an optional therapy for patients with STAT1 
deficiencies and patients with complete IFN-γR deficiencies. First attempts of transplantation 
were not always successful, only two of the eight patients experienced recovery [2]. Active 
infections may impede stem cell transplantation. In addition, the circulating IFN-γ in these 
patients may evoke graft rejection [161], whereby IFN-γ depletion is required for successful 
transplantation in these patients.
Additional IFN-α treatment has also been suggested as a therapeutic option for patients 
with IFN-γR deficiencies, since both IFN-α and IFN-γ are able to induce a broad range of 
interferon inducible genes. Three patients with disseminated M. avium infections have been 
treated with IFN-α [162, 163], though the benefit of this additional treatment was not clear. 
Type I interferons stimulate mature immune cells, but inhibit the immature immune cells 
[118]. For instance, IFN-α enhances the antigenic function of maturing monocyte-derived 
dendritic cells. In this way IFN-α may promote Th1 responses [164]. On the other hand 
IFN-α inhibits the IFN-γ responsiveness of primary monocytes [165]. Besides the effects 
on monocytes, IFN-α also has dual effects on the establishment of B and T cell responses. 
The isotype class switch and the antibody production of plasma cells are stimulated by type 
I interferons, while the development of CD19+ pro-B cells is inhibited [118]. The cytotoxic 
effects of CD8+ T cells against virus-infected cells is enhanced by IFN-α, while CD4+ T cell 
responses and early T cell development are inhibited [118]. Thus, the outcome of IFN-α 










































Outline of the thesis
This thesis focuses on the causes of impaired type I immune responses, important in the 
control of non-tuberculous and tuberculous mycobacterial infections. The first part of the 
thesis (chapters 2-6) covers the investigations of genetic variations in the genes of key cytokine 
receptors in the control of type I immune responses. Studying the impact of polymorphisms 
and mutations in the IL-12, IL-23 and IFN-γ receptors on cytokine responses will help in the 
diagnosis and treatment of patients with severe NTM or BCG infections. The second part of 
the thesis (chapters 7 and 8) focuses on other causes of repressed IFN-γ mediated immune 
responses involved in the manifestation of tuberculous mycobacterial infections.
Chapter 2 is a case report of a patient with a disseminated Mycobacterium genavense 
infection. Functional tests revealed a deficiency in IL-12Rβ1. The genetic analysis showed 
two variations, which are putative mutations, within the transcript of IL12RB1: a -2C>T 
variation in the translational start site and a 1561C>G variation resulting in an amino acid 
substitution at position 521 of the protein. Using a cellular model with retroviral expression 
of wild type and mutant IL-12Rβ1, the R521G variation was found to be the cause of the 
disease. In the addendum of chapter 2 a summary is given of the functional characterization 
of the naturally occurring amino acid substitutions within IL-12Rβ1.
In chapter 3 the function of various IL-23R variants is investigated. Until now several 
MSMD causing mutations, leading to impaired IL-12 and IL-23 responses, were found in 
IL12RB1, but not in IL12RB2 or IL23R. Still some IL-23R variations were found the impact 
of which on receptor function was unknown. An amino acid substitution Y173H in the IL-
23R of a patient with pulmonary tuberculosis was reported. In chapter 3 the influence of the 
Y173H amino acid substitution on the receptor function was studied using a cellular model 
with retroviral expression of the IL-23 receptor. Two other variations, the frequently found 
polymorphisms P310L and R381Q, which were previously reported to be associated with 
autoimmune diseases, were also under investigation. In addition, the effects of IL-12 and IL-
23 were compared in this cellular model.
Little is known about the IL-23R expression patterns in vivo due to the lack of a good 
antibody against the IL-23R. In chapter 4 the presence of a functional IL-23R on NK-like T 
cells was determined by studying the direct effects of IL-23 on the receptor-specific signaling. 
Next, a first comparison was made between the effects of IL-12 and IL-23 on these primary 
cells.
Chapters 5 and 6 describe the functional characterization of variations in the IFN-γR, 
in order to designate them as polymorphisms or mutations. To assess the nature of IFN-γR 
defects is important, since patients with partial and patients with complete IFN-γR deficiencies 











































patients who are unresponsive to IFN-γ. In some of these patients single amino acid variations 
were found in one of the two IFN-γR genes. Whether such a variation is the cause of an IFN-
γR deficiency needs to be proven. Therefore, we developed two models. Chapter 5 evaluates 
the use of a cellular model to test and compare the cell surface expression and function of 
IFN-γR1 variants. In chapter 6 we evaluate a model to test IFN-γR2 variants. With the use 
of these models it was possible to distinguish MSMD-causing mutant receptor variants from 
polymorphic variants.
In chapters 7 and 8 the role of IFN-α in the type I immunity is investigated. One of the 
current hypotheses is that IFN-α/β aggravates the course of tuberculosis. Previously, it was 
found that the IFN-γ signaling, necessary to control mycobacterial infections, was impaired 
in the blood cells of patients with tuberculosis. IFN-α and IFN-β seem to be able to inhibit the 
IFN-γ mediated type I immune responses of monocytes in tuberculosis patients. In the study 
presented in chapter 7 the extent of the inhibitory effects of IFN-α and IFN-β on monocytes 
was investigated. In addition we reveal some of the mechanisms whereby IFN-α inhibits the 
type I immune response. 
The fact that IFN-α/β has been shown to strongly inhibit the type I immunity leads to the 
following hypothesis; viral infections cause the resuscitation of dormant M. tuberculosis and 
aggravate the course of tuberculosis. In chapter 8 we tested the latter for influenza infections. 
Influenza viruses induce IFN-α/β in the respiratory tract and could make the host susceptible 
to M. tuberculosis infections in the lung. We studied the plasmas of tuberculosis patients 
and controls, which were previously collected in Jakarta in Indonesia, for the presence of 
antibodies against recent influenza viruses. In the group of tuberculosis patients more recent 
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An adult patient with a severe disseminated M. genavense infection was investigated. The 
patient had a novel mutation in IL12RB1, leading to the amino acid substitution R521G. 
The R5212G variation was confirmed to be a mutation in a study using a cellular model, 
with retroviral expression of cloned IL-12Rβ1 variants in cells from a completely IL-12Rβ1 
deficient patient. We demonstrate that the R521G variation results in a strong reduction of 
the cell surface expression of IL-12Rβ1 and a minimal response upon IL-12 stimulation. 
Another variation, -2C>T, was found in the Kozak consensus sequence, but this variation 
did not influence receptor expression in our experiments and appears to be a functional 
polymorphism. R521G is, next to C198R, only the second known mutation in IL-12Rβ1 
leading to a partial defect, and is a cause of Mendelian susceptibility to mycobacterial disease. 
This case illustrates that Mendelian susceptibility to mycobacterial disease may manifest 












































Mendelian susceptibility to mycobacterial disease (MSMD, MIM #209950) is a rare disease 
which usually manifests in early childhood. MSMD patients often suffer from disseminated 
nontuberculous mycobacteria (NTM), Bacillus Calmette-Guerin (BCG) and/or Salmonella 
infections. Individuals with MSMD have an impaired type I immune response due to 
deficiencies in the type I cytokine pathway [1, 2]. MSMD causing mutations have been 
identified in five genes; IL12RB1, IL12B, IFNGR1, IFNGR2, and STAT1. While most patients 
suffer only from infections with Mycobacteria and Salmonellae, STAT1 deficient patients 
suffer in most cases from severe viral infections [3]. Complete defects in the IFN-γ receptor 
(IFN-γR) result in a severe manifestation of MSMD, while partial IFN-γR deficiency and 
complete IL-12p40 or IL-12Rβ1 deficiency usually results in a less severe disease. Until now 
only one IL-12Rβ1 mutation, C198R, identified in three MSMD patients [4, 5] was found to 
result in a partial IL-12Rβ1 deficiency [6]. 
Human immunity against intracellular pathogens, such as Mycobacteria and Salmonellae, 
is dependent on an effective cell-mediated type I immune response. Dendritic cells and 
macrophages can recognize these pathogens via innate pattern recognition receptors (PRRs) 
which interact with specific pathogen associated molecular patterns (PAMPs). Activation of 
PRRs by mycobacterial PAMPs induces the production of various type I cytokines cytokines, 
such as IL-12, IL-23, IL-1β and tumor necrosis factor (TNF). 
IL-12 and IL-23 are heterodimers with IL-12p40 as a common subunit. IL-12 and IL-23 
signal via their own receptor complex, respectively consisting of a specific IL-12Rβ2 and IL-
23R chain and a common IL-12Rβ1 chain. Hence, IL-12p40 and IL-12Rβ1 deficiency results 
in both impaired IL-12 and IL-23 responses. IL-12 and IL-23 activate T cells, for instance 
to produce IFN-γ. IL-12 signals via STAT4 and thereby induces the IFN-γ production of 
various subsets of T cells [7]. IL-23 may also stimulate natural-killer-like T cells to produce 
IFN-γ [8]. IFN-γ acts in concert with other type I cytokines to regulate effective innate and 
adaptive immune responses [9] and granuloma formation [10, 11]. Defects in this IL-12/
IFN-γ pathway, such as defects in IL-12Rβ1, results in a lack of the IFN-γ mediated type 
I immunity and impaired granuloma formation giving rise to disseminated infections with 
otherwise poorly pathogenic Mycobacteria and Salmonellae species. 
We present a case of disseminated NTM infection in an adult, middle aged, patient with a 
partial IL-12Rβ1 deficiency. The clinical phenotype of this patient and the immunological 
investigations, in order to unravell the nature of the deficiency, are described. We found two 
homozygous variations within the transcript of IL12RB1 from the patient. The variations were 
functionally characterized using a cellular model with retroviral transduction of IL12RB1 










































2. Patient and Methods
2.1. Case report
A 43 year old man was admitted to the hospital because of anorexia, fatigue and weight 
loss (27 kg) since 2 months. He had intermittent subfebrile temperatures, night sweats and a 
productive cough with clear sputum. The patient smoked five to ten cigarettes a day and never 
used (intravenous) drugs. His medical history showed congenital hearing loss and cataract at 
the age of 38. On physical examination a cachectic male was seen with a temperature of 38.3 
oC. He had cervical lymphadenopathy and hepatomegaly, no other abnormalities were found. 
Laboratory evaluation showed elevated inflammation parameters (ESR 41 mm, CRP 122 
mg/L) and a pancytopenia (hemoglobin 6.3 mmol/L, leucocytes 1.8 * 109 /L with a normal 
differentation, thrombocytes 94 * 10 9 /L). An X-ray of the lungs showed no abnormalities. 
A CT scan of thorax and abdomen showed retroperitoneal, mesenterial and cervical 
lymphadenopathy and hepatosplenomegaly. A cervical lymphnode and bone marrow biopsy 
showed granulomatous infiltrations with intracellular mycobacteria. In the Ziehl Neelsen 
stain acid-fast rods were seen. Mycobacterium genavense was cultured from blood and 
sputum. The patient repeatedly tested negative for HIV by polymerase chain reaction (PCR).
Treatment was started with clarithromycin, ethambutol and rifampicin. After three 
weeks, the patient was discharged in a reasonably good physical and mental condition. A few 
months later he had completely recovered, and after 18 months triple antibiotic therapy was 
stopped. Because of the disseminated NTM infection and the absence of HIV or extensive 
immunosuppression, MSMD was suspected and further examination of the patient’s host 
immunity was performed.
2.2. Generation of T cell blasts
PBMCs were isolated from the blood by Ficoll separation. Cells were cultured in IMDM 
supplemented 20 mM GlutaMax, 100 U/ml penicillin, 100 µg/ml streptomycin and 10 % 
fetal calf serum (Invitrogen). To generate T cell blasts (TCB) the PBMCs were stimulated 
with 800 ng/ml PHA-16 (Murex) and cultured in medium with 30 U/ml IL-2 (Chiron) in 
24-wellsplates and tested in 96-wellplates (Greiner bio-one).
2.3. Detection of the IL-12Rβ1 expression
1*105 PHA blasts were washed in FACS buffer; 0.2% bovine serum albumin (Roche) in 
phosphate buffered saline. The cells were labeled with one of the PE conjugated specific IL-
12Rβ1 antibodies (clone 4D1 and 2.4E6, BD Biosciences). As controls unlabeled cells and 
cells labeled with a PE conjugated isotype control IgG1 (DAKO) were used. After labeling, 
the cells were washed twice with FACS buffer. Subsequently the cells were analyzed using a 
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2.4. IFN-γ production assay
TCB were used 14 days after PHA stimulation. 1*105 TCB were cultured in 200 μl medium 
and left unstimulated or stimulated with 2 μg/ml anti-CD2 (CLB-T11.1/1 and CLB-T11.2/1) 
and 2 μg/ml anti CD28 (CLB-CD28/1) in the presence of various concentrations of IL-12 
(R&D). After 72 h the supernatants were removed and analyzed for the presence of IFN-γ by 
ELISA (Invitrogen). 
2.5. STAT4 phosphorylation assay
To study the signal transduction 2*105 cells were prestimulated overnight in 150 μl culture 
medium supplemented with anti CD2 and anti CD28 antibodies. Thereafter the cells were 
pulsed with 200, 1000 or 5000 pg/ml of IL-12. After the pulse, the cells were fixed with 
paraformaldehyde (Sigma) and permeabilized with methanol (Merck). Subsequently, the 
cells were washed with FACS buffer, blocked with 10% normal goat serum (Sanquin) and 
stained with a specific antibody against pY693-STAT4-alexafluor647 (BD Biosciences). 
Before FACS analysis the cells were washed twice.
2.6. Genetic screening
The IL12RB1 mRNA was amplified by reverse transcription polymerase chain reaction (RT-
PCR) (Invitrogen) from TCB-derived RNA and sequenced. To confirm the presence of the 
detected variations in the genomic DNA the relevant exons were amplified by PCR from the 
genomic DNA, isolated by the high salt method. The PCR products were sequenced by the 
Leiden Genome Technology Centre (LGTC in Leiden, The Netherlands). Primers and PCR 
conditions are available upon request.
2.7. Expression cloning of IL-12Rβ1and retroviral transduction
The coding sequences of wild type IL-12Rβ1 and the R521G variant were 
cloned, respectively from control and patient cDNA in the pGEM-T easy vector 
as described before using the following primers [6]; primer IL12RB1-2C-ATG: 
5’-GGCTCTACGTGGATCCGATGGAGCCGCTGGTGACC-3’, primer IL12RB1-2T-
ATG: 5’-GGCTCTACGTGGATCTGATGGAGCCGCTGGTGACC-3’ and the reverse 
primer IL12RB1-STOP: 5’-GGGTCCAAATGTGACTCCTGTGT-3’.The coding sequences 
for wild type IL-12Rβ1 and the R521G variant were transferred from the pGEM-Teasy vector 
into the bicistronic retroviral pLZRS-IRES-GFP vector with either the wild type translational 
start site or with the start site containing the -2C>T variation. All constructs were verified by 
sequencing. Helper free recombinant virus was produced and used to transduce TCB, from a 
patient with a Q32X mutation in IL12RB1, as described before [6]. GFP positive TCB were 











































The student t-test was used to determine statistical significance between two groups of 
measurements. Results were regarded significantly different when p<0.05. In order to 
determine the difference between the kinetics of STAT4 phosphorylation, non linear least 
squares regression analysis was performed with GraphPad Prism software, using 95% 
confidential intervals to designate significant differences.
3. Results
3.1. Phenotypic and functional evidence for an IL-12Rβ1 deficiency
Although the patient developed disease at middle-age and not in childhood, we suspected 
the patient has MSMD, because M. genavense rarely causes disseminated infections in 
immunocompetent individuals. Therefore we tested the blood cells from the patient for thier 
ability to respond to IFN-γ and IL-12. The monocytes of the patient and a control responded 
upon LPS and IFN-γ stimulations, with a similar induction of TNF and IL-12p40 production 
(data not shown). Next, we determined the IL-12Rβ1 expression and IL-12 responsiveness of 
the TCB from the patient. The IL-12Rβ1 expression could be detected on control TCB but not 
on the TCB from the patient (Figure 1). Surprisingly, the TCB from the patient showed upon 
IL-12 stimulation no abrogated, but a severely reduced STAT4 phosphorylation as compared 
to the response of the control TCB (Figure 2). Next, we examined the IFN-γ production of 
the activated TCB. The TCB from the patient showed upon CD2 and CD28 stimulation a 
strongly reduced IFN-γ production as compared to the TCB from the control (Figure 3). 
Addition of IL-12 enhanced the IFN-γ production by the control cells already with low IL-12 
concentrations, while the IFN-γ production of the patient’s TCB was only slightly enhanced 
after stimulation with high concentrations of IL-12 (Figure 3). Taken together the results 




























































































Figure 1. No detectable expression of IL-12Rβ1 on the T cells from the patient. TCB from the 
patient and an unrelated control were stained with an isotype antibody or an IL-12Rβ1 specific antibody 
(4D1). The mean fluorescence of the cells was determined by FACS. The experiment was performed in 







































































































































Figure 2. Minimal IL-12 induced STAT4 phosphorylation in the T cells of the patient. TCB of 
the patient and an unrelated control were stimulated with 5000 pg/ml IL-12. After 0, 15, 30, 60, 90 
minutes the STAT4 phosphorylation was analysed by FACS using a specific antibody against tyrosine 
phosphorylated STAT4. The TCB from the patient cells showed a minimal but statistical significant 
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Figure 3. Strongly reduced IFN-γ production by the cells of the patient. TCB of the patient and an 
unrelated control were cultured without stimuli or stimulated with various concentrations of IL-12 in 
the presence of antibodies against CD2 and CD28. After 72h the amount of IFN-γ in the supernatant 
was measured by ELISA. The mean +/- standard deviation is displayed of an experiment performed in 
triplo. * Significantly different from the control and from the CD2 and CD28 stimulated cells (0 pg/ml 
IL-12), p< 0.05 (student t-test). 
3.2. Sequence analysis of IL12RB1 
To reveal the underlying genetic basis of the impaired IL-12 responsiveness, we sequenced 
the IL12RB1 transcript. We identified several homozygous variations within the transcript of 
IL12RB1 of the patient (data not shown). Several of these encode amino acid variations that 
are known not to influence IL-12Rβ1 function: R156H, Q214R, M365T, and G378R [7]. In 










































variation resulting in an R521G amino acid substitution within the extracellular domain of 
IL-12Rβ1. Sequencing of genomic DNA from the patient revealed that both variations were 
homozygously present in respectively exon 1 and exon 13 of IL12RB1 (data not shown). The 
r.1561C>G variation was not described before and could not be found in the genomic DNA 
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Figure 4. The influence of the -2C/T and R521G variation on the IL-12Rβ1 expression. TCB from 
a complete IL-12Rβ1 deficient patient were untransduced, transduced with GFP, with the wild type 
IL12RB1 cDNA or with an IL12RB1 construct carrying one or both of the genetic variations as found in 
the patient under study, -2C/T and R521G. The cells were labelled with a PE conjugated isotype control 
or an IL-12Rβ1 specific antibody (2.4E6 or 4D1). The mean fluorescence of the cells was determined 
by FACS. The mean +/- standard deviation is displayed of a triplo experiment. * significantly different 
from the untransduced and GFP controls, p<0.05 (student t-test).
3.3. Functional consequences of the -2C/T and the R521G variations
To establish whether the -2C>T or the R521G variation is the cause of the impaired IL-12 
responsiveness we used a previously developed model system to study the functional effect 
of the variations in the IL-12/IL-23Rβ1 by e ploying a retroviral expression vector in IL-12/
IL-23Rβ1 deficient cells [6]. We made four retroviral constructs carrying a GFP marker gene 
and the open reading frame coding for one of the four IL-12Rβ1 variants to be investigated; 
the wild type IL-12Rβ1, the -2C>T variant, the R521G variant and the variant with both 
the -2C>T and the R521G variation. TCB cells from a patient with a complete IL-12Rβ1 
defect were transduced with one of these retroviral constructs and as a control TCBs were 
transduced with a vector carrying the GFP marker alone. GFP positive TCBs were selected 
by FACS sort and analyzed for IL-12Rβ1 expression. The -2C>T variation had no influence 





































































































anti IL-12R 1 (2.4E6)































































C                   STAT4 phosphorylation
time in min.





































































anti IL-12R 1 (2.4E6)































































C                   STAT4 phosphorylation
time in min.











Figure 5. Influence of the R521G variation on the IL-12 signalling. TCB from a complete IL-12Rβ1 
deficient patient, transduced with a GFP control vector or a vector carrying the c DNA from the wild 
type IL-12Rβ1 or the R521G variant were stimulated for 0, 15, 45, 90 minutes with 200 pg/ml (A), 
1000 pg/ml (B) or 5000 pg/ml (C) IL-12. The kinetics of the IL-12 induced STAT4 phosphorytion was 
analysed by FACS using a specific antibody against tyrosine phosphorylated STAT4. The kinetics of 
STAT4 phosphorylation was significantly different from that of the GFP control and that from the wild 
type IL12RB1 control at all three IL-12 concentrations tested.
The R521G variation resulted in a severely reduced IL-12Rβ1 expression at the cell surface, 
which was about a factor 450 lower than wild-type protein (Figure 4). Next we analyzed 
the effect of the R521G variation on the IL-12 induced signal transduction via STAT4. In 
cells transduced with the R521G variant phosphorylation of STAT4 in response to IL-12 
stimulation was greatly reduced (Figure 5). And as a consequence of reduced signaling, the 
IL-12 induced IFN-γ production was also severely reduced by the R521G variation (Figure 








































































Figure 6. Influence of the R521G variation on the IL-12 induced IFN-γ production. TCB from 
a complete IL-12Rβ1 deficient patient, transduced with a GFP control vector or a vector carrying the 
cDNA from the wild type IL-12Rβ1 or the R521G variant were cultured in medium or stimulated with 
various concentrations of IL-12 in the presence of antibodies against CD2 and CD28. After 72h the 
IFN-γ production was measured by ELISA. The mean +/- standard deviation is displayed of a triplo 
experiment. * significantly different from the GFP control and the wild type IL12RB1 construct, p<0,05 
(student t-test).
4. Discussion
We report the case of a middle-aged patient, who developed a severe disseminated infection of 
M. genavense. The patient appeared to have a partial IL-12Rβ1 deficiency due to homozygous 
inheritance of the r.1561C>G mutation in IL12RB1, leading to the amino acid substitution 
R521G. As a result of this mutation no IL-12Rβ1 protein was detectable on the T cells from 
the patient, although the IL-12 response was not completely abrogated. This was confirmed 
in a cellular model using retroviral expression constructs carrying various IL-12Rβ1 variants. 
The patient also had another variation, -2C>T, within the IL12RB1 gene. This variation in the 
Kozak consensus sequence has no influence on the cell surface expression of IL-12Rβ1 and 
is therefore regarded as a functional polymorphism.
The patient described in this study had a severe partial defect in IL-12Rβ1. Remarkably, the 
patient did not suffer from severe Mycobacteria nor Salmonellae infections in childhood and 
the first severe NTM infection manifested at the age of 43, although usually, infections in 
MSMD patients occur at a mean age of 2.4 years [12]. It has been previously reported that 
some siblings of IL-12Rβ1 deficient MSMD patients, who were also found to be homozygous 
for the IL-12Rβ1 mutation, have remained asymptomatic for many years [2]. Nine such 
asymptomatic individuals were described with complete IL-12Rβ1 deficiency, which were 
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they developed mycobacterial disease later in life (before the age of 14 and 33), of most 
however no follow-up is known. IL-12Rβ1 deficient individuals may remain symptom free 
for several reasons. For example, it may be that there is a lack of exposure to NTM, in 
case of BCG-vaccination the vaccine in use was of poor quality, young BCG-vaccinated 
children may benefit form antibodies in breast milk or that some other compensatory immune 
mechanisms in early childhood contributes to enough resistance to NTM infections. 
Recently, a survey of 141 patients from 30 countries with an IL-12Rβ1 deficiency was 
published [12]. In all but 2 kindreds, the patients lacked expression of the receptor on the 
cell surface. FACS analysis of IL-12Rβ1 expression on activated T lymphocytes from our 
patient was also indicative for an IL-12Rβ1 deficiency. Hence, we sequenced the transcript 
and parts of the IL12RB1gene. The patient had two unknown variations within the transcript 
of IL12RB1. The -2C>T variation, within the Kozak consensus sequence, could potentially 
influence the rate of translation and thereby the expression of the protein. The presence 
of a thymidine at 2 nucleotides before the ATG start codon could potentially decrease 
the rate of translation [14, 15]. However, the -2C>T substitution did not decrease the IL-
12Rβ1 expression as was proven with a cellular model using a retroviral expression vector 
containing the open reading frame of IL-12Rβ1 and 17 bases of the Kozak sequence before 
the start codon. The R521G variation appeared to be a mutation, leading to a 450 times 
reduced cell surface expression of IL-12Rβ1 in our model system. The minimal expressed 
R521G protein could still elicit a marginal IL-12 response. Previously, another mutation was 
identified to cause a partial defect due to a C198R amino acid substitution within the cytokine 
binding region of the receptor [6]. The C198R mutation resulted in a severe reduction of IL-
12Rβ1 expression at the cell surface, of about 250 times, as was quantified with the same 
cellular model as used in this study. As a consequence, the function of IL-12Rβ1 was almost 
completely abrogated. One of the patients, homozygous for the C198R mutation, was a child 
who developed BCG adenitis after vaccination with M. bovis BCG in the neonatal period [5]. 
After anti-tuberculous treatment infections recurred over a period of many years, and extra 
antibiotic treatment was necessary . Thus, both the C198R and the novel R521G variations are 
MSMD causing mutations, despite the fact that both mutations do lead to a partial functional 
IL-12Rβ1 protein product. 
In conclusion, our study demonstrates that IL-12Rβ1 deficiency can lead to an adult onset 
of severe disseminated NTM infections. The patient in this study had a novel homozygous 
mutation, leading to the amino acid substitution R521G. The R521G variant of IL-12Rβ1 
results in an almost abrogated IL-12 response, due to a severely reduced cell surface 
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1. Introduction
Patients with Mendelian susceptibility to mycobacterial disease (MSMD; MIM #209950) 
develop severe infections with usually poorly pathogenic non-tuberculous Mycobacteria 
(NTM) or non-typhoid Salmonellae (NTS) [1]. The patients are susceptible to these infections 
due to a deficiency in one of the genes of the IL-12/IFN-γ pathway, amongst them IL12RB1. 
Various kinds of IL12RB1 mutations have been identified in MSMD patients. For example, 
null mutations as a result of premature stop codons, splice mutations, base pair deletions or 
insertions have been identified [2]. Next to these mutations single nucleotide substitutions 
resulting in single amino acid substitutions, were found in the IL12RB1 gene. Whether the 
latter variations are intrinsically deleterious is difficult to predict by in silico protein modeling 
only, but can be studied with the use of cellular models. 
IL-12Rβ1 (Figure 1) is the common chain of the IL-12 receptor and the IL-23 receptor 
complex. IL-12 signals via a receptor complex, which also contains the IL-12Rβ2 chain, 
while IL-23 signals via a distinct receptor complex, which contains the IL-23R chain next to 
the IL-12Rβ1 chain. The heterodimeric cytokines IL-12 and IL-23 share a common subunit, 
IL-12p40, which binds to the IL-12Rβ1 receptor chain. Both IL-12 and IL-23 can be produced 
by monocytes, macrophages and dendritic cells, and both cytokines are able to induce IFN-γ 
production in certain subsets of T cells and NK cells. IFN-γ is the central cytokine in type I 
immune responses, important in the control of infections with intracellular pathogens. Thus, 
a mutation in IL12RB1 that results in impaired type I immune responses may have as a 
consequence an enhanced susceptibility to atypical Mycobacteria and Salmonellae infections.
The relation of the IL12RB1 genotype and the clinical phenotype of MSMD patients 
has previously been reviewed [2-4]. Still, in many case reports the impact of amino acid 
substitutions within IL12RB1 on the function of the protein product was unclear. To study the 
influence of subtle amino acid (aa) changes, we developed a cellular model with retroviral 
IL-12Rβ1 expression that can be tested functionally [5]. Receptor variants were cloned and 
retrovirally expressed in T cells from a patient with a null mutation in IL12RB1. In this way, 
the expression and function of the various IL-12Rβ1 variants are compared within the same 
genetic background. The results obtained with this system are displayed in Table 1. The 
IL-12Rβ1 expression of the variants was analyzed using at least two different antibodies, 
recognizing different parts of the protein. In addition, the receptor function of the variants 
was tested by analyzing the IFN-γ and IL-10 production [5] and STAT4 phosphorylation 
(unpublished data) upon IL-12 stimulation. In this report an overview of the functional 
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2. MSMD causing mutations in IL-12Rβ1
Using our cellular model, the variants L77P, Q171P, R173P, C186S, R213W and Y367C were 
functionally characterized and confirmed to be deleterious mutations leading to complete 
IL-12Rβ1 deficiency [5] (Table 1). In the L77P variant, expression of the IL-12Rβ1 on the 
cell surface was severely reduced, while the other four variants were not expressed at all on 
the cell surface but could be detected in the intracellular compartment. In IL-12 stimulation 
assays, the L77P expressed on the cell surface appeared to be non-functional. Because the 
L77P variation is located within the cytokine binding region of IL-12Rβ1 (aa 43-237, see 
Figure 1), it was expected that ligation of IL-12 to its receptor was abrogated. This was 
confirmed by studying the binding of IL-12 to the IL-12R on cell lines, transiently transfected 
with IL12RB1 constructs, and using recombinant IL-12p70 and IL-12p40 specific antibodies 
[2].
The cell surface expression of the C198R variant [6] and the R521G variant of IL-12Rβ1 
([7] and chapter 2 of this thesis) was also severely reduced, 250 and 450 times respectively. 
In contrast to the L77P variant, however, these two variants are able to respond to IL-12 
stimulation, though the response to IL-12 was in both cases almost abrogated, due to the 
very low cell surface expression. This explains why the T cells from patients homozygous 
for the C198R and R521G mutation show a minimal response upon stimulation with high 
concentrations of IL-12 ([6, 7] and chapter 2). These rare patients, with a partial IL-12Rβ1 
deficiency, and all reported patients with complete IL-12Rβ1 deficiency, suggest that the 
IL-12Rβ1 function has to be strongly reduced to impair the mounting of sufficient immune 
responses against atypical Mycobacteria and Salmonellae. A reduction of 50 % in IL-
12Rβ1 expression apparently does not affect immunity to these pathogens substantially: 
individuals with just one mutated allele showed intermediate expression of IL-12Rβ1 and an 
intermediate response to IL-12 has not been associated with clinical manifestation of NTM 
or NTS infections (unpublished data). 
In addition, it was found that some siblings from patients with NTM infections, which 
are also IL-12Rβ1 deficient, may remain asymptomatic for many years. This may be due to 
a lack of relevant exposure to NTM and NTS. On the other hand, the threshold of minimal 
required IL-12 and IL-23 responses to combat infections is low and other host-factors 
may also contribute to the susceptibility to NTM infections. Thus, sufficient residual type 
I immunity is present in some cases with complete IL-12Rβ1 deficiency. However, in the 
reported cases with severe disseminated infections and complete IL-12Rβ1 deficiency, the 
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The functional characterization of the Q171P variant was not published before. Two 
patients were described to be heterozygous for the Q171P variation, while having a premature 
stop mutation on the other allele [4]. Both patients suffered from severe disseminated BCG 
infections at the age of two and three, of which one died due to the infection. The severe 
infections and the null mutation in one allele, suggested that the Q171P variation was also 
a mutation rather than a polymorphism without phenotype. Using our cellular model, the 
Q171P variant was confirmed to be a deleterious mutation. The Q171P variant was expressed 
within the cell and not at the cell surface and no residual function was detected for the Q171P 
variant (unpublished data).
Using a similar cellular model, not with stable retroviral expression but with transient 
expression, the C62G, R173W, R175W, C186S, R211P and I369T variations were also 
determined to be mutations, based on loss of expression and loss of IL-12 binding to the 
receptor [2] (Table 1). However, these variants were not tested for their ability to respond to 
IL-12. Thus, it remains unclear whether these mutations exhibit residual responses to high 
concentrations of IL-12. 
3. Effects of mutations in IL-12Rβ1 on receptor expression
In a previous report the IL-12Rβ1 mutations of 141 MSMD patients were discussed [2]. 
Remarkably, all currently characterized mutations due to single amino acid substitutions or 
premature stop codons reduced the cell surface expression completely or in a few cases 
nearly complete (Table 1). Two of the 141 patients lacked cell surface expression of the 
receptor [2, 8]. These patients did not carry a single amino acid substitution in IL-12RB1, but 
had a large in frame deletion. The protein products from the latter mutation were detected 
on the cell surface by some but not all of the available antibodies against IL-12Rβ1. Thus, 
antibodies against the different parts of the extracellular domain of the receptor are useful in 
the diagnosis of all currently known IL-12Rβ1 deficiencies, because the lack of IL-12Rβ1 
expression at the cell surface already gives a strong indication for an IL-12Rβ1 deficiency. 
Single nucleotide substitutions can also lead to a premature stop codon. The variations 
Q32X, E67X, Y88X, Q285X, K305X, S321X, Q376X, E480X, R486X, R521X, W531X, 
Q542X are mutations found in MSMD patients [2]. All these mutations occurred in the 
extracellular part or in the transmembrane domain of the receptor, resulting in the synthesis 
of truncated protein products lacking the transmembrane domain (aa 541-572) and the 
intracellular signaling domain (aa 573-662) (Figure 1). Thus far, all amino acid substitutions 
and all premature stop codons resulting in severe dysfunction of the receptor were found 
in the extracellular part or the transmembrane region and not in the intracellular part of the 
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at the cell surface or loss of IL-12 binding, suggest that perhaps the intracellular part of the 
receptor is dispensable for minimal required receptor function. To investigate the latter, an 
IL12RB1 construct was made with a stop codon at position 578. This construct codes for a 
truncated IL-12Rβ1 protein with an extracellular and a transmembrane domain, but without 
the intracellular domain. The artificial C578X variant was expressed at the cell surface, but 
was unable to induce STAT4 phosphorylation and IFN-γ production upon IL-12 stimulation 
(unpublished data). Thus, the intracellular domain of IL-12Rβ1 is not dispensable for 
receptor function. Consequently, in the investigation of a putative IL-12Rβ1 deficiency of a 
new MSMD case, it is advisable to measure the IL-12 responsiveness of the T cells from the 
patient and not the IL-12Rβ1 expression and IL-12 binding only. According to current reports 
[2, 4], putative MSMD patients are not always screened for IL-12 responsiveness. Hence, the 
finding that all MSMD causing mutations in IL12RB1 affect the IL-12Rβ1 expression and/or 
the IL-12 binding, may be biased. We recommend in the diagnosis of MSMD, to test for the 
IL-12 responsiveness.
Until now, 14 amino acid substitutions were proven to be the cause of IL-Rβ1 deficiency. 
As a consequence the receptor is totally or mainly expressed within the cell, and not on 
the cell surface. Eleven of the 14 amino acid substitutions are located within the IL-12p40 
binding region, which is a 195 aa long segment of the extracellular domain of 541 aa. In 
contrast, the identified early stop codons are more equally distributed within the extracellular 
domain. Only 2 of the 12 premature stop codons were located within the IL-12p40 binding 
region. Taken together, this indicates that the IL-12p40 binding region is not only important 
for cytokine binding but that the conformation of this region is also crucial for receptor 
expression on the outer surface of the cellular membrane.
4. Harmless polymorphisms in IL-12Rβ1
The most common polymorphisms in IL-12Rβ1 are R214Q, T365M and R378G. These 
polymorphisms are tightly linked to each other [9], and hence they form the two major 
haplotypes RTR and QMG, which are present in several human populations in almost equal 
proportions. In the studies with the cellular model of retroviral IL-12Rβ1 expression the 
QMG variant was somewhat higher expressed and showed slightly higher responses upon 
IL-12 stimulation as compared to the RTR variant [5], while both variants responded similar 
to IL-23 stimulations [10]. This is in line with the earlier finding that the T cells from RTR 
homozygotes appeared to respond less well upon IL-12 stimulation [9]. In addition, it was 
found that the RTR haplotype is overrepresented in Japanese tuberculosis patients [9]. 
The latter indicates that a reduction of the Th1 immune responses may play a role in the 
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indicate that the type I immunity in tuberculosis patients is impaired. It was found that in the 
blood cells from tuberculosis patients a transcript signature was found that indicated a typical 
type I interferon signaling which coincides with a repressed IFN-γ mediated signaling [11]. 
Furthermore, it was shown that the IFN-γ production of T cells in TB patients was strongly 
suppressed, which recovered during treatment with antibiotics [12] (R. Hari Dass, submitted 
for publication).
The three R214Q, T365M and R378G polymorphisms are strongly linked. The strong, but 
not 100% linkage suggests that other less common haplotypes exist, for example RMG, RTG, 
QTR or QMR. Whether one or more of these variants exist and whether they are functionally 
distinct from the wild type receptor is unknown. This would be of interest to know if such 
a haplotype is over- or underrepresented in a certain patient group, either with particular 
infections or in autoimmune disease.
The variants S74R, A91T, R156H, H438Y, A525T and G594E are abundantly expressed 
at the cell surface and are fully functional (Table 1). The R156H variant is present in several 
populations, while the S74R and the A91T variant are rare variants that were identified in 
MSMD patients. The H438Y, A525T and G594E variants were identified in tuberculosis 
patients [5]. These six amino acid substitutions are considered to be harmless polymorphisms 
and not disease causing deleterious mutations. For example, the A91T variation was found in 
a Chinese patient who initially presented with a chronic skin infection with a poorly virulent 
mycobacterium and eventually died from a brain infection (personal communication with 
Dr. Sun Dong-Jie). Using our cellular model, the A91T variant was characterized as a fully 
functional variant (unpublished data). Thus, this variation could not explain why the immune 
system of the patient had failed to control the mycobacterial infection. More extensive 
analyses of immune responses in the patient were unfortunately not performed.
Amino acid substitutions in the second exon of IL12RB1 are probably harmless 
polymorphisms, because this exon (encoding aa 21 to aa 42) seems to be dispensable for 
sufficient receptor function. Investigation of exon-skipping, to sidestep the consequences 
of premature stop codons within the second exon, showed that a protein product without 
the amino acids encoded by the second exon was functional [13]. The deletion of the exon 
resulted in a reduction of 90% in receptor expression, while the receptor lacking exon 2 
responded similar to IL-12 and IL-23 stimulations as compared to the wild type receptor 
[13]. The response is probably still enough for sufficient immunity against non-tuberculous 
Mycobacteria or non-typhoid Salmonellae. Thus far, all reported cases with complete or 
nearly complete IL-12Rβ1 deficiency, had more impact on receptor expression. The cases with 
partial IL-12Rβ1 deficiency showed more than 250 times reduction in receptor expression. 
The -2C>T variation within the Kozak consensus sequence was found occasionally 
within the IL12RB1 transcripts of MSMD patients (unpublished data). This variation could 
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first three bases before the ATG start codon are underrepresented in eukaryotic transcripts [14]. 
The -2C>T variation in the transcript of IL12RB1 appeared to be a functional polymorphism 
with no impact on the translation and the cell surface expression of the receptor ([7] and 
chapter 2 of this thesis). This was determined with the use of our cellular model, in which the 
IL-12Rβ1 was retrovirally expressed, using an expression vector containing the open reading 
frame of IL12RB1 and 17 bases before the ATG start codon. To ascertain that the -2C>T has 
no influence on the transcriptional activity of the natural transcript an in vitro translation 
assay should be performed using RNA material from T cells from patients and controls.
5. Conclusion
Recent research into the genetic nature of IL-12Rβ1 deficiencies gave insights for the diagnosis 
of MSMD and the role of IL-12 and IL-23 in cellular immunity. Only mutations leading to 
severe IL-12Rβ1 deficiency impair immunity sufficiently to enhance the susceptibility to 
infections with otherwise poorly pathogenic Mycobacteria and to Salmonellae. Variations 
in IL-12Rβ1 leading to weak or moderate changes in expression and function can be 
considered as harmless polymorphisms, which may be associated with subtle differences in 
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CHAPTER 3
IL-23 and IL-12 responses in activated human T cells 
retrovirally transduced with IL-23 receptor variants
Roelof A. de Paus, Diederik van de Wetering,
Jaap T. van Dissel, Esther van de Vosse.
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Interleukin-23 (IL-23) is a regulator of cellular immune responses involved in controlling 
infections and autoimmune diseases. Effects of IL-23 on T cells are mediated via a receptor 
complex consisting of an IL-12Rß1 and a specific IL-23R chain. The R381Q and P310L 
variants of the IL-23R were recently reported to be associated with autoimmune diseases, 
suggesting they have an effect on IL-23R function. To investigate this matter, these variants 
and a newly identified variant, Y173H, were retrovirally transduced into human T cell blasts 
and functionally characterized by measuring the IL-23-induced signal transduction pathway 
(i.e., STAT1, STAT3 and STAT4 phosphorylation), and IFN-γ and IL-10 production. No 
differences were detected between the genetic variants and wild-type in the function of the 
IL-23R-chain. Furthermore, while comparing IFN-γ and IL-10 production in response to IL-
23 and IL-12, we found IL-23 to be a more potent IL-10 inducer, and IL-12 a more potent 
IFN-γ inducer. In addition, IL-23 also exerted a minor IL-12-like effect by inducing IL-
23R-independent, IL-12Rß1-dependent STAT4 phosphorylation and IFN-γ production. In 
conclusion, the reported association between R381Q and P310L variants of the IL-23R and 
autoimmune diseases does not depend on differences in functional activity between wild-












































Interleukin-23 (IL-23) is a member of the IL-12 family of cytokines which plays an essential 
role in the cellular immune response. IL-12 directs Th1 polarization and induces IFN-γ 
release by CD4+ T-cells in concert with IL-27 or IFN-α (Hibbert et al., 2003; Lucas et al., 
2003). IL-23 plays a role in the maintenance of immune responses by controlling T cell 
memory function (Frucht, 2002) and by influencing the proliferation and survival of IL-17-
producing Th17 cells (Bettelli et al., 2007). Furthermore, IL-23 can shape Th1-immunity via 
CD3+CD56+ T cells, through the production of IFN-γ early in the immune response (Van de 
Wetering, manuscript in preparation). IL-23 and IL-12 are heterogenic cytokines composed 
of a shared IL-12p40 subunit bound to an IL-23p19 or IL-12p35 subunit, respectively. IL-
23 and IL-12 signal through a common IL-12Rß1 chain complemented by the IL-23R and 
the IL-12Rß2 (Trinchieri et al., 2003). IL-12Rß1 is expressed on lymphocytes and can be 
upregulated via activation and costimulation of the T-cell and by the cytokines IL-2, IL-7 and 
IL-15 (Wu et al., 1997). The IL-12Rß2 is only expressed on CD4+ T cells after activation 
(Gately et al., 1998), whereas the membrane expression patterns of the IL-23R chain are 
still undefined. IL-23R transcripts are however found in bone marrow and in various T cell 
subsets (Parham et al., 2002). 
The IL-12 and IL-23 receptor complexes signal via JAK2 and STAT modules to regulate 
gene expression (Parham et al., 2002). IL-12 activates STAT4 thereby inducing IFN-γ 
(Watford et al., 2004) and IL-10 production in various T-cell subsets (Meyaard et al., 1996; 
Mehrotra et al., 1998). IL-23 activates STAT1, STAT3, STAT4 and STAT5 and can induce 
IFN-γ, IL-10 and IL-17 depending on the celltype (Parham et al., 2002; van den Eijnden et 
al., 2005). 
IL-23 is important in controlling mucosal host defenses (Happel et al., 2005; Uhlig et al., 
2006) and is involved in autoimmune diseases such as inflammatory bowel diseases (IBD) 
(McGovern and Powrie, 2007), psoriasis (Torti and Feldman, 2007) and rheumatoid arthritis 
(Kim et al., 2007). Patients with Mendelian susceptibility to mycobacterial disease (MSMD) 
due to IL-12Rß1 or IL-12p40 deficiency lack both IL-12 and IL-23 mediated signaling, have 
impaired Th1 immunity and suffer from severe recurrent infections with poorly virulent 
Salmonella or Mycobacterium species (van de Vosse et al., 2004). 
Polymorphisms in the IL-23R chain may influence IL-23 responses. The polymorphism 
P310L occurs at a frequency of 2-30 % and the R381Q polymorphism at a frequency of 0-17 
% depending on the population. The R381Q allele confers protection against IBD (Duerr 
et al., 2006), psoriasis (Capon et al., 2007), ankylosing spondylitis (Rueda et al., 2008), 
and graft versus host disease after bone marrow transplantation (Elmaagacli et al., 2008). 
The P310L allelic variant was overrepresented in patients with Grave’s Disease (Huber et 










































P310L variants of the IL-23R may be functionally different. To investigate this matter we 
functionally characterized the IL-23R allelic variants P310L, R381Q and Y173H (a newly 
identified allele), as well as an IL-23R lacking the intracellular domain. 
We cloned the IL-23R variants into a retroviral expression vector and transduced them 
into T cell blasts (TCB). IL-23 and IL-12 responsiveness in signal transduction and cytokine 
production by the TCB were compared.
2. Materials and Methods 
2.1. Cloning IL-23R variants into a retroviral expression vector 
Full-length IL23R coding sequence was PCR amplified using cDNA from a healthy control. 
The PCR product of the wild-type allele (wtIL23R) was first cloned into pGEMT-Easy 
(Promega), variations were introduced by site directed mutagenesis (Higuchi et al., 1988). 
Three constructs were made with the variations, P310L, Y173H and R381Q. One construct 
designated as -∆23R was made by introducing an early stop codon (at aa 400) and an Y397F 
mutation. The IL23R constructs were released from the pGEM-Teasy vector by digestion 
with NotI and ligated into pLZRS–IRES–GFP (Heemskerk et al., 1997) or into pLZRS-
IRES-∆NGFR (Ruggieri et al., 1997). As negative controls vectors without an IL23R insert 
were used. All constructs were verified by sequencing. Helper-free recombinant retrovirus 
was produced after introducing the constructs into a 293T-based amphotropic retroviral 
packaging cell line, Phoenix (Kinsella and Nolan, 1996), using a calcium-phosphate 
transfection kit (Invitrogen). The virus producing cells were cultured for 2–3 weeks under 2 
µg/ml puromycin (Clontech) selection after which a 20 h supernatant was harvested. 
2.2. Cells, culture conditions and retroviral transduction 
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy donors by Ficoll 
separation and cultured in IMDM supplemented with 20 mM GlutaMAX, 10% FCS, 100 
U/ml Penicillin, 100 µg/ml Streptomycin (Invitrogen) supplemented with 30 U/ml IL-2 
(Proleucin, Chiron). T-cell blasts (TCB) were generated by stimulating PBMCs with 800 ng/
ml phytohemagglutinin (PHA) (Murex). On day 2, after PHA-stimulation, 0.5*106 TCB were 
transduced on a CH-296 coated (RetroNectintm, Takara Shuzo) 48-wells plate using 0.5 ml 
of virus containing supernatants as described previously (Heemskerk et al., 2001). On day 
10, cells were sorted on GFP or NGFR signal by fluorescence activated cell sorting (FACS) 
and restimulated in the presence of 800 ng/ml PHA and irradiated allogeneic PBMCs (pool 
from two donors) and irradiated B-LCL in a cellular ratio of 2:10:1 respectively. After each 
restimulation, cells were allowed to expand for at least 14 days. The cells were washed three 
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supplemented with 20 mM GlutaMAX, 10% FCS, 10% Horse serum (Gibco), 100 U/ml 
Penicillin, 100 µg/ml Streptomycin (Invitrogen) supplemented with 100 U/ml IL-2 and 50 
µM 2-mercaptoethanol (Merck) and transduced as described above. 
2.3. Co-transduction of IL-12Rß1 and IL-23R into IL-12Rß1-/- TCB 
TCB of a patient (TCBp1) with a null mutation in IL-12Rß1 were transduced as described 
above with one or two retroviral vectors. Namely the pLZRS-IRES-GFP vector in which 
one of the IL-12Rß1 variants (QMG or RTR) was cloned (van de Vosse et al., 2005) and 
the pLZRS-IRES-∆NGFR vector in which the wild-type IL23R (wtIL23R) or the P310L 
variant was cloned. As controls TCBp1 cells were transduced with empty vectors (GFP and 
∆NGFR). Cells were selected for comparable GFP and NGF-R expression by FACS sorting 
after staining the cells with a PE conjugated antibody against the NGF-R (BD biosciences).
 
2.4. FACS analysis 
To detect IL-23R expression two commercial IL-23R antibodies, the biotinylated BAF1400 
polyclonal and the PE conjugated FAB14001P monoclonal antibody (R&D Systems) and two 
IL-23R antibodies raised in-house in rabbits against peptides (FLB2, aa 343-352 and FLJ2, aa 
62-75) were used. Cells were blocked with 10% normal mouse serum or normal goat serum 
in PBS, 0.2% BSA (Fraction V, Sigma) and washed before labeling with antibody. The cells 
were washed three times and where necessary counterstained with streptavidine-PE (BD) or 
goat-anti-rabbit-PE (SouthernBiotech), washed again and analyzed on a FACScalibur (BD 
biosciences). 
2.5. Cytokine production analysis and proliferation assay 
1*105 TCB were cultured in 200 µl of culture medium in 96-wellsplates (Greiner bio-
one). The cells were stimulated with or without 2 µg/ml anti-CD2 (CLB-T11.1/1 and .2/1, 
Sanquin) and 2 µg/ml anti-CD28 (CLB-CD28/1, Sanquin) in the presence of various amounts 
of IL-23 or IL-12 (R&D). After two days 150 µl supernatant of each well was removed. 
The concentrations of IFN-γ, IL-10, TNF and IL-17 were determined by cytokine-specific 
ELISAs (Biosource). To the remaining cells 25µl of RPMI-medium (Invitrogen) containing 
0.5 µCi 3H-thymidine (PerkinElmer) was added. After 8 hours of incubation the cells were 
harvested and incorporated 3H was determined using a liquid scintillation counter (Wallac). 
Results were calculated as a stimulation index (ratio mean cpm of the test sample/mean cpm 
of the medium). 
2.6. STAT phosphorylation assays
To study signal transduction 105 TCB were pre-stimulated overnight in 150 µl culture 










































Thereafter the cells were pulsed with 10 ng/ml IL-23, 1 ng/ml IL-12, 6.8 ng/ml IL-12p40 
(Peprotech) or 6.8 ng/ml IL- 12p80 (Peprotech). For use in blocking experiments IL-23 and 
IL-12 were preincubated for 30 minutes with 5 µg/ml anti-IL-23p19 (R&D). The cells were 
fixed with paraformaldehyde and permeabilized with methanol. Then the cells were washed 
with PBS, 0.2% BSA, blocked with normal goat serum, and stained with the phospho-
specific antibodies pY701-STAT1-alexa 647, pY705-STAT3- PE, pY693-STAT4-alexa 647 




3.1. Retroviral transduction of IL-23R alleles results in functional IL-23 receptor complexes 
We used a retroviral expression system to study the impact of various IL-23R polymorphisms 
on the function of the IL-23 receptor in normal control PHA stimulated TCB that express IL-
12Rß1. The retroviral expression vector, pLZRS, ensures transcription and expression of the 
IL23R gene and green fluorescent protein (GFP) genes in tandem and allows for selection of 
transduced cells by FACS for the GFP signal. Transduction efficiency was typical between 
5 and 20%; after FACS sorting 96-99% (98% average) of the cells were GFP positive. The 
IL-23 responses of sorted TCB cultures transduced with the wild-type and the P310L IL-23R 
variant (TCB-wtIL23R and TCB-310L) were compared with GFP transduced (TCB-GFP) 
and untransduced (TCB) cultures. In the absence of anti-CD2 and anti-CD28 neither IL-
23 nor IL-12 induced any effect (data not shown). Therefore all subsequent cultures were 
stimulated with cytokines in the presence of anti-CD2 and anti- CD28. IL-12 induced IFN-γ 
and IL-10 production in all cultures, indicating that IL- 12Rß1 and IL-12Rß2 are present 
on all cells (Fig. 1A and 1B). In response to IL-23 stimulation TCB-wtIL23R and TCB-
310L produced large amounts of IFN-γ (Fig. 1A) and IL-10 (Fig. 1B). TCB and TCB-GFP 
produced a small amount of IFN-γ (Fig. 1A) but no IL-10 (Fig. 1B) in response to increasing 
doses of IL-23. Tumor necrosis factor (TNF) or IL-17 production was not detectable in any 
of the cultures (data not shown).
3.2. Detection of IL-23R expression on the cell membrane 
To detect IL-23R expression on the membrane FACS analysis was performed with two 
commercially available IL-23R antibodies (BAF1400 and FAB14001P; R&D systems) 
as well as two antibodies (FLB2 and FLJ2) raised in-house in rabbits against two IL-23R 
peptides. The FLB2 and FLJ2 antibodies specifically detect the immunizing peptides in an 























































































































Figure 1. IL-23 induces IFN-γ and IL-10 production via retrovirally expressed IL-23R. Normal 
TCB, GFP transduced TCB and TCB transduced with the wtIL23R or the 310L variant were tested 
for their IFN-γ (A) and the IL-10 (B) production in response to anti-CD2/anti-CD28 with or without 
various amounts of IL-23 or as a control to 1 ng/ml IL-12. The graph represents the average data of four 
donors, one donor was tested twice, the error bars indicate the standard deviation. 
TCB, TCB-GFP and TCB-IL23R cells were stained with these four IL-23R antibodies 
and identical staining patterns were detected (data not shown) even though we have shown 
in the paragraph above that a functional IL-23R is only present on the TCB-IL23R cells. 
Similar results were obtained with IL-23 responsive, NK-92 cells transduced with the IL-
23R construct and with IL-23 unresponsive, untransduced NK-92 cells (Van de Wetering, 
unpublished data). The antibody BAF1400 was recently used in a study to select a subset of 
CD45RO+ T cells that were however not analyzed for IL-23 responsiveness (Wilson et al., 
2007). We were able to stain the same subset of human CD45RO+ T cells with the BAF1400 
antibody (data not shown). Moreover, no staining with the BAF1400 was observed of IL-23 
responsive primary CD3+CD56+ T cells from various donors (Van de Wetering, unpublished 
data). 
3.3. Kinetics of IL-23 induced STAT phosphorylation 
It was previously reported that IL-23 induces STAT1, STAT3, STAT4 and STAT5 
phosphorylation (Parham et al., 2002). We have shown previously that IL-23 induces 










































CD3+CD56+ T cells (Van de Wetering, manuscript in preparation). We also found that 
phosphorylation of STAT1, STAT3 and STAT4 but not STAT5 in an IL-23R transduced 
NK-92 cell line (unpublished data). To assay IL-23 induced STAT phosphorylation kinetics 
in T cells, TCB containing IL-23R constructs (TCB-wtIL23R, TCB-310L) and TCB-GFP 
were pre-stimulated with anti-CD2 and anti-CD28 and subsequently stimulated for 5 to 60 
minutes with IL-23 or with IL-12. STAT1, STAT3, STAT4 and STAT5 phosphorylations were 
determined by intracellular FACS. IL-23 induced STAT1, STAT3 and STAT4 phosphorylation 
in TCB-wtIL23R and TCB-310L (Fig. 2A-C). STAT1 phosphorylation diminished after 15 
minutes, whereas STAT3 and STAT4 phosphorylation persisted. IL-12 induced STAT4 but 
no STAT1 or STAT3 phosphorylation in all cultures examined (data not shown). TCB-GFP 
cultures stimulated with 10 ng/ml IL-23 showed a small amount of STAT4 (Fig. 2C), but no 
STAT1 or STAT3 phosphorylation (Fig. 2A and 2B). STAT5 was strongly phosphorylated in 
cells pre-stimulated with anti-CD2 and anti-CD28, upon stimulation with IL-23 or IL-12 no 





































































































































































































Figure 2. Kinetics of IL-23 induced STAT phosphorylation. TCB transduced with the wild-type 
(wtIL23R), the 310L variant or GFP alone were stimulated with 10 ng/ml IL-23 for 0, 5, 15, 30 and 
60 minutes. The amount of STAT1 (A), STAT3 (B) and STAT4 (C) phosphorylation was determined 
by FACS using phospho-specific antibodies. The graph displays the mean fluorescence signal of three 
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3.4. IL-23 also exhibits a minor IL-12-like effect independent of IL-23R expression 
We observed that IL-23 induced in normal, untransduced TCB some STAT4 but no STAT1 
and STAT3 phosphorylation, which resulted in the production of small amounts of IFN-γ 
This effect may be induced by IL-23 itself or by potential IL-23-byproducts such as IL-
12p40 monomers or IL-12p40 dimers (IL-12p80). Therefore we determined whether a 
specific antibody against the IL-23p19 subunit could block the STAT4 phosphorylation 
and whether IL-12p40 or IL-12p80 alone could induce STAT4 phosphorylation. In normal, 
untransduced TCB prestimulated with anti-CD2 and anti-CD28 an anti-IL23p19 antibody 
was able to block 82% of the IL-23 induced STAT4 phosphorylation, while it did not block 
IL-12 induced STAT4 phosphorylation (Fig. 3). IL-12p40 or IL-12p80 did not induce STAT4 























Figure 3. IL-23 but not IL-12p40 monomers or homodimers induce IL-12-like IL-23R independent 
STAT4 phosphorylation. Normal TCB were stimulated in the presence of anti-CD2 and anti-CD28 
with 10 ng/ml IL-23, 1 ng/ml IL-12, 6.8 ng/ml IL-12p40, IL-12p80, or with IL-23 or IL-12 preincubated 
for 30 minutes with anti-IL-23p19. STAT4 phosphorylation was determined by FACS using a phospho-
specific antibody. Displayed are the mean minus the mean of the anti-CD2/ anti-CD28 stimulation and 
the standard deviations of eight measurements from two donors.
3.5. Effect of variations in the IL-23R on IL-23 induced IFN-γ and IL-10 production 
Variations in the IL-23R may influence IL-23 mediated responses. To investigate this we 
transduced TCB cultures with two IL-23R variants (TCB-173H and TCB-381Q). These two 
variants were compared with TCB-wtIL23R and with TCB transduced with a truncated form 
of the receptor (TCB-∆23R). TCB and TCB-GFP cultures were used as controls. IFN-γ and 
IL-10 production were determined after two days of culture in the presence of anti-CD2/anti-
CD28 with or without IL-23 or IL-12 (Fig. 4). No major differences in the IL-23 induced 
IFN-γ production by TCB-wtIL23R, TCB-173H and TCB-381Q cultures were detected. 
Although it appeared that IFN-γ production in response to IL-23 stimulation of TCB-
173H and TCB-381Q, as compared to the TCB-wtIL23R, reached a plateau at lower IL-23 










































of IFN-γ production in the TCB-∆23R culture, comparable with other cells lacking the IL-
23R: the control TCB and the TCB-GFP cultures (Fig. 4A). Comparable large amounts of 













































































Figure 4. The IL-23R variants do not differ in IL-23 induced cytokine production. TCB transduced 
with the constructs of the wtIL23R, the 173H- and the 381Q-variants were compared with normal 
TCB, TCB-GFP and TCB-.23R. The cell-lines were tested for IFN-γ (A) and IL-10 (B) production in 
response to various amounts of IL-23 or as a control to 1 ng/ml IL-12 in the presence of CD2/CD28. 
Displayed are the means and the standard deviation of two experiments with three donors each. 
3.6. IL-23 enhances IL-10 production relatively more than IFN-γ production 
We demonstrated that IL-23, similar to IL-12, is a potent inducer of both IFN-γ and IL-10. To 
compare the induction capacity of IL-23 to the induction capacity of IL-12 the ratios of IL-10 
and IFN-γ production were calculated (Fig. 5). All TCB cultures stimulated with anti-CD2 
and anti-CD28 produced around twenty times less IL-10 than IFN-γ (ratio ~ 0.05), a similar 
ratio was observed in response to IL-12. Addition of IL-23 to TCB lacking a functional 
IL-23R (TCB, TCB-GFP and TCB-∆23R) had no effect on the ratio, whereas addition of 
IL-23 to TCB with a functional IL-23R (TCB-wtIL23R, TCB-310L, TCB-173H and TCB-
381Q) increased the IL-10/ IFN-γ ratio by a factor five. No major differences were observed 































































Figure 5. Influence of IL-23R expression on the IL-10/ IFN-γ ratio after IL-23 and IL-12 
stimulation. The IL-10/ IFN-γ ratio was determined for each stimulation of the TCB cultures with anti-
CD2/anti-CD28 alone or together with 10 ng/ml IL-23 or 1 ng/ml IL-12. Displayed are the means and 
standard deviations of TCB (n=13), -GFP (n=13), -wtIL23R (n=13), -310L (n=6), -173H (n=6), -381Q 
(n=5) and -∆23R (n=3). 
3.7. Effect of variations in the IL-23R on signal transduction 
Although no difference was detected in IFN-γ or IL-10 production, a difference may exist in 
the production of an as yet unknown factor. To analyze putative effects of IL-23R variants 
we assayed STAT phosphorylation in the TCB cultures transduced with the variants R381Q 
and Y173H together with the controls (TCB-wtIL23R, TCB, TCB-GFP and TCB-∆23R). 
Cells were pre-stimulated with anti-CD2 and anti-CD28 followed by a short incubation 
with or without IL-23. STAT1, STAT3 and STAT4 phosphorylation were analyzed by FACS 
using phospho-specific antibodies. STAT 1 and STAT3 phosphorylation was induced by IL-
23 in all TCB cells transduced with an IL-23R variant (Fig. 6A and 6B). Truncation of the 
intracellular domain of the IL-23R completely abolished STAT1 and STAT3 phosphorylation 
(data not shown). IL-23 induced STAT4 phosphorylation was high in all the cells transduced 
with IL-23R variants (Fig. 6C). As observed before, IL-23 also induced a low amount of 
STAT4 phosphorylation due to the IL-12-like effect of IL-23 in cells lacking a functional IL-
23R (control TCB, TCB-GFP) (Fig. 6C). 
3.8. Effect of IL-23R variants on IL-23 induced proliferation 
IL-23 has been reported to affect proliferation and survival of T cells (Bettelli et al., 2007). 
We tested the IL-23 and IL-12 induced proliferation using a tritium thymidine incorporation 
assay of TCB, TCB-GFP and TCB transduced with one of the natural variants of the IL-
23R. IL-12 had no effect on the proliferation. TCB and TCB-GFP had no increased tritium 
incorporation upon IL-23 stimulation (data not shown). Cells carrying an IL-23R variant 
incorporated 1.2 to 1.5 times more tritium upon IL-23 and anti-CD2/anti-CD28 stimulation 
compared to anti-CD2/anti-CD28 stimulation alone (data not shown). No significant 


































































































Figure 6. The IL-23R variants do not differ in IL-23 induced STAT phosphorylation. Normal TCB, 
TCB transduced with GFP and TCB transduced with the various IL-23R constructs (wtIL23R, 173H 
and 381Q) were stimulated with 10 ng/ml IL-23 for 15 (STAT1) or 30 minutes (STAT3 and STAT4). 
The amount of STAT1 (A), STAT3 (B) and STAT4 (C) phosphorylation was determined by FACS using 
phospho-specific antibodies. Displayed is the mean fluorescence signal of one representative of three 
experiments.
3.9. Combined effects of IL-12Rß1 and IL-23R variations on IL-23 driven responses 
The IL-23 receptor does not only consist of the IL-23R chain but also of the IL-12Rß1 chain, 
therefore common IL-12Rß1 haplotypes (QMG and RTR) may differentially influence the 
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an IL-12Rß1 null mutation. TCBp1 cells were transduced with a retroviral vector expressing 
an IL-12Rß1 allele in tandem with GFP, or transduced with a retroviral vector expressing 
an IL-23R allele in tandem with a truncated NGF-R as marker, or co-transduced with both. 
We selected the cells for expression of the markers and examined the cytokine release in 
response to IL-12 and IL-23. TCBp1 transduced with the IL-12Rß1 alleles QMG or RTR 
produced IFN-γ (Fig. 7A) and IL-10 (Fig. 7B) in response to IL-12. The IL-12 induced IL-
10 production was reduced for the QMG allele when the IL-23R was co-expressed. IL-23 
induced low amounts of IFN-γ, but relatively more IL-10 in cultures of TCBp1 co-transduced 
with both receptor subunits. No major differences were detected in the IL-23 responses 
between the TCBp1 carrying various combinations of IL-12R.1 and IL-23R chains. As 
observed before, IL-23 induced IFN-γ (Fig. 7A) and small amounts of IL-10 (Fig. 7B) in the 
IL-12Rß1 expressing cultures (TCBp1-QMG, TCBp1-RTR) but not in the TCBp1, TCBp1-
wtIL23R or TCBp1-310L cultures. This IL-12-like effect of IL-23 on the IFN-γ production 
by TCBp1-QMG and TCBp1-RTR was relatively high as compared with the effect of IL-23 
on the TCBp1 expressing both receptor chains, probably due to overexpression of the IL-
12Rß1 on these cells.
 
Figure 7 
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Figure 7. Influence of common IL-12Rß1 and IL-23R polymorphisms on the IL-23 response. 
The IL-23 responsiveness was tested on TCBp1-QMG-wtIL23R, TCBp1-QMG-310L, TCBp1-RTR-
wtIL23R and TCBp1-RTR-310L and compared with the responsiveness of TCBp1 and controls 
(TCBp1-GFP-NGFR, -QMG, -RTR, -wtIL23R and -310L). The cells were stimulated with or without 
various concentrations of IL-23 or IL-12 in the presence of anti-CD2/anti-CD28. IFN-γ (A) and IL-10 
(B) production were measured by ELISA. Displayed are the means and the standard deviations of a 











































The main finding of the present study is that the natural variants of the human IL-23R, 
P310L, Y173H and R381Q do not differ in receptor transfer function from the wild-type 
allele. This conclusion is based on analysis of IL-23R downstream intracellular signaling 
pathways (STAT1, STAT3 and STAT4 phosphorylation) following ligand binding, as well 
as the IFN-γ and IL-10 production of human T cells retrovirally transduced with the IL-23R 
variants. In recent population studies, two of the IL-23R variants were linked to increased 
incidence of autoimmune disease. The present findings show that such an association cannot 
readily be explained by differences in the function of the IL-23R variants after binding of 
their natural ligand. Moreover, we found that IL-23 stimulation results in a ratio of IFN-γ 
-to-IL-10 production that is distinct from that induced by IL-12. Finally, IL-23 exhibited 
a minor IL-12-like effect by inducing STAT4 phosphorylation dependent on IL-12Rß1 but 
independent of IL-23R expression. 
To reach the conclusion that the IL-23R variants do not differ in receptor function, we 
retrovirally expressed the IL-23R in human T-cells and analyzed its functional activity. In 
this respect, the following points should be considered. First, although there is consensus 
in the literature that T-cells are the relevant effector cells of IL-23 mediated signaling in 
humans and thus provide a relevant model to study these effects, the TCB used in this study 
may not fully resemble the T-cell subsets that are normally IL-23 responsive, even though 
TCB appear to have all the factors to enable STAT signaling and IFN-γ production up to 
biological active concentrations (Janssen et al., 2002). Second, the concentrations of stimuli 
chosen may not resemble physiological relevant conditions. The present approach cannot 
exclude small subtle differences in the lowest range of ligand binding. However we failed to 
detect differences within the range of IL-23 stimulation (0.4 to 10 ng/ml) which resulted in 
reproducible cytokine production. Third, the STAT1, STAT3 and STAT4 phosphorylation and 
subsequent IFN-γ and IL-10 production may not be the only important responses. However, 
both cytokines are important mediators in controlling autoimmunity (Hill and Sarvetnick, 
2002) and other read-out functions of IL-23R ligand binding are presently unknown. Fourth, 
the overexpression of the IL-23R by the retroviral system could mask differences in effects 
due to alterations in transcript or protein stability. Furthermore, post-transcriptional and post-
translational modifications of normal or retroviral expressed IL-23R may differ, but thus far 
no findings suggest that such modifications occur. 
We show that the three variants P310L, Y173H and R381Q, were fully functional and 
not different in receptor function from the wild-type form. Several associations of the 
R381Q and P310L alleles with immune related diseases have been identified. Identifying 
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mean that the allele itself conveys a functional difference. The functional difference may 
be due to a variation that is merely linked to the single nucleotide polymorphism (SNP) 
under study. Indeed, several other SNPs in the IL-23R besides the R381Q polymorphism 
also correlated with decreased susceptibility for IBD (Cummings et al., 2007) and psoriasis 
(Capon et al., 2007). The SNP designated rs11465804 for instance is strongly linked to the 
R381Q polymorphism (Capon et al., 2007). These or other SNPs in the IL- 23R may be 
responsible for the observed associations with immune related diseases. We can however not 
exclude functional differences of the studied alleles due to an effect of these variants on the 
level of expression of the receptor, since we used overexpression constructs of the IL-23R. 
We demonstrated that IL-23 via its receptor induced STAT1, STAT3 and STAT4 
phosphorylation, but not STAT5 phosphorylation whereas IL-12 could only induce STAT4 
phosphorylation. Both cytokines can induce IFN-γ and IL-10, although IL-23 is a more potent 
inducer of IL-10 in this system. In this way, IL-23 and IL-12 have a different impact on the 
balance of pro- and anti-inflammatory immune responses. Furthermore IL-23 enhanced the 
proliferation of IL-23R transduced human T-cells slightly, whereas IL-12 did not. 
We discovered that in addition to the signaling through the IL-23 receptor, IL-23 also 
exhibits an IL-12-like effect. This effect is independent of IL-23R expression and results 
through phosphorylation of small amounts of STAT4 in the production of small amounts 
of IFN-γ. The effect could be blocked by a specific antibody against IL-23p19, while IL-
12p40 or IL-12p80 could not induce this IL-12 like effect, indicating that IL-23 itself and 
not IL-23 byproducts mediate this effect. These findings demonstrate that IL-23 is also able 
to signal through another receptor besides the IL-23 receptor, albeit with a much lower 
efficiency. Because this signal transduction, similar to IL-12 signaling, only involves STAT4 
phosphorylation, an obvious candidate would be the IL-12 receptor. Indeed, in T cells from 
an IL-12Rß1-/- patient this IL-12-like effect of IL-23 was only observed after transduction 
with an IL-12Rß1 expression construct, indicating that the IL-12Rß1 chain is indeed involved 
in this signaling. Whether the IL-12Rß2 chain or another receptor chain is involved and to 
which extent IL-23 can achieve this IL-12-like effect in vivo remains to be investigated. 
Based on our findings we conclude that IL-23 exerts an IL-12-like effect that depends on 
IL-12Rß1 and not on IL-23R expression. Cells from an IL-12Rß1-/- patient were used to 
study the influence of various combinations of IL-12Rß1 and IL-23R polymorphisms. The 
QMG and RTR alleles of the IL-12Rß1 in the IL-23 receptor complex were comparable 
in IL-23 responsiveness. When the IL-23R was co-expressed with the QMG allele the IL-
12 responsiveness was decreased. This effect was however seen with TCB of one specific 
patient, in a model of overexpression of both receptor chains, while normal TCB did not 
show decreased responsiveness for IL-12 when transduced with the IL-23R. 
We have provided ample evidence that we could express functional IL-23R in human T 










































T cells, membrane expression of IL-23R could not be detected by FACS using four different 
antibodies, suggesting that perhaps the secondary structure of the IL-23R protein hampers 
detection with peptide-raised antibodies. One of the commercially available antibodies 
(BAF1400) was previously used in a study to describe the cytokine profile of IL-23R positive 
CD45RO+ T cells (Wilson et al., 2007). The authors did not test the IL-23 responsiveness 
of the ‘IL-23R positive’ cells, which might have proven whether or not these cells indeed 
expressed a functional IL-23R. We were also able to stain this subset of human CD45RO+ 
T cells with the BAF1400 antibody. We were however unable to obtain specific staining of 
various IL-23 responsive cells that expressed IL-23R naturally or retrovirally with this or 
three other antibodies. Based on our results we conclude that none of the available ‘IL-23R 
antibodies’ is specific for the IL-23R. Generation of new antibodies directed against a larger 
part of the IL-23R or the full-length protein may solve this problem in the future. 
We conclude that IL-23 can induce STAT1, STAT3 and STAT4 phosphorylation via the IL-23R, 
but that IL-23 also exhibits IL-12-like effects, via STAT4 phosphorylation, dependent on IL-
12Rß1 but independent of IL-23R expression. The P310L, Y173H and the R381Q variations 
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CHAPTER 4
IL-23 modulates CD56+/CD3- Natural Killer Cell and 
CD56+/CD3+ Natural Killer-like T Cell 
function differentially from IL-12
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Natural killer (NK) and natural killer-like T (NK-like T) cells play an essential role in linking 
innate and adaptive immunity, through their ability to secrete interferon-g (IFN-g). The exact 
trigger initiating production of IFN-g is uncertain. Antigen presenting cell (APC)-derived 
interleukin-12 (IL-12) is thought to be the classical IFN-g inducing cytokine, but requires 
an additional stimulus such as IFN-γ itself. IL-23 and IL-18 are among the first cytokines 
secreted by APC in response to binding of pathogen-associated molecular patterns (PAMPs) 
such as lipopolysaccharide (LPS). Thus, early APC-derived IL-23 may be an initial trigger of 
IFN-g production in NK and NK-like T cells. 
Herein, we characterized the effect of IL-23 on IFN-g secretion by NK and NK-like T 
cells. Our findings show that IL-23 and IL-18 synergistically elicit IFN-g production in NK-
like T cells but not in NK cells. In contrast, IL-12 together with IL-18 induced secretion of 
IFN-g in both populations. The observed synergy between IL-23 and IL-18 in NK-like T cells 
coincided with IL-23 mediated up-regulation of IL-18Ra. Furthermore, IL-23 up-regulated 
CD56 expression in NK-like T cells and, together with IL-18, induced proliferation of NK 
and NK-like T cells. We postulate a role for APC-derived IL-23 in the activation of NK and 
NK-like T cell early in infection and in shaping Th1-differentiation, via induction of IFN-g, 












































Innate immunity plays an essential role in the defense against pathogens. NK cells constitute 
an important arm of the innate immune system and several murine models have shown NK 
cell-derived cytokines to be critical in the early response against intracellular pathogens such 
as Salmonella typhimurium (1;2) and Mycobacterium tuberculosis (3). Early in infection, NK 
cells are thought to be the primary source of interferon-g (IFN-γ) (4-6), shaping the acquired 
immune response through differentiation of T helper (Th) cells to the Th1 subclass (6;7). At 
a later stage of infection, Th1 cells become the predominant source of IFN-γ. 
Host defense against intracellular bacterial pathogens such as Salmonellae and 
Mycobacteria is dependent on the type-1 cytokine pathway (8). Generally thought, this 
pathway is initiated by bacterial stimulation of pattern recognition receptors on APC, 
resulting in the production of interleuk in-23 (IL-23), IL-12 and IL-18 (9). IL-12 and IL-
18 subsequently induce IFN-γ production in NK cells and Th1 cells by binding to their 
respective receptors (10), while IL-23 is known to induce IFN-γ production in naïve T cells 
and in memory T cells (11). IFN-γ in turn binds to the IFN-γR on the macrophages and 
dendritic cells to enhance their bactericidal activity and antigen presentation and increase 
production of IL-12 (12). 
Interleukin-23 and IL-12 are heterogenic cytokines composed of a shared IL-12p40 
subunit bound to an IL-23p19 or IL-12p35 subunit, respectively. IL-23 and IL-12 signal 
through a common IL-12Rβ1 chain complemented by the IL-23R and the IL-12Rβ2 
respectively. While IL-12Rβ1 is constitutively expressed in naive CD4+ T cells, CD56+ NK-
like T cells and NK cells (13;14), IL-23R and IL-12Rβ2 expression are critical for the ability 
to respond to IL-23 and IL-12, respectively. 
The role of IL-23 in shaping the immune response is poorly defined. IL-23 is produced 
by APC in response to PAMPs like LPS. Moreover, IL-23 rather than IL-12 is the first type 
1 cytokine released by activated proinflammatory macrophages (9). To induce production of 
IL-12 by monocytes and macrophages, IFN-γ signaling is required in addition to a PAMP (9). 
In dendritic cells both IFN-g and IL-4 can enhance PAMP induced IL-12 production (15). 
Since IL-23 is expressed early in infections (16) and capable of inducing IFN-γ (17-19), we 
hypothesized that IL-23 may serve as a factor important in initiating early Th1 differentiation 
by inducing the extra signal needed, IFN-γ, for APC to produce IL-12 in response to pathogens 
or PAMPs. In order to achieve this, IL-23 needs to target cells of the innate immune system 
and induce IFN-γ production in these cells. NK and NK-like T cells may be candidate cells 
providing IFN-γ as they are part of the innate immune system and both known to express 
IL-12Rβ1 mRNA (14;20). Moreover, NK cells are reported to express IL23R mRNA (20). To 
verify this hypothesis, we tested the ability of IL-23 to induce activation and IFN-g secretion 










































2. Materials and Methods
2.1. Cells and culture conditions
CD56+ cells were isolated from buffy coats from healthy donors (Sanquin, Leiden, The 
Netherlands) by Ficoll-Amidotrizoate density gradient centrifugation and subsequent 
selection using anti-CD56 MACS beads (Miltenyi Biotech, Utrecht, The Netherlands). For 
the proliferation assay, CD56+ bead isolated cells were labeled with PE-labeled anti-human 
CD3 (BD PharMingen, Amsterdam, The Netherlands) and CD3- cells were sorted with a 
FACSVantage SE (BD Biosciences, Amsterdam, The Netherlands). Cells were cultured in 
Iscove’s modified Dulbecco’s medium (IMDM) (Bio-Whittaker) supplemented with 20 mM 
GlutaMAX (Gibco/Invitrogen, Breda, The Netherlands), 10% FCS, 100 U/ml Penicillin, 
100 µg/ml Streptomycin (Gibco/Invitrogen, Breda, The Netherlands).
2.2. FACS analysis
To assess STAT phosphorylation by FACS analysis, overnight-rested CD56+ bead isolated 
cells were stimulated with recombinant human 10 ng/ml IL-23 or 1 ng/ml IL-12 for times 
indicated. Cells were fixed using 4% formaldehyde and permeabilised with 90% methanol. 
Cells then were labeled directly with anti-phosphorylated STAT1 (pY701)-alexa 647, anti-
phosphorylated STAT3 (pY705)-PE or STAT3 (pY705)-alexa 647, anti-phosphorylated 
STAT4 (pY693)-alexa 647 or anti-phosphorylated STAT5 (pY694)-PE (BD PharMingen). 
CD56+ magnetic bead isolated cells were stained in combination with anti-human CD3 and 
anti-human CD56.
For intracellular staining for IFN-γ, CD56+ isolated cells were seeded 105 cells/well in 
96-well plates and stimulated with IL-23 (R&D Systems, Abingdon, United Kingdom), IL-
12 (R&D Systems), IL-18 (MBL, Woburn, USA) or a combination of these cytokines for 
48 hours. The last 6 hours of stimulation BD GolgiPlug (BD PharMingen) was added (final 
concentration 1:1000). Cells were fixed in 4% paraformaldehyde (Sigma, Zwijndrecht, The 
Netherlands) and permeabilised in 90% methanol. Cells were stained with Alexa 647-labeled 
anti-human IFN-γ in combination with PE-labeled anti-human CD56 and FITC-labeled anti-
human CD3 (BD PharMingen). To asses IL-18Ra expression, overnight rested CD56+ beads 
isolated cells were stimulated for 2 days with IL-23 10 ng/ml, IL-12 1 ng/ml, IL-18 100 
ng/ml or a combination of these cytokines. Cells were directly labeled with PE-conjugated 
mouse-anti-human IL-18Ra mAb FAB840P (R&D Systems) in combination with with FITC 












































To determine cytokine production, overnight rested CD56+ beads isolated cells were seeded 
100.000 cells per well and stimulated for 48h with IL-23, IL-12, IL-18 or a combination of 
these cytokines in a 96-well plate in a final volume of 200 ml. Concentrations are indicated in 
the figures. The concentration of IFN-γ, IL-10 and IL-17 in the supernatants was determined 
by cytokine-specific ELISAs (Biosource, Etten-Leur, The Netherlands). For proliferation 
assays in CD56+ isolated cells, cells were carboxyfluorescein (CFSE) (Celltrace, Invitrogen, 
Breda, The Netherlands) labelled. 106 cells were labelled in 2 ml medium containing 1 μM 
CFSE for 15 minutes. After labelling cells were washed twice and seeded 105 cells/well in 
96 well plate (Costar, Badhoevedorp, The Netherlands). Cells were stimulated with 10 ng/
ml IL-23, 1 ng/ml IL-12, 100 ng/ml IL-18 or a combination of these cytokines. Four days 
after stimulation cells were directly labelled with PE-labelled anti-human CD3 and Alexa 
647-labelled anti-human CD56 and analyzed on a FACS Calibur (BD Bioscience). 
3. Results
3.1. IL-23 synergizes with IL-18 in inducing IFN-γ production in primary human CD56+ cells
IL-23 is one of the first cytokines produced by APC in response to PAMPs, while NK and 
NK-like T cells may be the first innate immune system cells to respond to IL-23. Therefore 
we determined whether IL-23 was able to induce IFN-g production in CD56+/CD3- NK 
and CD56+/CD3+ NK-like T cells. As IL-18 has been reported to stimulate Th1 responses 
synergistically with IL-12 by enhancing NK activity and IFN-γ production (21), we also 
tested the effect of IL-18 in combination with IL-23 on IFN-γ production. Isolated human 
CD56+ cells were analyzed by FACS for CD56 and CD3 expression. More than 90% of the 
cells were CD56+ and of these 30-70% were CD3+. To determine the kinetics of the IFN-γ 
production, CD56+ cells were stimulated for 4, 8, 24 and 48 hours with IL-12 or IL-23 with or 
without IL-18. IL-23 or IL-18 alone did not induce IFN-γ production at any time point (Fig. 
1A and table 1). IL-12 alone induced IFN-γ production 48 hours after stimulation. Four hours 
after stimulation, small amounts of IFN-γ were detected in supernatants from cells stimulated 
with IL-12 plus IL-18 (Fig. 1A). IL-23 plus IL-18 induced IFN-γ with slower kinetics and 
IFN-γ was not detected until 8 hours of stimulation. Highest amounts of IFN-γ were detected 
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Figure 1. IL-23, in combination with IL-18, induces IFN-γ in primary human CD56+ cells. 
(A) Anti-CD56 MACS bead isolated cells were rested overnight and then left unstimulated or stimulated 
with indicated concentrations of IL-23 or IL-12 plus or minus IL-18. Supernatants were collected 4, 
8, 24 and 48 hours after stimulation and IFN-g concentration was measured by ELISA. Both IL-23 
and IL-12 synergize with IL-18 in the induction of IFN-g. (B) Overnight rested CD56+ cells were 
left unstimulated or stimulated with indicated concentrations of IL-23 or IL-12 in combination with 
various concentrations of IL-18 for 48 hours. IFN-γ concentrations were determined by ELISA. One 
representative of experiments with cells from 3 donors.
To determine the response to various concentrations of IL-23 and IL-12 in combination with 
various concentrations of IL-18, CD56+ cells were stimulated for 48 hours. Again, IL-23 or 
IL-18 alone did not induce IFN-g production in CD56+ cells (Fig. 1B). However, when IL-
23 was combined with IL-18, we observed synergistic effects on IFN-γ secretion (Fig. 1A 
and 1B). IL-12 alone induced minimal IFN-g production. As expected, a synergistic effect 
on IFN-g production was observed when IL-12 and IL-18 were combined (Fig. 1A and 1B). 
Both IL-23 and IL-12 showed strongest synergy with the highest concentrations of IL-18 
(Fig. 1B). 
Furthermore, as IL-15 is known to enhance IL-12 induced IFN-γ production, we tested 
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by CD56+ cells, however, this synergy was not as strong as the synergy observed between 
IL-18 and IL-23 (data not shown). We also stimulated CD56+ cells with IL-18 in combination 
with IL-12 plus IL-23. IL-23 slightly inhibited the effect of IL-12 (data not shown). As 
IL-23 is reported to play a role in the induction of IL-17, we tested IL-17 production in 
these supernatants as well. However, no IL-17 was detected (data not shown). In antiCD2/
antiCD28 activated CD56+ cells, IL-23 inhibited the production of the Th2 cytokines IL-4 
and IL-13 (data not shown). 
3.2. IL-23 induces STAT phosphorylation in CD56+/CD3+ NK-like T, but not in CD56+/CD3- 
NK cells
IL-23 has been reported to induce STAT1, STAT3, STAT4 and STAT5 tyrosine phosphorylation 
in the human T cell line Kit225 (20). Primary human CD56+ can be divided into CD56+/CD3- 
NK cells and CD56+/CD3+ NK-like T cells. To test in which of these CD56+ populations 
IL-23 induces STAT phosphorylation, we stimulated CD56+ cells for 30-90 minutes with 
IL-23 and determined STAT phosphorylation by FACS analysis, using antibodies specifically 
directed against phosphorylated STAT1, STAT3, STAT4 or STAT5, in combination with anti-
CD3 and anti-CD56. IL-23 induced both STAT3 and STAT4 phosphorylation in CD56+/CD3+ 
NK-like T cells, but not in CD56+/CD3- NK cells (Fig. 2). We did not observe any STAT1 or 
STAT5 phosphorylation in response to IL-23 (Fig. 2). These results suggest a direct effect 
of IL-23 on CD56+/CD3+ NK-like T cells. For control purposes, cells were also stimulated 
with IL-12 and IL-2. IL-12 induced STAT4 phosphorylation in both NK and NK-like T cells 
(Fig. 2). IL-2 induced STAT5 phosphorylation in both CD3+ and CD3- populations (data not 
shown). The fact that only CD3+ NK-like T-cells and not in CD3- NK cells are responsive 
to IL-23 may indicate that only NK-like T cells express the IL-23R. To date, no antibody is 
available for the detection of the IL-23R on the cell membrane (22) Instead, we analyzed 
IL23R mRNA expression in both CD3+ NK-like T and in CD3- NK cells by real time PCR and 
observed a 5-6 fold higher expression of IL23R mRNA in CD3+ NK-like T cells, compared 



























































































Figure 2. IL-23 induces STAT phosphorylation in CD56+/CD3+ NK-like T but not in CD56+/CD3- 
NK cells. Anti-CD56 MACS bead isolated cells were rested overnight, and subsequently stimulated 
with 10 ng/ml IL-23 or 1 ng/ml IL-12 for indicated times. Cells were labelled with anti-human pSTAT1, 
pSTAT3 or pSTAT4-Alexa 647 in combination with anti-human CD3-FITC and anti-human CD56-
PE and analyzed by FACS. Graph shows fold increase of the mean fluorescence intensity (mfi) as 
compared to medium stimulated cells. IL-23 induces phosphorylation of STAT3 and STAT4, but not 
STAT1 and STAT5, in CD56+/CD3+ NK-like T cells, but not in CD56+/CD3- NK cells. IL-12 induces 
STAT4 phosphorylation in both populations. One representative of experiments with cells from 3 
donors.
3.3. IL-23, in concert with IL-18, induces IFN-γ in CD56+/CD3+ NK-like T, but not in CD56+/
CD3- NK cells.
In the STAT phosphorylation assay we observed a specific effect of IL-23 on CD56+/CD3+ 
NK-like T cells. We next wanted to determine whether these IL-23 responsive CD56+/CD3+ 
NK-like T cells were responsible for the observed IFN-γ production by CD56+ cells.CD56+ 
cells were stimulated with IL-23, IL-12, IL-18, combinations of these cytokines, or left 
unstimulated two days. Intracellular IFN-γ production, as well as CD56 and CD3 expression 
were assessed by FACS, to compare IFN-γ production by CD56+/CD3- NK cells and CD56+/
CD3+ NK-like T cells. Unstimulated cells did not produce IFN-γ (Fig. 3A and Table 1). 
In response to IL-12 or IL-23 or IL-18 alone no IFN-γ production could be detected (Fig. 
3B-D and Table 1). IL-12 in combination with IL-18 induced IFN-γ production in both NK 
cells and NK-like T cells (Fig. 3E and Table 1). In contrast, after stimulation with IL-23 in 
combination with IL-18, NK-like T cells produced IFN-γ, whereas NK cells did not (Fig. 3F 
and Table 1). Moreover, IL-23 plus IL-18 induced IFN-γ production only in CD56bright NK-
like T cells, whereas IL-12 plus IL-18 induced IFN-γ production in CD56bright and CD56dim 












































































































































































































































































Figure 3. IL-23 in combination with IL-18 induces IFN-γ production in CD56+/CD3+ NK-like T 
cell but not in CD56+/CD3- NK cells. Anti-CD56 MACS bead isolated cells were rested overnight and 
then left unstimulated (A) or stimulated with 1 ng/ml IL-12 (B), 10 ng/ml IL-23 (C), 100 ng/ml IL-18 
(D), 100 ng/ml IL-18 plus 1 ng/ml IL-12 (E), 100 ng/ml IL-18 plus 10 ng/ml IL-23 (F), for 48 hours. 
Cells were fixed and permeabilised and labeled with anti-human CD3-PE, anti-human CD56-FITC and 
anti-human IFN-γ-Alexa 647. Unstimulated cells and cells stimulated with IL-12, IL-23 or IL-18 do not 
produce IFN-g. IL-12 plus IL-18 induce IFN-g production in CD3- NK and CD3+ NK-like T cells. IL-23 
in concert with IL-18 induced IFN-γ production in CD3+ NK-like T cells, but not in CD3- NK cells. One 
representative of experiments with cells obtained from 6 donors.













IFN-g+ve NK cells 0.24 (0.22) 0.55 (0.57) 0.16 (0.13) 0.23 (0.22) 33.6 (11.8)* 2.05 (1.38)
IFN-g+ve NK-like T cells 0.53 (0.38) 1.06 (0.88) 0.56 (0.30) 0.70 (0.53) 26.57 (9.11)* 10.76 (3.56)**
Isolated CD56 cells were stimulated and analysed exactly as in Figure 3. Average percentages and 
standard deviation (SD) of IFN-g positive cells are shown of 6 donors. Two-tailed paired t-tests were 
performed od stimulated versus unstimulated cells. S.D., standard deviation. * indicates a p-value 










































3.4. IL-23 in combination with IL-18 induces proliferation of CD56+/CD3- NK and CD56+/
CD3+ NK-like T cells
Because the above observed expansion of the CD56bright CD3- NK cells could be due to 
upregulation of CD56, to enhanced survival, or to proliferation of CD56bright cells we analyzed 
proliferation in response to cytokines. CD56+ cells were CFSE labeled and stimulated with 
IL-23, IL-12, IL-18, combinations of these cytokines, or left unstimulated. Proliferation was 
measured by FACS six days after stimulation. Cells were anti-CD56 and anti-CD3 labeled. 
Unstimulated cells did not proliferate (Fig. 4A and G and Table 2). IL-12 induced proliferation 
of CD56+/CD3- NK cells (Fig. 4B and table 2), predominantly of CD56bright cells (Fig. 4H and 
Table 2). In contrast to IL-12, IL-23 alone did not induce proliferation of NK or NK-like T 
cells (Fig. 4C and I and Table 2).
IL-18 alone induced proliferation of a small population of CD56+/CD3- NK cells (Fig. 
4D and Table 2), these cells were mostly CD56bright (Fig. 4J). IL-12 in combination with 
IL-18 (Fig. 4E and Table 2) induced proliferation of CD56+/CD3- NK cells and, to a lesser 
extent, of CD56+/CD3+ NK-like T cells. Both CD56bright and CD56dim cells proliferated in 
response to IL-12 plus IL-18 (Fig 4K). IL-23 in combination with IL-18 induced proliferation 
of CD56+/CD3- NK cells (Fig. 4F and Table 2). Both IL-12 and IL-23 in combination with 
IL-18 induced proliferation of CD56+/CD3+ NK-like T cells, but less compared to CD56+/
CD3- NK cells (Fig. 4E and F). 
Because in these experiments CD56+/CD3- NK and CD56+/CD3+ NK-like T cells are 
co-cultured, the effects observed in CD3- NK cells could have been induced directly in CD3- 
NK cells or induced indirectly via IL-23 activated CD3+ NK-like T cells. However, when 
CD3+ NK-like T cells were depleted from the CD56+ cells using FACS sort, proliferation 
in response to IL-23 plus IL-18 was still observed in the CD56+/CD3- NK cells (data not 
shown). The purity of the sorted CD56+/CD3- NK cells was >99%.













Proliferating NK cells 1.53 (0.32) 7.08 (2.38)* 1.39 (0.43) 2.54 (0.83) 22.17 (2.04)* 9.47 (3.76)*
Proliferating NK-like T cells 0.28 (0.09) 0.99 (0.74)* 1.16 (2.40) 0.29 (0.27) 3.83 (1.53)** 2.16 (0.69)*
Isolated CD56+ cells were stimulated and analysed exactly as in Figure 4. Average percentages of 
proliferating NK and NK-like T cells obtained from 6 different donors. Two-tailed paired t-tests were 
performed of stimulated cells versus unstimulated cells. S.D., standard deviation. * indicates a p-value 
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Figure 4. IL-23 in combination with IL-18 induces proliferation of CD56+/CD3- NK cells and in 
CD56+/CD3+ NK-like T cells. Anti-CD56 MACS bead isolated cells were rested overnight and then 
CFSE labeled. These labeled cells were left unstimulated (A and G) or stimulated with 1 ng/ml IL-12 
(B and H), 10 ng/ml IL-23 (C and I), 100 ng/ml IL-18 (D and J), 100 ng/ml IL-18 plus 1 ng/ml IL-12 
(E and K), 100 ng/ml IL-18 plus 10 ng/ml IL-23 (F and L). Six days after stimulation cells were labeled 
with anti-human CD3-PE and CD56 alexa 647 and analyzed by FACS. IL-23 and IL-18 alone do not 
induce or induce only little proliferation. IL-23 and IL-18 together induce proliferation of CD3- NK 
cells. IL-12 alone induces proliferation of CD3- NK cells. IL-18 enhances the proliferative effect of 
IL-12. CD3+ NK-like T cells proliferate less compared to CD3- NK cells in response to all stimuli 











































3.5. IL-23 enhances IL-18Ra expression in CD56+/CD3+ NK-like T but not in CD56+/CD3- 
NK cells
We have shown that IL-23 induces IFN-γ production in CD56+/CD3+ NK-like T cells in 
synergy with IL-18. We have also shown that IL-23 in synergy with IL-18 induced enhanced 
CD56 expression in NK-like T cells and that IL-23 plus IL-18 induced proliferation in CD56+/
CD3- NK cells. The mechanism underlying the synergy between IL-18 and IL-12 involves 
IL-12 induced IL-18Ra expression (23). To determine whether the synergy between IL-23 
and IL-18 is similarly dependent on the up-regulation of IL-18Ra, CD56 isolated cells were 
stimulated for two days with IL-23, IL-12, IL-18, IL-23 plus IL-18 or IL-12 plus IL-18. Cells 
were then analyzed for IL-18Ra, CD3 and CD56 expression. Unstimulated NK and NK-like 
T cells expressed low amounts of IL-18Ra (Fig. 5A and Table 3). IL-12 enhanced IL-18Ra 
expression in both NK and NK-like T cells (Fig. 5B and Table 3). IL-23 up-regulated the 
IL-18Ra expression in NK-like T cells, but only marginally in NK cells (Fig. 5C and Table 
3). IL-18 alone enhanced the expression of the IL-18Ra only marginally in both populations 
(Fig. 5D and Table 3), but synergized with the effect of IL-12 on the expression of IL-18Ra 
in both NK and NK-like T cells (Fig. 5E and Table 3). IL-18 synergized with IL-23 in the 
up-regulation of the IL-18Ra in NK-like T cells (Fig. 5F and Table 3). In NK cells a slight 
upregulation of the IL-18Rα was observed in response to IL-23 plus IL-18 (Fig. 5F and Table 
3). Regardless of the stimulation, cells with high expression of the IL-18Ra were CD56bright 
(data not shown).
4. Discussion
The main finding of this study is that IL-23, an APC-derived cytokine, in combination with 
IL-18, another cytokine elicited in APCs early after binding of pathogen-associated molecular 
patterns, can elicit the production of IFN-γ by NK-like T cells as well as proliferation and 
activation of human NK and NK-like T cells. We hypothesize that in this way, APCs become 
primed to subsequently produce large amounts of IL-12 and thus amplify the production 
of IFN-γ. This conclusion is supported by the following findings. Firstly, IL-23 and IL-18 
synergistically increase IFN-g production in CD56+/CD3+ NK-like T cells. This synergy 
between IL-23 and IL-18 in NK-like T cells coincided with IL-23 mediated up-regulation 
of IL-18Ra. Secondly, IL-23 plus IL-18 induced proliferation of CD56+/CD3- NK cells and 
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Figure 5. IL-23 up-regulates IL-18Ra expression in CD56+/CD3+ NK-like T, but not in CD56+/
CD3- NK cells. Anti-CD56 MACS bead isolated cells were left unstimulated (A) or stimulated with 
1 ng/ml IL-12 (B), 10 ng/ml IL-23 (C), 100 ng/ml IL-18 (D), 1 ng/ml IL-12 plus 100 ng/ml IL-18 
(E) or 10 ng/ml IL-23 plus 100 ng/ml IL-18 (F). 48 hours after stimulation cells were labelled with 
anti-human CD56-Alexa 647, anti-human CD3-FITC and anti-human IL-18Ra-PE and analyzed by 
FACS. Unstimulated CD3+ NK-like T cells express slightly more IL-18Ra as compared to CD3- NK 
cells. IL-12 up-regulates IL-18Ra in NK and NK-like T cells. IL-23 up-regulates IL-18Ra expression 
mainly in NK-like T cells. IL-18 alone slightly enhances IL-18Ra in NK cells. IL-I8 synergizes with 
IL-12 and IL-23 in the up-regulation of IL-18Ra expression. One representative of experiments with 














CD3- NK cells upper 
left quadrant
0.19 (0.08) 10.30 (5.48)** 0.85 (0.48)** 1.11 (1.60) 34.99 (21.24)* 4.17 (1.23)
CD3+ NK-like T cells 
upper right quadrant
0.36 (0.26) 11.84 (10.4) 3.98 (4.85) 0.65 (0.49) 50.98 (24.12)* 36.34 (2.92)*
Isolated CD56 cells were stimulated and analysed exactly as in Figure 5. Average percentages and 
standard deviation of data obtained from 6 different donors are shown. Two-tailed paired t-test were 
performed of stimulated cells versus unstimulated cells. S.D., standard deviation. * Indicates a p-value 










































We observed a strong synergy between IL-23 and IL-18 to induce cytokine production and 
induce cell proliferation. In this respect, the combination of IL-23 and IL-18 on NK and NK-
like T cells differed from that induced by IL-12 in combination with IL-18: IL-23 plus IL-18 
induced IFN-γ production in NK-like T cells only, whereas IL-12 plus IL-18 induced IFN-γ 
in both NK as well as NK-like T cells. Previously it has been described that IFN-γ production 
by NK-like T cells can be triggered by IL-12/IL-18 (14) stimulation or TCR stimulation. We 
show that in NK-like T cells, IL-23 plus IL-18 can also induce IFN-γ production, in absence 
of TCR ligation. In CD56+/CD3- NK cells and to a lesser extent in CD56+/CD3+ NK-like T 
cells, IL-23 and IL-18 synergized in eliciting cell proliferation. 
In CD56+/CD3+ NK-like T cells IL-18Rα expression was up-regulated by IL-23. The 
synergy between IL-23 and IL-18 in inducing IFN-γ production in these cells is likely to be 
dependent on this upregulation of IL-18Rα expression. In CD56+/CD3- NK cells the IL-18Rα 
expression was not enhanced by IL-23, suggesting that in these cells the synergistic effect 
of IL-23 and IL-18 on proliferation is achieved via another mechanism. The proliferation 
observed in NK cells could be indirectly induced via NK-like T cells. However, IL-23 in 
combination with IL-18 also induced proliferation in FACS sorted CD56+/CD3- NK cells 
that were cultured without CD56+/CD3+ NK-like T cells (>99% pure). This result suggests a 
direct effect of these cytokines on NK cells. 
Upon contact with pathogens APCs are unable to release IL-12 in sufficient amounts to 
recruit and activate T-helper cells and thus initiate a cellular immune response. For substantial 
IL-12 production by APC, in addition to PAMPs or pathogens, an extra stimulus such as 
IFN-γ is needed (9;24). IL-23 on the other hand is produced by APC in response to PAMPs 
or pathogens without the need of an additional stimulus (9). Because IL-23 and IL-18 are 
both released soon after first contact between phagocytes and pathogens, we hypothesize 
that, in vivo, IL-23 plus IL-18 triggers release of IFN-γ by NK-like T cells and that this 
IFN-γ could provide APCs with the necessary priming to subsequently produce IL-12. The 
IFN-g induced by IL-23 plus IL-18 might thus be important to initiate Th1 immunity at early 
stages of infection. In line with this hypothesis, IL-23 is shown to be critical for the induction 
of Ag-specific Th1 development in an experimental autoimmune encephalomyelitis mouse 
model (25). Moreover, IL-23 inhibited the induction of the Th2 cytokines IL-4 and IL-13 in 
antiCD2/antiCD28 activated CD56+ cells. Taken together, the synergy of IL-18 with IL-23 
is likely important in initiating Th1 differentiation early in infections, whereas the synergy 
between IL-18 and IL-12 may be important in further Th1 response in subsequent stages of 
infection.
Host defense against intracellular bacterial pathogens such as Salmonellae and 
Mycobacteria depends on the IL-23/IL-12/IFN-γ cytokine pathway (12;26). However, the 
cells that produce IL-23/IL-12 and IFN-γ at different stages of infection in human are not well 
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infections has not been studied widely. These cells are likely important because of the following 
observations. First, the number of peripheral blood CD56+ T-cells are increased during these 
infections in humans (27;28). Second, high numbers of CD56+ NK-like T cells at diagnosis 
of pulmonary tuberculosis correlated significantly with negative sputum culture after 8 weeks 
of treatment (29). Third, in the presence of macrophages infected with live M. bovis BCG or 
S. typhimurium, CD56+ NK-like T cells, but not CD56– T cells, produce IFN-γ in the absence 
of TCR stimulation (14). Fourth, in patients with unusual susceptibility to Mycobacteria and 
Salmonellae infections due to deficiency of IL-12Rb1 or IL-12p40, the number of CD56+ 
NK-like T-cells is drastically reduced (14). The reduced numbers of NK-like T cells in 
these last patients indicate that IL-12 and IL-23 are also needed for the differentiation and/
or maintenance of these cells. In addition to these findings, we have shown that IL-23, in 
combination with IL-18, is able to drive IFN-γ production in CD56+ NK-like T cells, in the 
absence of IL-12 and TCR ligation. This finding indicates that IL-23 could be important in 
driving IFN-γ production in these cells in early stages of infection, before sufficient IL-12 is 
produced to drive IFN-γ production. Consistent with this hypothesis, p40-/- mice, lacking both 
IL-12 and IL-23, infected with S. enteritidis or M. tuberculosis produce lower levels of IFN-γ 
than p35-/- mice, lacking only IL-12 (30;31). Moreover, p35-/- mice infected with S. enteritidis 
show higher survival rates or longer survival times than p40-/- mice (31). In mycobacterial 
infection, IL-23 provides protection in the absence of IL-12 (32). Together, this points to a 
role for IL-23 in protection, independent of IL-12. The relative roles of either IL-12 or IL-
23 in driving the IFN-γ response early in infection have not been addressed yet. Monitoring 
the kinetics of IFN-γ in response to infections with Salmonellae and Mycobacteria in 
p19-/- and p35-/- mice could provide information about the contribution of IL-23 and IL-12 to 
the induction of IFN-γ.  
Taken together, these observations indicate that IL-23 has different effects on NK cells as 
compared with NK-like T cells. The effects of IL-23 in combination with IL-18 on NK 
and NK-like T cells differ from the effects induced by IL-12 in combination with IL-18. 
Moreover, we showed that IL-23, in synergy with IL-18, activates NK-like T cells. This 
activation was independent of IL-12 and independent of TCR ligation. In conclusion, IL-23 
may have an important role in activating NK and NK-like T cells and the initiation of the 
(Th1) immune response early in an infection. 
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CHAPTER 5
Functional analysis of naturally occurring amino acid 
substitutions in human IFN-γR1
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IFN-γ plays an essential role in the IL-12/IL-23/ IFN-γ pathway that is required for the defense 
against intracellular pathogens. In the IFN-γR1 several amino acid substitutions have been 
reported that abrogate IFN-γ signaling. These substitutions can lead to a null phenotype and 
enhanced susceptibility to infection by poorly pathogenic mycobacteria, a disorder known 
as Mendelian Susceptibility to Mycobacterial Disease (MSMD). More common amino 
acid variations in the IFN-γR1 may also influence IFN-γR function, albeit more subtle. To 
determine the effect of various amino acid substitutions on IFN-γR1 expression and function 
we cloned two newly identified amino acid substitutions (S149L, I352M), four common 
variations (V14M, V61I, H335P, L467P), seven reported missense mutations (V61Q, V63G, 
Y66C, C77Y, C77F, C85Y, I87T) and the 818delTTAA mutation in a retroviral expression 
vector. IFN-γR1 expression was determined as well as responsiveness to IFN-γ stimulation. 
The two newly discovered variants, and the four common polymorphisms could be detected 
on the cell surface, however, the V14M, H335P and I352M variants were significantly lower 
expressed at the cell membrane, compared to the wild type receptor. Despite the variance 
in cell surface expression, these IFN-γR1 variants did not affect function. In contrast to 
literature, in our model the expression of the V63G variant was severely reduced and its 
function was severely impaired but not completely abrogated. In addition, we confirmed 
the severely reduced function of the I87T mutant receptor, the completely abrogated 
expression and function of the V61E, V61Q, C77F, C77Y and the C85Y mutations, as well 
as the overexpression pattern of the 818delTTAA mutant receptor. The Y66C mutation was 
expressed at the cell surface, it was however, not functional. We conclude that the V14M, 
V61I, S149L, H335P, I352M and L467P are functional polymorphisms. The other variants are 
deleterious mutations with V61E, V61Q, Y66C, C77F, C77Y and C85Y leading to complete 












































Interferon-γ (IFN-γ) is a pleiotropic cytokine playing a central role in type-1 immunity. 
Human host immunity against intracellular pathogens such as Mycobacteria and Salmonellae 
depends on an effective cell-mediated immune response mediated by type1 cytokines 
(Ottenhoff et al., 2002). Upon encounter of these pathogens, antigen presenting cells (APC) 
produce cytokines such as IL-23, IL-1β, IL-18, IL-12 and TNF via the stimulation of pattern 
recognition receptors, including Toll-like receptors. Type-1 helper T (Th1) cells and natural 
killer (NK) cells express receptors for these cytokines and produce IFN-γ in response to IL-
12 or IL-23 which can be enhanced by IL-1. and IL-18. IFN-γ in turn, binds to the IFN-γ 
receptor (IFN-γR), present on nearly all cell types (Valente et al., 1992). APCs, including 
monocytes, macrophages and DCs, are activated by IFN-γ to produce increased levels of 
IL-12 and to enhance both antigen presentation and bactericidal activity (Leenen et al., 1994; 
Nathan and Hibbs, 1991). In addition IFN-γ can, depending on cell type, block proliferation, 
induce apoptosis and enhance expression of cell surface molecules such as HLA Class I and 
II, CD54 and CD64. 
The IFN-γR is comprised of two ligand-binding IFN-γR1 chains associated with two 
signal-transducing IFN-γR2 chains (Boehm et al., 1997). Binding of IFN-γ to its receptor 
induces receptor oligomerization and activation of the receptor-associated Janus kinases 
JAK1 and JAK2 by trans-phosphorylation. The JAKs phosphorylate the tyrosine 440 that 
is part of the STAT1 docking site in the intracellular domain of the IFN-γR1, allowing for 
subsequent STAT1 phosphorylation (Boehm et al., 1997). Phosphorylated STAT1 dissociates 
from the receptor, dimerizes and translocates to the nucleus, where it regulates the expression 
of IFN-γ responsive genes directly (e.g. CD54)(Ramana et al., 2002), or indirectly via the 
induction of other transcription factors such as IRF1, IRF7 and CIITA (e.g. B2M and HLA)
(Boehm et al., 1997). Although STAT1 is the main mediator of IFN-γ responses, IFN-γ has 
also been reported to induce STAT3 or STAT5 phosphorylation in a few other cell types 
(van Boxel-Dezaire and Stark, 2007). In Fig. 1 a schematic representation of the IFN-γR1 is 
provided. 
Polymorphisms and mutations in the IFN-γR1 chain influence IFN-γ responses. For 
example, patients with Mendelian Susceptibility to Mycobacterial Disease (MSMD) due to 
IFN-γR1 deficiency, have impaired Th1-immunity and suffer from unusually severe infections 
caused by weakly virulent Mycobacteria (van de Vosse et al., 2004). Most recessive IFN-γR1 
deficiencies result in complete loss of cellular responsiveness to IFN-γ, due to mutations 
that preclude the expression of IFN-γR1 on the cell surface (Pierre-Audigier et al., 1997; 




































































Figure 1. Schematic presentation of the IFN-γR1. On the left the various domains are indicated, on 
the right the variations that were analyzed are indicated. TM = Transmembrane domain, SP = signal 
peptide. 
Another group of IFN-γR1 deficiencies is due to missense mutations which result in 
normal expression of IFN-γR1 at the cell surface, however, the resulting receptors show 
no or diminished binding of IFN-γ (Allende et al., 2001; Jouanguy et al., 2000). Dominant-
negative defects such as the 818delTTAA mutation in the intracellular domain of the receptor 
result in milder forms of MSMD. The 818delTTAA mutation product lacks the JAK1 and 
STAT docking site as well as the receptor recycling domain which leads to accumulation of 
aberrant receptor complexes on the cell surface (Jouanguy et al., 1999; Glosli et al., 2008). 
In addition, several polymorphisms of the IFN-γR1 have been found that may have an effect 
on IFN-γ responses. The H335P and L467P variants of the IFN-γR1 have been associated 








































Functional analysis of IFN-γR1 variants
107
5
susceptibility to allergic disease and the production of high IgE titers (Aoki et al., 2003). The 
frequency of the V14M allele in SLE patients is significantly higher than that of the healthy 
control population and the presence of a V14M allele correlated with an altered Th1/Th2 
balance in favor of Th2 (Tanaka et al., 1999; Nakashima et al., 1999). 
In this report we compare the effect of two novel variations, identified in patients suffering 
mycobacterial infections (S149L, I352M unpublished data), four known polymorphisms 
(V14M (Nakao et al., 2001; Tanaka et al., 1999), V61I (SNP database, 2006), H335P, L467P 
(Thye et al., 2003; Aoki et al., 2003), all seven reported missense mutations (V61Q (Jouanguy 
et al., 2000), V63G (Allende et al., 2001), Y66C (Dorman et al., 2004), C77Y (Jouanguy et 
al., 2000), C77F (Chantrain et al., 2006), C85Y (Noordzij et al., 2007), I87T (Jouanguy et al., 
1997; Remiszewski et al., 2006)) and the 818delTTAA mutation (Jouanguy et al., 1999) on 
the expression and function of IFN-γR1 in the same genetic background. In addition, because 
the mutation at nucleotide 182 (gTA . gAA) reported by Jouanguy et al. (2000) may have 
been aberrantly designated as V61Q (Val . Gln), instead of V61E (Val . Glu), we analyzed 
both variations. For this purpose we cloned wild type IFNGR1 and the IFNGR1 variants 
(see also Fig. 1), into a retroviral expression vector and transduced the constructs into the 
IFN-γR1 deficient cell line SKLC-7. We analyzed the signal transduction, the regulation of 
CD54, CD64, HLA-DR and HLA class I expression and the cytokine production in response 
to IFN-γ. 
2. Materials and methods 
2.1. Cloning IFN-γR1 variants into a retroviral expression vector
The full-length IFNGR1 coding sequence was PCR amplified from cDNA of a healthy 
control with the sense primer 5’-AATTGGATCCGGTAGCAGCATGGCTCTCCT-3’ and 
the anti-sense primer 5’-AAGGCTCGAGTCATGAAAATTCTTTGGAATCT-‘ and cloned 
into the retroviral vector pLZRS-IRES-GFP (Heemskerk et al., 1997) after digestion with 
the enzymes BamHI and XhoI (Fermentas). Variations were introduced by site directed 
mutagenesis (Higuchi et al., 1988). All constructs were sequence verified and were transfected 
in the Phoenix-A packaging cell line using calciumphosphate (Invitrogen). Supernatants with 
retroviral particles carrying the expression construct were generated as described before (de 
Paus et al., 2008). 
2.2. Cells, culture conditions and retroviral transduction 
The human IFN-γR1-/- cell-line SKLC-7 (Kaplan et al., 1998) and the human monocytic 










































10% FCS, 20 mM GlutaMax, 100 U/ml Penicillin and 100 µg/ml Streptomycin (Gibco/
Invitrogen). 0.25 × 106 cells were retrovirally transduced by overnight incubation on a CH-
296 (RetroNectinTM, Takara Shuzo) coated 48 wells plate in the presence of 1 ml of virus 
containing supernatant. Cells were washed and cultured for at least four days before analysis 
in further assays. All subsequent FACS measurements were performed on cells gated for 
equal GFP expression. 
2.3. Analysis of IFN-γR1 expression 
To detect IFN-γR1 membrane expression cells were labeled with IRγ2 (Watzka et al., 1998) 
and 177.10 (Novick et al., 1989) antibodies (kindly provided by Heiner Böttinger and 
Daniela Novick respectively) and PE conjugated monoclonal antibodies GIR94, GIR208, 
and as an isotype control IgG1 (BD Biosciences). After labeling with the γR99 antibody 
(Garotta et al., 1990) (kindly provided by Francesco Novelli) the cells were counterstained 
with goat-anti-mouse-PE (BD Biosciences). 1 × 105 cells were stained in PBS supplemented 
with 0.2% BSA (Fraction V, Sigma) and washed twice before analysis on a FACSCalibur 
(BD Biosciences). In order to detect intracellular expression 1 × 105 cells were fixated with 
4% paraformaldehyde (Sigma) and permeabilized with 4% saponin (Sigma–Aldrich) before 
staining with a directly labeled antibody. 
2.4. Detection of cell surface markers 
Regulation of CD54, HLA Class I, CD64 and HLA-DR expression in response to IFN-γ was 
determined by stimulation of 2 × 105 transduced SKLC-7 or THP-1 cells in 200 µl culture 
medium with various amounts of IFN-γ for 20 hours in 96-wellsplates (Greiner bio-one). 
Subsequently, the cells were washed and stained with either PE conjugated anti-CD54, the 
HLA Class-I antibody W6.32 and counterstained with goat-anti-mouse-PE, PE conjugated 
anti-CD64 or with PE conjugated anti-HLA-DR (BD Biosciences). After staining the cells 
were washed twice and analyzed on a FACSCalibur (BD Biosciences). 
2.5. STAT phosphorylation assays 
To study signal transduction, 2 × 105 transduced or untransduced SKLC-7 cells in 200 
µl of culture medium were pulsed with various concentrations of IFN-γ (Biosource) in 
96-wellsplates (Greiner bio-one). The cells were fixated with 4% paraformaldehyde and 
permeabilized with 90% methanol (Merck). Subsequently, the cells were washed with 
PBS, 0.2% BSA, blocked with normal goat serum (Sanquin), and stained with the phospho-
specific antibodies pY701-STAT1-Alexa 647, pY705STAT3-PE or pY694-STAT5-PE (BD 












































3.1. Functional transfer of the IFNGR1 in SKLC-7 cells 
We cloned and expressed the wild type IFN-γR1 in the IFN-γR1 deficient cell line SKLC-7. 
The use of the retroviral expression vector pLZRS ensures transcription and expression of 
the IFNGR1 and green fluorescent protein (GFP) genes in tandem and allows for selection of 
transduced cells by fluorescence-activated cell sorting (FACS) for the GFP signal. Transduction 
efficiency of SKLC-7 cells was typically between 20 and 40%. The transduction efficiency 
depends on target cell type and its proliferation rate. SKLC-7 cells divide slowly and are 
therefore more difficult to transduce than other cell types. With the same viral supernatants 
we obtained transduction efficiencies of up to 80% in Jurkat or K562 cells. 
SKLC-7 cells do not express the IFN-γR1 on their cell surface, nor do they express GFP 
(Fig. 2A–D). After retroviral transduction of the wild-type IFNGR1 into the SKLC-7 cells the 
IFN-γR1 could be detected on the cell membrane (Fig. 2A–D), whereas in cells transduced 
with the empty vector (GFP) it could not (Fig. 2A–D). Next we tested the responsiveness of 
transduced cells to IFN-γ. SKLC7 cells expressing wild type IFN-γR1 were stimulated with 
various concentrations of IFN-γ for 5 to 90 min before assessing STAT1) phosphorylation. 
STAT1 phosphorylation peaked 10–15 min after stimulation with high doses of IFN-γ, 
whereas with lower doses of IFN-γ STAT1 phosphorylation peaked later (Fig. 3). In 
addition, the induction of STAT1 phosphorylation was dose dependent and the highest IFN-γ 
concentrations induced the largest amounts of STAT1 phosphorylation (Fig. 3). No induction 
of STAT3 or STAT5 phosphorylation was observed in response to IFN-γ at any time point 
(data not shown). 
3.2. Expression pattern of the IFN-γR1 variants 
Four known polymorphisms (V14M, V61I, H335P, L467P), the known mutations (V61E, 
V61Q, V63G, Y66C, C77Y, C77F, C77Y, C85Y, I87T, and 818delTTAA) and two novel 
amino acid substitutions (S149L and I352M) in IFN-γR1 were cloned and retrovirally 
transduced into the IFN-γR1-/- SKLC-7 cell line. We first determined whether the IFN-γR1 
variants were expressed at the cell surface, using four different IFN-γR1 specific antibodies. 
Untransduced or GFP-transduced cells did not express IFN-γR1 (Fig. 2A–D). On the SKLC-
7 cells transduced with wild type IFN-γR1, the receptor was detected on the cell surface 
(Fig. 2A–D). The V61I, Y66C, S149L and L467P variants could be detected on the cell 
surface in similar amounts as the wild type receptor while the H335P and I352M variants, 
showed a small (13% and 18% respectively) reduction of expression that was significant with 
three out of four antibodies. The V14M variant showed significant reduced expression (42%) 
compared to the wild type construct with all four antibodies. As expected, the 818delTTAA 
mutant lacking the receptor recycling-domain was expressed ten times higher on the cell 








































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Extracellular and intracellular expression of the IFN-γR1 variants. SKLC-7 cells and 
the cells retrovirally transduced with GFP or with one of the IFNGR1 gene variants were stained 
without pretreatment to detect extracellular expression (A–D or after permeabilization to detect both 
intracellular and extracellular expression of IFN-γR1 (E). Cells were analyzed for IFN-γR1 expression 
using four IFN-γR1 specific antibodies (GIR94 (A), GIR208 (B), IRγ2 (C) and 177.10 (D)). Mean ± 
SD fluorescence of these antibodies of 2 (IRγ2 and 177.10) or 3 (GIR94 and GIR208) experiments in 





































































Figure 3. Kinetics of STAT1 phosporylation in response to IFN-γ. SKLC-7 cells transduced with 
wild type IFNGR1 were stimulated with various concentrations of IFN-γ (25–25,000 pg/ml IFN-γ), 
whereafter STAT1 phosphorylation was analyzed at various time points. One representative experiment 
out of 2 is depicted. 
In contrast, membrane expression of the V61E, V61Q, C77F and C77Y variants could not 
be detected (Fig. 2A–D). A small amount of cell-surface expression of the V63G, C85Y and 
I87T variants was detected by one antibody (Fig. 2D). 
Lack of cell surface expression can be due to a lack of protein production, or due to 
misfolded proteins being sequestered in the endoplasmic reticulum (ER) or due to a defect 
in trafficking of the receptor to the cell membrane. To determine whether the variants that 
were undetectable at the cell surface were synthesized, we stained the cells for intracellular 
IFN-γR1 expression. Except for the GFP transduced cells and the V61E and V61Q variants, 
in all other transduced cells the IFN-γR1 could be detected intracellular, indicating protein 
is synthesized (Fig. 2E). The results of the expression analysis experiments are summarized 
in Table 1. 
3.3. The effect of IFN-γR1 variations on IFN-γ induced STAT1 phosphorylation 
STAT1 plays a critical role in the IFN-γ signal transduction and the IFN-γ induced host 
defence against infections (Platanias and Fish, 1999). To test the influence of the IFN-γR1 
alleles on IFN-γ signal transduction, STAT1 phosphorylation was assessed. The kinetics of 
STAT1 phosphorylation in response to IFN-γ was determined in cells transduced with each 
of the variants. In cells expressing the wild type IFN-γR1 or the V14M, S149L, H335P, 
I352M, and L467P variants, comparable STAT1 phosphorylation was observed (Fig. 4A). In 
cells transduced with the V63G or the I87T variant, STAT1 phosphorylation was detected, 
however, it was significantly reduced compared to cells transduced with the wild type 
receptor (Fig. 4B and C). In cells transduced with the V61E, V61Q, Y66C, C77F, C77Y and 
C85Y variants, no STAT1 phosphorylation could be observed in response to IFN-γ (Fig. 4B 
















































































































































































































































































































































































































































































































































































































































































































































































Figure 4. The influence of IFN-γR1 variations on the kinetics of STAT1 phosphorylation. 
SKLC-7 cells transduced with wild type IFNGR1, GFP or with the V14M, V61I, S149L, H335P, I352M 
and L467P (A), V61E, V61Q, V63G, Y66C, C77F, C77Y, C85Y and I87T (B) or V63G and I87T 
variants (C), were stimulated for 5–90 min with 2500 pg/ml IFN-γ (A) or 250,000 pg/ml IFN-γ (B 
and C). The phosphorylation of STAT1 was determined by FACS, using a STAT1 phospho-specific 
antibody. One representative experiment out of 3 are depicted. 
3.4. Influence of IFN-γR1 variations on CD54 and HLA Class I regulation by IFN-γ
IFN-γ stimulates the expression of many cell surface markers,including CD54 and HLA 
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endothelia and transmigration into tissues (Shang and Issekutz, 1998). CD54 functions as a 
costimulatory molecule on APC and other cell types, to activate CD4+ T cells and cytotoxic 
CD8+ T cells, respectively (van de Stolpe and van der Saag, 1996). IFN-γ increases antigen 
processing and the expression of the HLA class I molecules, thereby increasing antigen 
presentation and promoting the induction of cell-mediated immunity (Boehm et al., 1997; 
Schroder et al., 2004). We assessed the influence of the IFN-γR1 variants on the IFN-γ 
induced expression of CD54 and HLA Class I molecules. IFN-γ upregulated the expression 
of CD54 in SKLC-7 cells expressing the wild type IFN-γR1, but not in GFP-transduced 
or in untransduced SKLC-7 cells (Fig. 5A). In cells expressing the V14M, V61I, S149L, 
H335P, I352M or L467P, similar upregulation of CD54 expression was observed as in cells 
expressing the wild type receptor (Fig. 5A). In cells expressing the V63G or the I87T variants, 
CD54 upregulation was seen when cells were stimulated with high concentrations of IFN-γ, 
however, this upregulation was less compared to cells expressing the wild type receptor (Fig. 
5B and C). No regulation of CD54 by IFN-γ was observed in cells expressing the V61E, 
V61Q, Y66C, C77F, or C77Y receptor variants (Fig. 5B). Similar results for all IFN-γR1 
variants were observed for IFN-γ induced HLA Class I cell surface expression (Fig. 5D–F). 
The results of the expression analysis experiments are summarized in Table 1. 
The expression of two other cell surface markers that can be regulated by IFN-γ, CD64 
and HLA-DR, was not altered by IFN-γ stimulation in the SKLC7 cell line with or without 
IFNGR1 construct (data not shown). Therefore expression of these two markers was not 
analyzed in the full panel of IFNGR1 variations. 
3.5. Influence of the IFN-γR1 Y66C variation on the function of the wild type receptor 
The Y66C variation was expressed on the cell surface but appeared to be non-functional. 
Since the IFN-γR contains two IFN-γR1 chains, in individuals heterozygous for a defective 
IFN-γR1 chain that is expressed on the membrane, incorporation of one defective IFN-γR1 
chain in the IFN-γR complex could potentially have a dominant-negative effect. To determine 
whether the Y66C variation exerts such an effect we transduced the IFN-γ responsive cell line 
THP-1 with the Y66C variation and as controls with the wild type IFN-γR1 or a GFP vector. 
While expressing large amounts of Y66C IFN-γR1, Y66C THP-1 transductants showed a 
dose dependent induction of CD54 after stimulation with IFN-γ, which was comparable to 
the dose response curve of untransduced THP-1 cells (data not shown). Transduction of the 
wild type receptor led to a higher total expression of IFN-γR1 at the cell surface, as well 
as a stronger upregulation of CD54 in response to IFN-γ (data not shown). In THP-1 cells 
transduced with the 818delTTAA IFN-γR1 variant, total receptor cell surface expression 
was increased, while the CD54 upregulation in response to IFN-γ was severely reduced, 
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Figure 5. The effect of IFN-γR1 variations on IFN-γ induced CD54 and HLA class I upregulation. 
SKLC-7 cells and the cells retrovirally transduced with GFP or with one of the IFNGR1 gene variants 
were stimulated for 20 h with various concentrations of IFN-γ. The CD54 expression (A–C) and 
the HLA Class I expression (D–F) was determined by FACS. CD54 expression is depicted as mean 
fluorescence, HLA Class I expression is depicted as fold increase compared to the mean of untransduced 
cells. Displayed is the mean ± SD of a triplo experiment. All variants were tested at least three times for 
comparison with the wild type variant. 
4. Discussion 
The main finding of this study is that the newly discovered IFN-γR1 variants, S149L and 
I352M, as well as the known V14M, V61I, H335P and L467P IFN-γR1 variants do not 
functionally differ from the wild type receptor and are therefore considered polymorphisms. 
In contrast to literature, we showed a severely reduced expression of the V63G receptor 
variant, and found that its function was severely reduced although not completely abrogated. 
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completely abrogated function of the V61E, V61Q, Y66C, C77F, C77Y and C85Y variants, 
as well as the overexpression patterns of the 818delTTAA mutant receptor. Thus far the 
only mutant proteins that have been characterised after transduction into cells were the 
818delTTAA (into HEK293 cells) and the I87T (into fibroblasts) variants (Okada et al., 2007; 
Jouanguy et al., 1997). 
To reach these conclusions, we retrovirally expressed the IFN-γR1 variants in the human 
IFN-γR1-deficient SKLC-7 cell line and analyzed its functional activity. The conclusions are 
summarized in Table 1. With the in vitro model used, we were able to distinguish between 
functional and non-functional variants and were also able to detect the partial responsiveness 
of the V63G and I87T variants. However, the following points should be considered. First, 
while the IFN-γR is expressed by all nucleated cells in the human body, the cells used in this 
study are not representative for all IFN-γ responsive cells. For example, in a few cell-types 
STAT3 and STAT5 phosphorylation in response to IFN-γ can be observed (vanBoxel-Dezaire 
and Stark, 2007), in our model no STAT3 or STAT5 phosphorylation could be detected, thus 
not allowing for detection of potential differences between the IFN-γR1 variants in signaling 
through these molecules. Second, the concentrations of stimuli chosen may not fully resemble 
physiologically relevant conditions. Though we tested a range of IFN-γ concentrations as 
commonly found in physiological relevant situations, the present approach cannot exclude 
subtle differences in the lowest range of ligand binding. Third, the overexpression of the IFN-
γR1 by the retroviral system could mask differences in effects due to alterations in transcript 
or protein stability. We were nevertheless able to detect accumulation on the membrane of the 
818delTTAA mutant, a significant lower expression of some of the polymorphisms, as well 
as the extremely low expression of partial mutations compared to the wild type IFN-γR1. 
Furthermore, post-transcriptional and post-translational modifications of normal or retroviral 
expressed IFN-γR1 may differ, although thus far no findings suggest that such modifications 
occur. Fourth, the IFN-γ induced STAT1 phosphorylation and subsequent induction of CD54 
and HLA class I molecules are not the only responses induced. Subtle differences between 
the different variants may be missed due to the choice of read-out system. 
The C77F and C77Y receptor variants could not be detected on the cell surface, however, 
these variants could be detected intracellularly. Lack of cell surface expression can be due 
to a lack of protein expression or due to a defect in trafficking of the receptor to the cell 
membrane. Alternatively, the protein quality control system in the endoplasmic reticulum 
(ER) could prevent transport of mutant, misfolded, or incorrectly complexed proteins, and 
target these for degradation (Klausner and Sitia, 1990), as we have also reported for several 
IL-12Rβ1 mutations (van de Vosse et al., 2005). In accordance with literature, we did not 
observe any IFN-γ responsiveness of these two variant receptors (Chantrain et al., 2006; 










































In contrast with previous publications (Jouanguy et al., 1997; Allende et al., 2001), we 
only detected low cell surface expression of the V63G and I87T receptor variants. With 
one out of the four antibodies used, low cell surface expression of the V63G, C85Y and 
I87T variants could be detected. In addition, we were able to detect STAT1 phosphorylation 
as well as a slight upregulation of CD54 and HLA Class I in the V63G and I87T variants 
in response to more than 10,000 times higher IFN-γ concentrations than needed to induce 
IFN-γ responses in cells expressing the wild type receptor. This confirms the observation 
by Jouanguy et al. (1997) that I87T is a partial deficiency and identifies V63G as a partial 
deficiency as well in contrast to the earlier report by Allende et al. (2001) that it results in 
complete deficiency. In line with our results with the I87T variant, Jouanguy et al. (1997) 
observed a response in B-cells and monocytes obtained from the patient expressing this 
variant when stimulated with very high doses of IFN-γ. The diminished response of the 
I87T variant to IFN-γ may be largely due to the low cell-surface expression. The diminished 
response observed of the V63G variant can be due to either the severely diminished cell-
surface expression or to disrupted binding of IFN-γ to the receptor since the neighboring 
amino acids (64 and 66–68) of the IFN-γR1 are known to be essential in the interaction 
between the high-affinity receptor and its ligand IFN-γ (Walter et al., 1995). Moreover, the 
adjacent lysine at position 64 directly interacts with IFN-γ. 
In the V61Q (V61E) variant IFN-γR1, the binding of IFN-γ was reported to be abrogated 
(Jouanguy et al., 2000). This was determined in patient cells expressing two mutant IFNGR1 
alleles (V61Q and 652del3) (Jouanguy et al., 2000). We tested both the V61Q and V61E 
variants. Interestingly, in our experiments, with four independently cloned and sequence-
verified V61Q and V61E constructs, neither variant was detected on the cell surface nor 
was the protein detectable intracellular. The fact that these mutants could not be detected 
on the cell surface with four different antibodies suggests that the variant detected on the 
cell surface by Jouanguy et al. (2000) may have been the 652del3 mutation. The failure to 
detect protein expression may be caused by a changed protein conformation, leading to the 
disappearance of epitopes recognized by the antibodies. Three of the antibodies (GIR-94, 
GIR-208 and IRγ2) were raised against the extracellular domain of IFN-γR1, one (177.10) 
was raised against full length IFN-γR1 but is known to block IFN-γ binding, suggesting it 
binds to the extracellular domain of IFN-γR1 as well. Of none of these antibodies the exact 
binding site is known. 
The V61I variant is an amino acid substitution at the same position as the V61Q and 
V61E variants that was however normally expressed on the cell surface and showed a 
normal STAT1 phosphorylation in response to IFN-γ· Both valine (V) and isoleucine (I) are 
hydrophobic aminoacids, V to I substitutions are conserved substitutions while substitutions 
of valine to amino acids glutamine (Q) or glutamic acid (E) substitutions are not. The Y66C 
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or HLA class I induction was observed in response to IFN-γ. This finding is in accordance 
with the fact that phenylalanine residue on position 66 is essential for IFN-γ binding (Walter 
et al., 1995). Although the non-functional Y66C variant was expressed on the cell surface, 
it did not hamper the function of the IFN-γR when this variant was co-expressed with wild 
type IFN-γR1. Whether or not the Y66C variant is incorporated in the IFN-γR complex is 
not known. 
We show that the variants V14M, V61I, H335P, L467P, S149L and 352M were detectable 
on the cell surface and were fully functional and not different in receptor function from 
the wild type receptor. Despite the fact that cell surface expression of the V14M variant 
was nearly halved, we were not able to detect a functional difference compared to the wild 
type receptor. The V14M variation is within the signal peptide, thereby likely influencing 
transport of the receptor to the cell surface. When IFN-γR1 is overexpressed, as is the case 
in our model, subtle differences in expression and the balance between the expression of 
the IFN-γR1 and the IFN-γR2 within our model may not resemble the normal expression 
pattern. In T lymphocytes IFN-γR1 and R2 expression can individually vary from low to 
high. For example, the expression density of the IFN-γR2 is an important mechanism in 
determining the fate of T lymphocytes (Bernabei et al., 2001). Therefore differences in IFN-
γR1 expression levels as seen with the V14M variant, which did not result in differences in 
our read outs, may nonetheless influence signaling in natural conditions. 
The H335P and L467P variants of the IFN-γR1 have been reported to be associated with 
the production of high antibody titers against H. pylori (Thye et al., 2003) and susceptibility 
to allergic disease and the production of high IgE titers (Aoki et al., 2003). The identification 
of associations between an allele and an observed clinical outcome does not necessarily mean 
that the allele itself conveys a functional difference. The functional difference may be due to a 
variation that is merely linked to the polymorphism under study. We can however not exclude 
more subtle functional differences of the studied alleles, since we used overexpression 
constructs of the IFN-γR1. In addition, the observed associations may be due to alterations in 
signaling pathways other than the ones we explored in this study. 
When a variation affects the function of a protein it is considered a mutation, when it does 
not affect protein function it is considered a polymorphism. We therefore conclude that the 
V14M, V61I, S149L, H335P, I352M and L467P are functional polymorphisms. Expression 
on the cell surface of V14M is reduced which may result in slightly reduced IFN-γ responses, 
when IFN-γR1 gene transcription is in vivo limited to natural amounts. This polymorphism 
may influence susceptibility to infections or predisposition to SLE. The other variants are 
deleterious mutations with V61E, V61Q, Y66C, C77F, C77Y and C85Y leading to complete 
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Patients with IFN-γR null mutations have severe infections with poorly pathogenic 
Mycobacteria. The IFN-γR complex involves two IFN-γR1 and two IFN-γR2 chains, in 
which several amino acid substitutions, some linked to disease and some apparently naturally 
occurring, have been described. We developed a model system to study functional effects of 
genetic variations in IFN-γR2. We retrovirally transduced wild-type IFN-γR2 and IFN-γR2 
carrying presently known amino acid substitutions, in various human cell lines and next 
determined the IFN-γR2 expression pattern as well as IFN-γ responsiveness. We determined 
that the T58R, Q64R, E147K and K182E variants of IFN-γR2 are fully functional, although 
the Q64R variant may be expressed higher on the cell membrane. The R114C, T168N 
and G227R variants were identified in patients that had disseminated infections with non-
tuberculous Mycobacteria. Of these genetic variants, T168N was confirmed to be completely 
non-functional, whereas the novel variant G227R, and the previously reported R114C, were 
partial functional. The impaired IFN-γ responsiveness of R114C and G227R is mainly due to 
reduced receptor function, although expression on the cell membrane is reduced as well. We 
conclude that the T58R, Q64R, E147K, and K182E variants are polymorphisms, while the 












































Deficiency in the interferon-γ receptor (IFN-γR) leads to susceptibility to infections with 
poorly pathogenic Mycobacteria.1,2 Individuals with such a deficiency are among the small 
number of persons with “Mendelian Susceptibility to Mycobacterial Disease” (MSMD) 
that are prone to develop infection by low pathogenic non-tuberculous Mycobacteria and 
Salmonellae. Upon encounter with these bacteria, antigen presenting cells will stimulate 
natural killer (NK) cells and next type-1 helper T (Th1) cells to produce IFN-γ. IFN-γ is 
a pleiotropic cytokine which upregulates proteasome complexes, various pro-inflammatory 
cytokines, chemokines and cell surface molecules. At the same time, IFN-γ downregulates 
the production of the anti-inflammatory cytokine IL-10. By consequence, IFN-γ responses 
result in enhanced cytotoxicity of NK cells, stimulation of antigen presentation, maturation 
of B-lymphocytes, expansion of Th1 lymphocytes and induction of apoptosis in Th2 cells.3-6
IFN-γ mediates immune responses via the IFN-γ receptor (IFN-γR), which is comprised 
of two ligand-binding IFN-γR1 chains associated with two signal-transducing IFN-γR2 
chains. Binding of IFN-γ to its receptor induces activation of the receptor-associated Janus 
kinases JAK1 and JAK2 by trans-phosphorylation,7 which in turn phosphorylate STAT1 on 
its Tyrosine 701 residue.8 Phosphorylated STAT1 dissociates from the receptor, dimerizes 
and translocates to the cell nucleus, where it regulates gene expression either directly (e.g. 
CD54, CXCL10 and CCL2)9-11 or indirectly via the induction of transcription factors such as 
IRFs and CIITA (e.g. IL12B, B2M and MHC).12,13 Although STAT1 is the main mediator of 
IFN-γ responses, IFN-γ has also been reported to induce STAT3 or STAT5 phosphorylation.14 
Besides the JAK2 binding site, the intracellular domain of IFN-γR2 contains a BAX inhibiting 
domain15 and an internalization motif16 (Figure 1). 
Amino acid variations in the IFN-γR1 or in the R2 chain can influence IFN-γ responses. 
Besides null mutations some additional amino acid variations of uncertain consequence were 
found in the IFN-γR. Recently, we determined the impact of naturally occurring amino acid 
variations on the function of the IFN-γR1.17 In the IFN-γR2 chain amino acid variations have 
similarly been reported in both patients as well as healthy individuals (Figure 1). For instance, 
an R114C variation was identified in a patient with mycobacterial disease and strongly 
impaired IFN-γ responses in vitro.18 The T168N mutation results in a gain of glycosylation 
and complete loss of function.19 A novel variation, G227R, was recently found in a MSMD 
patient (S.S. Kilic, manuscript in preparation). Variations reported in healthy individuals are 
T58R (population allele frequency 0~18%), Q64R (9~57%), E147K (0~2%) and K182E 
(0~4%) (NCBI, SNP database). Previous studies suggested an association between the Q64R 
polymorphism and immune related disease: for instance, the 64Q allele was described as a 
risk factor for systemic lupus erythematosis (SLE),20 while in patients with multiple sclerosis 










































was weakly associated with low serum IgE levels.22 The exact impact of the variations on 
IFN-γR2 function, with the exception of the T168N mutation, is unknown.
In this study, we analysed the impact of previously described amino acid variations in 
IFN-γR2 on receptor expression and function. We cloned the cDNA from wild type IFN-γR2 
and its variants into a retroviral vector and transduced these into several human cell lines. In 
this way the variants could be compared functionally within the same genetic background. 
The transductants were tested for both receptor expression as well as function. 


















Figure 1. Schematic presentation of IFN-γR2. 
On the left the various domains are indicated, on the right the amino acid variations that were analysed 
are indicated. TM=transmembrane domain, SP=signal peptide, C=Cysteine, E=Glutamic acid, 
G=Glycine, K=Lysine, N=Asparagine, Q=Glutamine, R=Arginine, T=Threonine.
2. Materials and Methods
2.1. Cloning IFNGR2 variants into a retroviral expression vector 
The full-length IFNGR2 coding sequence was PCR amplified from cDNA of a healthy 
control with the sense primer 5`-AATTGGATCCCGGGGCCATGCGACCGAC-3` and the 
anti-sense primer 5`-CCGGCTCGAGTTCAAAGCGTTTGGAGAACAT-3` and cloned 
into the retroviral vector pLZRS-IRES-GFP26 as previously described.27 Variations were 
introduced by site directed mutagenesis.28 All constructs were sequence verified and were 
transfected in the Phoenix-A29 packaging cell line using a calciumphosphate transfection kit 
(Invitrogen, Breda, The Netherlands). The virus producing cells were cultured for 2–3 weeks 
under 2 μg/ml puromycin (Clontech, Saint-Germain-en-Laye, France) selection after which 
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2.2. Cell culture and retroviral transduction
Human Jurkat (T lymphoblastic cell line, ATCC TIB-152), THP-1 (myeloid cell line, 
ATCC TIB-202) and G1A cells30 (fibroblasts, kind gift from George Stark) were cultured in 
RPMI1640 medium. B-LCL and T cell blasts (TCB) were cultured in IMDM (Lonza, Vervier, 
Belgium) as described before.27 Culture media were supplemented with 10% FCS, 20 mM 
GlutaMax, 100 U/ml Penicillin and 100 µg/ml Streptomycin (Invitrogen). For propagation 
the adherent G1A cells were trypsinized in the presence of EDTA. Prior to testing, G1A cells 
were collected using only EDTA (Invitrogen). 0.25*106 THP-1 or TCB were retrovirally 
transduced on a CH-296 (RetroNectin®, Takara, Saint-Germain-en-Laye, France) coated 48 
wells plate by adding 1 ml of virus containing supernatant. 0.5*106 B-LCL, Jurkat and G1A 
cells were transduced by adding 1 ml virus containing supernatant supplemented with 10 µl 
DOTAP (Roche, Almere, The Netherlands) to the cells. After overnight incubation the cells 
were washed and cultured for at least four days before analysing in further assays. 
2.3. FACS analysis of IFN-γR2 expression
To detect IFN-γR2 membrane expression cells were stained with an APC conjugated 
polyclonal antibody BAF773 (R&D Systems, Abingdon, UK), with PE conjugated 
monoclonal 2HUB159, 2HUB145 (SantaCruz, Heidelberg, Germany), with monoclonal 
MMHGR-2 (PBL, New Brunswick, NJ- USA) and counterstained with goat-anti-mouse IgG-
PE (BD biosciences, Breda, The Netherlands), or stained with biotin conjugated monoclonal 
MHCD119B25 (DAKO, Heverlee, Belgium) and counterstained with streptavidin-PE (BD 
biosciences). As a negative control the cells were stained with an IgG1 antibody. After 
staining, the cells were washed twice in PBS with 0.2% BSA (Sigma, Zwijndrecht, The 
Netherlands). All subsequent FACS measurements and analyses, using a FACSCalibur and 
CellQuest (BD Biosciences), were performed on cells gated for equal GFP expression. In 
order to detect total (intra- and extracellular) IFN-γR2 expression, cells were treated with 4% 
paraformaldehyde and 0.1% saponin (Sigma) prior to staining with APC conjugated BAF773.
2.4. STAT phosphorylation assay
To study signal transduction, 2*105 G1A cells or TCB in 200 µl of culture medium were 
pulsed for 0 to 30 minutes with various concentrations of IFN-γ (Invitrogen) in 96-wellsplates 
(Greiner bio-one). The cells were fixated with 4% paraformaldehyde and permeabilised with 
90% methanol (Merck, Amsterdam, The Netherlands). Subsequently, the cells were washed 
with PBS containing 0.2% BSA (Sigma), blocked with 10% normal goat serum (Sanquin, 
Amsterdam, The Netherlands), and stained with the phospho-specific antibody pY701-
STAT1-Alexa 647, pY705-STAT3-PE or pY694-STAT5-PE (BD Biosciences). Before 










































2.5. IFN-γ response assays
To study the upregulation of cell surface markers 0.25*106 G1A cells were stimulated in 24 
Wellsplates (Greiner bio-one) for 20 h in 1 ml of culture medium with various concentrations 
of IFN-γ. Afterwards the cells were washed in medium and stained with PE-conjugated 
antibodies against CD54, CD64, HLA-DR or stained with the W6.32 antibody against HLA 
Class I and counterstained with GAM-PE (BD biosciences). The cells were washed twice 
before FACS measurements and analyses were performed on G1A cells gated for relatively 
low GFP expression.
Prior to cytokine production assays G1A cells were sorted by FACS for low GFP 
expression using a FACSAria (BD biosciences). 0.1*105 G1A cells were cultured in 0.2 ml of 
culture medium and pulsed with various concentrations of IFN-γ (Invitrogen) using microlon 
plates (Greiner bio-one). After 48 hours cell free supernatants were collected and tested for 
the presence of CXCL10 with a specific ELISA (Invitrogen).
3. Results
3.1. Functional transfer of wild type IFNGR2 into cell lines
In order to set up a model system we cloned wild-type IFN-γR2 cDNA into the retroviral 
expression vector pLZRS-GFP. The use of pLZRS-GFP allows for tandem expression of 
IFN-γR2 and green fluorescent protein (GFP). We expressed the receptor in various human 
cell lines: B-LCL, THP-1, Jurkat, TCB and IFN-γR2 deficient fibroblastic G1A cells. The 
cell surface expression of IFN-γR2 was determined by FACS with five distinct anti-IFN-
γR2 antibodies. We did not detect natural expression of IFN-γR2 on untransduced or GFP-
transduced cells with any of the antibodies (data not shown). With the BAF773 antibody we 
detected retrovirally achieved overexpression of wild-type IFN-γR2 in all cell lines tested 
(Figure 2A), whereas the other four antibodies failed to detect expression of wild-type IFN-
γR2 (data not shown). Cotransduction of IFN-γR1 did not influence detection of IFN-γR2 
expression and vice versa (data not shown).
Next, we tested the IFN-γ responsiveness of the transduced cells by studying the 
intracellular signalling. The kinetics of STAT1 phosphorylation was determined by FACS. 
After 0 to 30 minutes of incubation with various concentrations of IFN-γ the STAT1 
phosphorylation in the cells was measured using a phospho-specific antibody against pY701-
STAT1. IFN-γ induced STAT1 phosphorylation in untransduced THP-1 cells and to a lesser 
extent in B-LCL. This indicates that, although there was no detectable natural expression 
of IFN-γR2 on these cells, there is a small amount of functional IFN-γR2 present. IFN-γ 
did not induce STAT1 phosphorylation in untransduced Jurkat, G1A and TCB cells. IFN-
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phosphorylated STAT1 in response to IFN-γ (data not shown). IFN-γR2 transduced G1A and 
TCB cells showed an IFN-γ-dose dependent increase in STAT1 phosphorylation upon IFN-γ 
stimulation (Figure 3A and 3B). The STAT1 phosphorylation in G1A (Figure 3A) and in TCB 
(Figure 3B) with the wild type IFN-γR2 was at maximum at 15 minutes and was strongest 
at the highest concentration of IFN-γ. No induction of STAT3 and STAT5 was observed in 
IFN-γR2 transduced B-LCL, Jurkat, TCB and G1A (data not shown). 
3.2. Differential expression patterns of the IFN-γR2 variants
One novel variation (G227R), two known mutations (R114C, T168N), and two common 
(T58R, Q64R) and two rare variations (E147K and K182E) in IFN-γR2 were cloned and 
retrovirally expressed in the human cell lines: B-LCL, THP-1, Jurkat, TCB and G1A. Next, 
we determined the expression of the IFN-γR2 variants on the cell surface by FACS, on cells 
gated for equal GFP expression, with five anti-IFN-γR2 antibodies. 
With the antibody BAF773 (Figure 2A) we detected cell surface expression on cells 
transduced with either wild-type IFN-γR2 or with the variants. Expression patterns, however, 
varied amongst the cell lines. For instance, the Q64R variant showed, in all experiments and 
in all cell lines, the highest detection signal as compared with all other variants tested. In G1A 
cells the expression of wild- type IFN-γR2 was similar to that of the variants T58R, R114C, 
E147K, T168N, K182E or G227R. By contrast, TCB cells showed a reduced expression 
of R114C and G227R, whereas the expression of T58R, E147K, T168N and K182E was 
again similar to wild-type IFN-γR2. TCB, B-LCL, THP-1 and Jurkat cells showed similar 
expression patterns of the IFN-γR2 variants, except that the expression of G227R on B-LCL 
and THP-1 varied between experiments from 29% to 123% of the expression level of wild-
type IFN-γR2. Of note, the expression of R114C on one of the six TCB lines tested, TCB-5, 
was significantly reduced as compared to the expression of R114C on the other TCB lines 
(p=0.001, student t-test) (data not shown).
Remarkably, of the four antibodies (2HUB159, 2HUB145, MMHGR-2, MHCD119B25) 
that failed to detect expression of wild-type receptor, 2HUB159 was able to detect cell surface 
expression of R114C and G227R on Jurkat, TCB and G1A cells (Figure 2B). Just like the 
wild-type, the other variants could not be detected by any of these four antibodies (Figure 2B 
and data not shown).
Differences in detection of cell surface expression might be ascribed to an altered 
affinity of the antibody caused by an amino acid variation or to an actual difference in the 
amount of protein present on the cell membrane. Differences in amount of protein can be 
due to differences in protein production, in protein stability, or in misfolding followed by 
sequestration and degradation of the protein in the endoplasmic reticulum. To determine 
whether the IFN-γR2 variants are present in equal amounts within the cell but differential 










































expression by staining TCB with BAF773 after permeabilisation of the cell membrane. In 
this way comparable amounts of proteins were detected for R114C, G227R, T58R, E147K, 
T168N, K182E and the wild type variant (Figure 2C). In contrast, the signal of Q64R was 




































































































































































































Figure 2. Extracellular and total expression of the IFN-γR2 variants.
(A) Extracellular expression of IFN-γR2 was measured on B-LCL (n=3), THP-1 (n=3), Jurkat (n=5), 
TCB (n=6) and G1A (n=3) cells that were untransduced, transduced with GFP alone or transduced with 
one of the IFNGR2 gene variants by FACS with the antibody BAF773. (B) Extracellular expression 
of IFN-γR2 was also measured on Jurkat, TCB, G1A cells that were untransduced, transduced with 
GFP alone or with one of the IFNGR2 gene variants with the 2HUB159 antibody. Experiment in triplo. 
(C) The total, intra- and extracellular, expression of IFN-γR2 in two TCB cell lines was measured 
after fixation and permeabilization of the cells. For all experiments the expression of IFN-γR2 was 
determined for the transduced cells with equal GFP expression. The mean fluorescence ± standard 
deviation (SD) is displayed. For A and C the mean fluorescence is depicted as percentage of the IFN-
γR2 wild type variant, where the mean fluorescence of cells labelled with an isotype antibody was set 
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Figure 3. Kinetics of IFN-γ induced STAT1 phosphorylation and the influence of IFN-γR2 
variations. 
The amount of intracellular phosphorylated STAT1 was determined as a measure of IFN-γ induced 
signal transduction. The kinetics of STAT1 phosphorylation was first determined for (A) G1A and (B) 
TCB-4 cells transduced with wild-type IFN-γR2. Cells were stimulated for 0 to 30 minutes with various 
concentrations of IFN-γ. Next we studied the impact of the variations on IFN-γ signalling. (C) G1A 
and (D) TCB cells, untransduced, transduced with GFP alone or transduced with one of the IFN-γR2 
variants were stimulated for 15 minutes with 500 or 1000 pg/ml IFN-γ. The amount of intracellular 
phosphorylated STAT1 was measured by FACS, using a phospho-specific antibody, in cells with equal 
GFP expression. For (C) the mean fluorescence ± SD of one representative out of two experiments is 
displayed. For (D) the mean fluorescence ± SD of four different TCB lines (each tested in triplo) was 
calculated as percentage of the IFN-γR2 wild type variant. (* p<0.05, variant and the wild type were 
compared using the student t-test).
3.3. Effect of IFN-γR2 variations on IFN-γ mediated signal transduction
Intracellular signalling via the IFN-γR complex is mediated by STAT1 molecules which are 
activated through tyrosine phosphorylation. We chose the TCB and G1A cells to study the 
functional effect of IFN-γR2 variants on STAT1 phosphorylation, because these cells are 
not responsive to IFN-γ, unless transduced with wild-type IFN-γR2 (Figure 3A and 3B). 
In untransduced and GFP transduced cells, no STAT1 phosphorylation could be detected 
after exposure of the cells to IFN-γ. G1A cells expressing wild-type IFN-γR2, T58R, 
Q64R, E147K or K182E showed similar STAT1 phosphorylation after IFN-γ exposure 
(Figure 3C). However, in G1A cells transduced with the T168N variant no IFN-γ induced 










































variant showed diminished, intermediate levels of STAT1 phosphorylation (Figure 3C). All 
variants expressed in G1A cells, with the exception of T168N, displayed similar STAT1 
phosphorylation plateau levels, after 60 to 90 minutes of stimulation with 500 pg/ml IFN-γ 
(data not shown).
The results obtained with the TCB cells (Figure 3D) did not differ from those obtained 
with the G1A cells. The reduction of STAT1 phosphorylation in TCB lines, transduced with 
R114C, varied from -34% to -98%. TCB-5 that was found to have the lowest cell surface 
expression of R114C (see previous section) also showed the lowest phosphorylation of 
STAT1.
3.4. Influence of IFN-γR2 variations on IFN-γ responses
IFN-γ stimulates, via STAT1 phosphorylation, the expression of a wide range of proteins. 
We tested the IFN-γ induced expression of CD54, CD64, HLA Class I and II in IFN-γR2 
transduced TCB and G1A cells by FACS. Additionally, we tested the supernatants of these cells 
for the presence of CXCL10 by ELISA. Stimulation with IFN-γ of TCB carrying wild-type 
IFN-γR2 did not or, only slightly enhance, the expression of these proteins (data not shown). 
By contrast, G1A cells carrying the wild-type receptor showed significant upregulation of 
CD54, HLA Class I and CXCL10 after stimulation with 25 000 pg/ml of IFN-γ (data not 
shown). Subsequently, we tested the IFN-γR2 variants in G1A cells for IFN-γ-induced CD54 
and HLA Class I upregulation and CXCL10 production. Untransduced and GFP transduced 
G1A cells did not respond to IFN-γ (Figure 4A-C). In G1A cells carrying the wild-type 
receptor or the T58R, Q64R, E147K or K182E variants, IFN-γ induced in a dose-dependent 
fashion the CD54 expression on the cell surface (Figure 4A). Cells transduced with R114C 
or G227R showed impaired responses; for instance in comparison to cells transduced with 
the wild-type receptor 8 (G227R) t o 100 times (R114C) as much IFN-γ needed to be added 
to the incubations to achieve the same level of CD54 expression. 
Similar results were obtained when the G1A cells were analysed for HLA-Class I 
expression (Figure 4B) or the production of CXCL10 (Figure 4C). While induction of CD54 
and HLA Class I expression could be detected after incubation of the cells with as little as 25 
pg/ml IFN-γ, CXCL10 expression was induced only at concentrations of 2500 pg/ml IFN-γ 
or higher. G1A cells with T168N showed in four independent experiments almost a total lack 
of response, as a slight yet significant upregulation of cell surface expression of CD54 and 
HLA Class I was noted at the highest dose of IFN-γ only (Figure 4A and 4B). An overview 
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Figure 4. The effect of the IFN-γR2 variations on IFN-γ responses.
Untransduced G1A cells and G1A cells retrovirally transduced with GFP alone or with one of the IFN-
γR2 variants were stimulated for 18 h (A and B) or 48 h (C) with various concentrations of IFN-γ. The 
CD54 expression (A) and the HLA Class I expression (B) were determined by FACS. The CXCL10 (C) 
production was determined by ELISA. One representative out of four (A) and one out of two (B and 
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3.5. No dominant negative effects of IFN-γR2 mutations
Since the IFN-γR consists of two IFN-γR1 and two R2 chains, incorporation of one defective 
chain in the IFN-γR could potentially have a dominant-negative effect on the receptor 
complex function. We determined whether the T168N, R114C or the G227R variants, which 
were partly or completely defective, could exert such an effect. To this end, we transduced 
the IFN-γ responsive cell line THP-1 with the T168N, R114C and G227R variants and as 
controls with wild-type IFN-γR2, wild-type IFN-γR1, a dominant negative IFN-γR1 mutant 
(IFN-γR1-delTTAA), or with an empty GFP vector. All THP-1 cells displayed induction of 
CD54 expression after stimulation with 2500 pg/ml IFN-γ. Overexpression of wild type IFN-
γR1 or IFN-γR2 resulted in an upregulation of CD54 of respectively 48% and 59%, whereas 
overexpression of the G227R variant resulted only in 30% CD54 upregulation (Figure 5). 
The GFP, R114C and T168N transduced THP-1 cells were similarly responsive to IFN-γ, 
whereas the IFN-γR1-delTTAA transduced THP-1 cells showed a 60% decreased response 
(Figure 5). Thus, no dominant-negative effects of the IFN-γR2 variants were seen.
Figure 5 



























































Figure 5. Influence of IFN-γR2 mutants on the function of the natural IFN-γ receptor complex. 
Normal and deficient IFN-γR1 and IFN-γR2 proteins were overexpressed in THP-1 cells to study their 
influence on the functioning of the native receptor IFN-γR complex. Untransduced THP-1 cells and 
THP-1 cells transduced with GFP, wild type IFN-γR2, R114C, T168N, G227R, wild type IFN-γR1 
and the dominant negative delTTAA variant of IFN-γR1 were stimulated for 20 h with 2500 pg/ml 
IFN-γ. Hereafter the cells were analysed for CD54 expression by FACS. One representative of two 
experiments in triplo is shown. * significantly higher and ** significantly lower induction of CD54 











































In an in vitro test model to analyse the functional impact of amino acid substitutions in 
IFN-γR2 we successfully characterized IFN-γR2 variants and could designate them as either 
innocuous polymorphisms or deleterious mutations affecting the function of the type-1 
cytokine pathway to macrophage activation. We could confirm the complete loss of function 
of IFN-γR2 due to the T168N variation. The R114C and the G227R variations, described 
previously in MSMD patients, were shown to constitute partially functional receptor chains. 
These findings have implications for the treatment of patients homozygous for R114C or 
G227R mutations, since in case of mycobacterial infection, they might still benefit from 
IFN-γ administration in addition to antibiotic treatment.18 Moreover, we showed that the 
T58R, Q64R, E147K and K182E variants do not differ in function from the wild-type 
receptor and can therefore be considered functional polymorphisms. 
Our conclusions, summarized in Table 1, are based on the findings obtained with an in 
vitro model wherein cells are retrovirally transduced with the respective IFN-γR2 variants. 
Employing this model system, we were able to distinguish normal from defective variants. 
In this respect, several aspects need consideration. First, IFN-γR2 is overexpressed after 
transduction by the retroviral vector and overexpression might mask subtle differences in 
receptor function. Still, we could define the impact of mutations that resulted in an intermediate 
phenotype of receptor expression and reduced receptor function, as opposed to a complete, 
null phenotype. Naturally and overexpressed IFN-γR2 may differ also in post-transcriptional 
or post-translational modification, although there are no indications that such modifications 
in fact occur. Second, all of the commercially available antibodies failed to detect native 
IFN-γR2 expression on THP-1 and primary monocytes. Previous research already indicated 
the inability of five antibodies (three of which we employed as well) to detect cell surface 
expression of native IFN-γR2.23 Apparently, the expression of native IFN-γR2 is too low 
to detect. In our model system, however, we successfully detected IFN-γR2, when it was 
overexpressed, with the BAF773 antibody but not with the other antibodies. The use of 
other antibodies, recognising additional, distinct epitopes, would have helped to determine 
whether a difference in detection is due to a difference in affinity towards the variants or 
due to an actual difference in the amount of protein present. However, in the system with 
overexpression, we observed for most variants a comparable total (i.e., intracellular and 
cell surface) receptor expression, suggesting the affinity is not different. Third, the IFN-γ 
responses in the host are not confined to the cellular responses we assayed in this report. 
Although this has not been reported, it cannot be excluded that other read-out systems may 
be more sensitive to subtle differences in IFN-γR2 at lower IFN-γ concentrations. Our model 
allowed us, nevertheless, to detect highly significant induction of CD54, HLA Class I and 
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The variations R114C and G227R were homozygously present in MSMD patients and 
could be the cause of IFN-γ deficiency, as was previously shown for the T168N variation. The 
T168N variation was described as a mutation resulting in a complete loss of function due to 
gain of glycosylation at the asparagine (N) residue.25 We could confirm the severe impact of 
the T168N variant on IFN-γR2 function. When T168N was overexpressed, some upregulation 
of CD54 and HLA Class I occurred at the highest concentration of IFN-γ used, and this 
response is considered to be marginal only. For instance, the latter finding might indicate that 
a very small portion of the T168N variant is not fully glycosylated, since deglycosylation 
of the receptor can restore receptor function.25 If the expression level of T168N is brought 
down to a physiological level, this effect may be absent. In all, we confirm the observation 
that the T168N variation results in a complete null mutation. The G227R variation, which 
was recently observed in a MSMD patient (S.S. Kilic, manuscript in preparation), appears 
to be a severe but not completely null mutation. We found that the cell surface expression of 
G227R on TCB was reduced, although the total expression in the cell was normal. The cell 
surface expression of G227R on G1A cells was normal. Both TCB and G1A transduced with 
G227R showed, however, a strongly reduced responsiveness to IFN-γ. Thus we conclude 
that G227R is a mutation leading to a partial receptor defect due to reduced functioning 
of the receptor and that G227R also results in a moderate loss of cell surface expression, 
which may depend on cell type or state of activation. The same conclusion is drawn for the 
R114C variation, which was first described in a patient who responded poorly to IFN-γ.18 The 
IFN-γ responsiveness of the patient’s cells could be restored in vitro by transfection with a 
vector carrying cDNA from IFNGR2, indicating a defect in IFN-γR2.18 Our results further 
demonstrate that R114C is the cause of this defect. In our experiments R114C and G227R 
showed comparable reductions on IFN-γR2 expression and function.
Some differences in expression patterns of IFN-γR2 could be distinguished. The 
expression of both R114C and G227R was reduced in TCB, but not in G1A. We also found 
that the expression of G227R in B-LCL and THP-1 varied between experiments. Additionally, 
we found that one of the six TCB lines, TCB-5, transduced with the R114C variant showed 
a highly significant reduced expression as compared to the other TCB lines carrying R114C. 
Taken together these findings suggest that the impact of the partial mutations depends on cell 
type, culture state and on individual host specific factors.
The 2HUB159 antibody we used failed to detect retroviral expression of wild type IFN-
γR2. 2HUB159 was raised against an unspecified fragment of the extracellular domain of 
the receptor and possibly recognises the receptor in a denatured, e.g. in blotting experiments, 
rather than natural conformation. Remarkably, we could detect cell surface expression of 
R114C and G227R with the 2HUB159 antibody. Therefore, the R114C and G227R variants 
are likely to result in an altered conformation of the receptor, as compared to wild-type 
IFN-γR2, and this may contribute to the reduced receptor function. Although the R114 and 










































structure these could be located close together. The crystal structure of IFN-γR2 has not been 
elucidated yet, the putative secondary structure elements identified by Krause et al7 suggest 
however that R114 and G227 may well be in close proximity after folding of the receptor.
We showed that the R114C, T168N and G227R mutations do not have a dominant negative 
effect on the function of the IFN-γ receptor complex. This is in line with the observation that 
heterozygous family members carrying one mutated allele are not more prone to develop 
Mycobacterial infections18,25 and in vitro the cells, from individuals heterozygous for the 
G227R mutation, do not show impaired responses in immunological analyses (S.S. Kilic, 
manuscript in preparation).
The variants T58R, Q64R, E147K and K182E constitute fully functional polymorphisms 
of the IFN-γR2. Although we could detect minor differences in cell surface expression, all 
IFN-γR2 variants displayed a similar IFN-γ response. The cell surface as well as total cellular 
expression of Q64R, as determined with the BAF773 antibody, was higher in all cell lines 
tested as compared to the other variants. Since the expression was determined in cells gated 
for equal GFP expression and the IFNGR2 and GFP genes are transcribed in tandem thus 
ensuring that equal amounts of transcripts are present, we expect that an equal amount of 
protein is translated of the wild-type IFN-γR2 and Q64R. An explanation may be that the 
Q64R variant is more stable, resulting in higher expression. Another explanation may be 
that the BAF773 antibody binds with higher affinity to the Q64R variant. Finally, higher 
expression of the Q64R variant is consistent with suggestions in the literature that this variant 
might be more responsive to IFN-γ. First, in agreement with the notion of a somewhat altered 
function, the 64R allele was overrepresented in patients with multiple sclerosis having a more 
progressive onset of the disease, in which Th1 immune response plays a role.21 Second, the 
64Q allele was positively associated with the occurrence of SLE, which is considered to be 
a Th2 disease.20 And third, in a British population the 64Q allele showed a weak association 
with low IgE levels.22 Taken together, altered cell surface expression of IFN-γR2 due to the 
Q64R polymorphism, may influence the strength of IFN-γ responses and by consequence 
the polarization of T cells towards Th1 or Th2.6 More population association studies will be 
necessary to confirm an association of the common Q64R polymorphism with Th1 and Th2 
mediated disease. Research on the expression pattern of IFN-γR2 variants at the cellular level 
urgently needs the characterization of a wider array of IFN-γR2 detecting antibodies.
We conclude that T58R, Q64R, E147K and K182E are fully functional polymorphisms of 
IFN-γR2. The R114C, T168N and G227R variations are deleterious mutations with T168N 
leading to a complete IFN-γR2 deficiency while R114C and G227R lead to a partial IFN-γR2 
deficiency. The severely reduced IFN-γ responsiveness of R114C and G227R is mainly due 
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Interleukin-12 (IL-12), IL-23 and interferon-γ (IFN-γ) are pivotal cytokines acting in concert 
with tumor necrosis factor (TNF) and IL-1β to shape type I immune responses against 
bacterial pathogens. Recently, several groups reported that type I immunity can be inhibited 
by IFN-α/β. Here we show the extent of the inhibitory effects of IFN-α and IFN-β on the 
responsiveness of human monocytes to Toll like receptor-ligands and IFN-γ. Both IFN-α 
and IFN-β strongly reduced the production of IL-12p40, IL-1β and TNF and the IFN-γ 
induced CD54 and CD64 expression. High IFN-γ concentrations could not counterbalance 
the inhibitions and IFN-α still inhibited monocytes 24 h after stimulation in vitro as well 
as in vivo in patients undergoing IFN-α treatment. Next, we explored the mechanism of 
inhibition. We confirm that IFN-α/β interferes with the IFN-γR1 expression, by studying 
the kinetics of IFN-γR1 downregulation. However, IFN-γR1 downregulation occurred 
only after two hours of IFN-α/β stimulation and was transient, which can not explain the 
IFN-γ unresponsiveness observed directly and late after IFN-α/β stimulation. Additional 
experiments indeed indicate that other mechanisms are involved. IFN-α may interfere with 
IFN-γ-elicited phosphorylation of signal transducer and activator of transcription 1 (STAT1). 
IFN-α may also activate methyltransferases which in turn reduce, at least partly, the TNF and 
IL-1β production and CD54 expression. IFN-α also induces the protein inhibitor of activated 
STAT1 (PIAS1). In conclusion, IFN-α and IFN-β strongly inhibit the IFN-γ responsiveness 
and the production of type I cytokines of monocytes, probably via various mechanisms. Our 
findings indicate that IFN-α/β play a significant role in the immunopathogenesis of bacterial 












































IFN-α and IFN-β as well as IFN-γ display immunomodulatory effects to help the host to 
combat infections. IFN-α and IFN-β are closely related cytokines, which are important in 
the defence against viruses. IFN-γ is the main mediator of the type I immune response and 
is essential in the control of infections with intracellular pathogens, such as Mycobacteria 
and Salmonellae [1]. IFN-α and IFN-β also play a role in various bacterial diseases, for 
example tuberculosis. Patients with active infection with Mycobacterium tuberculosis were 
recently shown to have an expression profile typical of IFN-α-induced immune related 
genes coinciding with reduced IFN-γ signalling within their blood cells [2, 3]. This is in 
line with the finding that virulent Mycobacterium tuberculosis strains isolated from humans 
induced IFN-α production in mice, which correlated with decreased type I immunity [4, 5]. 
Thus, Mycobacterium tuberculosis survival in the host may benefit from enhanced IFN-α/β 
signalling and repressed IFN-γ signalling. In addition, virulent strains of the intracellular 
pathogens Bordetella pertussis and Francisella tularensis were also found to inhibit the type 
I immune responses of human dendritic cells, via induction of IFN-β [6, 7].
IFN-α/β and IFN-γ have both common and distinct effects on human cells [8, 9]. IFN-
α/β act inhibitory on immature and stimulatory on mature antigen presenting cells, B- and 
T-lymphocytes [10]. Therefore IFN-α/β may favour late antibacterial responses [11], although 
IFN-α/β may actually dampen antibacterial responses in the early phase of infection. For 
example, IFN-β exposure during naïve T cell stimulation inhibits Th1 cell generation by 
inhibiting the IL-12 and IL-23 production of cultured human dendritic cells [12]. We recently 
reported that IFN-α can also reduce the IFN-γ responsiveness of human primary monocytes 
[13]. Yet, little is known about the precise extent and mechanisms whereby IFN-α/β inhibits 
type I immune responses. IFN-α/β may very well interfere with the control of infections with 
intracellular pathogens. The inhibitory effects of IFN-α/β may thus explain why in influenza 
virus infected mice, virus-induced IFN-α renders the mice highly susceptible to bacterial 
infections [14], and why mice that lack a functional IFN-α/β receptor are relatively resistant 
to infections with the intracellular pathogen Listeria monocytogenes [15]. 
Upon IFN-γ stimulation, via the IFN-γR, STAT1 is tyrosine phosphorylated, dimerizes and 
translocates to the nucleus. STAT1 homodimers can activate transcription of several genes via 
binding to IFN-γ activated sequences (GAS) in promoters [16]. IFN-α and IFN-β both signal 
via the IFN-α receptor complex (IFN-αR) resulting in STAT1-STAT2 heterodimers, which 
associate mostly with interferon regulatory factor 9 (IRF-9) to form interferon-stimulated 
gene factor 3 (ISGF3) complexes [17]. The transcription factor ISGF3 binds to interferon-
stimulated response elements (ISREs), while STAT1-STAT2 heterodimers can also bind to 
certain GAS sites [9]. IFN-α/β and IFN-γ signalling may thus result in both common and 










































with different efficacy [8]. For example, the transcription factor IRF-1 can be effectively 
induced by both IFN-α and IFN-γ. On the other hand, IFN-γ upregulates IRF-8 [18], CD54 
and CD64 expression and enhances LPS-induced cytokine production of interleukin-1β (IL-
1β), IL-12, IL-23 and TNF [13], while IFN-α on the contrary inhibits these IFN-γ effects. 
Inhibition of IFN-γ responses by IFN-α/β could potentially be achieved via for instance 
IFN-γ receptor (IFN-γR) downregulation, prevention of STAT1 homodimer formation 
or activation of protein arginine methyltransferase 1 (PRMT1). PRMT1 was found to be 
associated with the IFN-αR1 subunit of the IFN-αR [19], which may indicate that PRMT1 is 
regulated by IFN-α/β [20]. Activation of PRMTs results in methylation of arginine residues 
of various proteins, thereby modulating their actions [21]. PRMT1 can, amongst others, 
methylate the protein inhibitor of activated STAT1 (PIAS1) [22]. Methylated PIAS1 binds 
to STAT1, thereby negatively influencing the DNA binding capacity of STAT1 homodimers 
to certain, but not all, GAS sites [23]. In this way PIAS1 selectively inhibits IFN-γ induced 
transcription of genes.
In this study, we focused first on the extent of the opposing effects of IFN-α and IFN-β on 
the type I immune responses of human monocytes in vitro. We investigated whether IFN-α and 
IFN-β display comparable opposing effects, and whether high doses of IFN-γ can overcome 
these effects. Second, we determined the duration of the inhibitory effects in vitro and in 
vivo. Third, we explored by which mechanism IFN-α can interfere with IFN-γ functions, 
by examining the effects of IFN-α on IFN-γR expression and STAT1 phosphorylation. 
Additionally, we investigated whether PRMT1 and PIAS1 could play a role in the inhibitory 
effects of IFN-α. 
2. Materials and Methods
2.1. Monocyte isolation and culture
PBMCs were isolated from blood of healthy blood bank donors, via ficoll separation. 
Subsequently monocytes were isolated using CD14 MACS beads (Miltenyi) according to 
the manufacturer’s protocol. The isolated monocytes contained less than 1.5 % CD3+ cells, 
as analysed by FACS using PE conjugated antibody against CD3 (BD Biosciences). Cells 
were cultured in 96 wellsplates in IMDM (Lonza) supplemented with 8% FCS, 100 U/ml 
penicillin, 100 μg/ml streptomycin and 20 mM glutamax (Life Technologies). Cells were 
stimulated, as indicated in each experiment, with 1 ng/ml LPS (Sigma), 10 μg/ml of heat 
killed Mycobacterium tuberculosis (MTB) (kind gift from L. Wilson), IFN-α, IFN-β, IFN-γ 
(PBL) and Arginine Methyltransferase Inhibitor 1 (AMI1, Calbiochem). The IFN-α is a 1:1 
mixture of the subtypes 2a and 2b. The IFN-β is of the 2b subtype. 10 Units/ml IFN-α/β 
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2.2. Patient materials and immunological screenings
Patients with cutaneous melanoma received IFN-α treatment prior to and after T cell 
infusions [24]. IFN-α (subtype 2a, 3 million IU Roferon, Roche) was injected subcutaneously 
each day. PBMCs were isolated from blood and stored in liquid nitrogen until use at two 
time points: once before the start of the treatment and once 2 to 4 weeks later during IFN-α 
treatment. Thawed PBMCs were washed three times with culture medium and directly used 
in further assays using 96 wellsplates (Greiner bio-one). The IFN-γR1 receptor expression 
and the IFN-γ induced CD54 expression were analyzed by FACS as described in section 
2.3, except that the cells were also stained with FITC conjugated CD14 (BD Biosciences) , 
in order to assess the expression on CD14+ monocytes. The LPS responsiveness was tested 
by stimulating 2*105 PBMCs (the standard deviation of cell counting was about 5%), from 
patients and controls, with or without 1 ng/ml LPS in 200 μl of IMDM supplemented with 
8% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin and 20 mM glutamax. After 24h 
of incubation supernatants were harvested and analyzed for the presence of IL-12p40 by 
ELISA (Invitrogen). All patients gave written informed consent. The treatment protocol was 
approved by the Medical Ethics Committee of the Leiden University Medical Center.
2.3. Analysis of receptor expression
1.5*105 PBMCs or CD14+ monocytes were incubated with various concentrations of IFN-γ 
or IFN-α in 200 µl of culture medium. Cells were washed with PBS supplemented with 0.2% 
bovine serum albumin (BSA) (Roche). To determine CD54 and CD64 expression the cells 
were stained with PE labelled anti-CD54 and FITC labelled anti-CD64 (clones HA58 and 
10.1, BD Biosciences). To determine the IFN-γR1 expression the cells were stained with PE 
labelled GIR94 (BD Biosciences). Cells were analyzed with a FACSCalibur using CellQuest 
software (BD Biosciences).
2.4. Measurements of cytokine production
1.5*105 CD14+ monocytes were incubated with various concentrations of IFN-γ and/or 
IFN-α in the presence or absence of 1 ng/ml LPS. After 24h supernatants were collected and 
analysed for the presence of IL-12p40, IL-1β and TNF by ELISA (Invitrogen) using microlon 
plates (Greiner bio-one). The detection limit of the ELISAs was 150 pg/ml.
2.5. FACS analysis of STAT1 phosphorylation
2*105 CD14+ monocytes were incubated for 5 to 60 minutes with various concentrations 
of IFN-γ and/or IFN-α in 200 µl of culture medium. In order to detect intracellular 
phosphorylation of STAT1, cells were fixated with 4% paraformaldehyd (Sigma) and 
permeabilized with 90% methanol (Merck). Subsequently, the cells were treated with 10% 










































pY701-STAT1 (clone 4a, BD Biosciences). After labelling, the cells were washed twice and 
analyzed by FACS using a FACSCalibur and CellQuest software (BD Biosciences).
2.6. Western blot analysis of STAT2 phosphorylation
To detect STAT2 tyrosine phosphorylation, we incubated 2*106 CD14+ monocytes with 
100 U/ml IFN-α and/or 2.5 ng/ml IFN-γ. After incubation the cells were washed with an 
excess of ice-cold PBS. The cells were lysed in a radioimmune-precipitation-assay (RIPA) 
buffer supplemented with PMSF, protein inhibitors and sodium-orthovanadate, according 
to the supplier’s recommendations (SantaCruz). Equal protein amounts, determined using a 
Bradford assay (Thermo Scientific), were run on a 10% polyacrylamidegel (Promega), and 
blotted on a polyvinylidene difluoride (PVDF) membrane (Perkin Elmer) using electrophoresis 
and blotting apparatuses according to the manufacturer’s protocols (BioRad). Membranes 
were blocked for 1 h in PBS supplemented with 5% milk powder (Campina). Subsequently, 
the membranes were incubated with mouse-anti-human-pY690-STAT2 (clone 7a, BD 
Biosciences) in PBS-2.5% milk powder, washed and incubated with a HRP-conjugated Fab 
fragment of a goat-anti-mouse antibody (SantaCruz) in PBS-2.5% milk powder. As a control 
the blot was subsequently incubated with a HRP-conjugated antibody against GAPDH (clone 
Fl335, SantaCruz). Binding was detected using an enhanced chemiluminescence kit (Thermo 
Scientific) and exposure to X-ray film (Fuji).
 
2.7. Western blot analysis of PRMT1 and PIAS1
The expression of PRMT1 and PIAS1 was analyzed by western blot as described above, with 
some slight modifications. Tris-buffered-saline (Roche) instead of PBS was used to incubate 
the PVDF membranes after blotting. Specific monoclonal rabbit-anti-human antibodies 
against PRMT1and PIAS1 (clone A33 and clone D33A7, Cell Signalling Technologies) and 
a secondary HRP-conjugated donkey-anti-rabbit antibody (sc-2077, SantaCruz) were used to 
determine expression. As a control GAPDH expression was subsequently analysed using a 
HRP-conjugated monoclonal antibody against GAPDH on the same blot.
2.8. Statistical analysis
Differences in responses were analyzed using one-way or two-way ANOVA analyses with 
Bonferroni adjustment, the two tailed student t-test or the paired student t-test. The statistical 












































3.1. IFN-α and IFN-β inhibit IFN-γ induced CD64 and CD54 expression
We have previously noted that IFN-α inhibited the expression of CD54 and CD64 induced 
by 2.5 ng/ml of IFN-γ [13]. Little is known about the dose response effects of IFN-α/β and 
IFN-γ, which we studied here in detail. Furthermore, we determined whether IFN-β displays 
similar effects and whether high concentrations of IFN-γ could overcome these inhibitory 
effects. CD14+ monocytes were cultured for 18 h with various concentrations of IFN-γ in 
the presence or absence of IFN-α or IFN-β. Incubation of the CD14+ monocytes with high 
concentrations of IFN-γ gave a 6 fold enhancement in CD64 expression (Fig. 1A and 1B). 
Culturing the cells with IFN-α or IFN-β alone did not affect CD64 expression. Addition of 
IFN-α or IFN-β together with IFN-γ gave a dose dependent reduction of the IFN-γ induced 
CD64 expression (Fig. 1A and 1B). IFN-α and IFN-β reduced the expression of CD64, at all 
IFN-γ concentrations. The IFN-γ induced enhancement of CD54 expression was reduced by 
IFN-α and IFN-β in a similar way (Fig. 1C and 1D). The inhibition by IFN-α and IFN-β was 
similar (Fig. 1E) and IFN-γ concentrations up to 250 ng/ml could not overcome the inhibitory 
effect of IFN-α or IFN-β (Fig 1A-D).
3.2. IFN-α and IFN-β inhibit production of IL-12p40, IL-1β and TNF
IFN-α and IFN-β are known to inhibit IL-12p40 production. We wanted to determine the 
extent of this inhibition and whether other cytokines are also inhibited. For the establishment 
of an effective type I immune response the cytokines TNF and IL-1β play a pivotal role. The 
production of these cytokines can be induced via TLR stimulation and is greatly enhanced by 
IFN-γ. Therefore, we studied the effects of IFN-α and IFN-β on the production of IL-12p40 
(the common subunit of IL-12 and IL-23), IL-1β and TNF by monocytes. CD14+ monocytes 
were stimulated with or without 1000 U/ml IFN-α or IFN-β and various concentrations of 
IFN-γ in the presence or absence of LPS. Incubation with one of the interferons alone did 
not induce cytokine production (data not shown). LPS induced the production of IL-12p40, 
IL-1β and TNF, which could be dose dependently enhanced by IFN-γ (Fig. 2 A, B, C). IFN-α 
and IFN-β strongly reduced the production of IL-12p40 induced by LPS alone or together 
with IFN-γ (Fig. 2A). The effect of IFN-γ on IL-1β production was also strongly reduced 
(Fig. 2B), while the effect of IFN-γ on TNF production was only partly reduced by IFN-α 
and IFN-β (Fig. 2C). Addition of high IFN-γ concentrations, up to 250 ng/ml, could not 
overcome the inhibitory effects of IFN-α or IFN-β on the LPS-induced IL-12p40, IL-1β and 
TNF production (Fig 2A, B, C). The extent of the inhibitory effects of IFN-α and IFN-β was 
compared in figure 2D. The inhibitory effect was significant for all three cytokines and was 
similar for IFN-α and IFN-β (Fig. 2D). The inhibitory effects of the IFN-α and IFN-β were 











































Besides LPS, which is a single TLR-ligand able to activate monocytes via TLR2 and 
TLR4, we investigated whether IFN-α and IFN-β could also inhibit the responses induced 
by Mycobacteria. Hereto, we stimulated CD14+ monocytes with or without IFN-α or IFN-β 
and IFN-γ in the presence or absence of MTB. The MTB induced production of the three 
measured cytokines was reduced by IFN-α and IFN-β (Fig. 2E, F, G). The synergistic effect 
of IFN-γ on the MTB induced IL-12p40 and IL-1β production was blocked by IFN-α and 
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Figure 1. Inhibition of IFN-γ induced CD54 and CD64 expression by IFN-α and IFN-β. CD14+ 
monocytes were stimulated with various concentrations of IFN-γ and IFN-α (A,B) or IFN-β (C,D). 
After 18 h the CD54 and CD64 expression was measured by FACS. Four donors were tested separately. 
One representative experiment is shown (A,B,C,D). The influence of 1000 U/ml of IFN-α on the CD64 
and CD54 expression (E), induced by 250 ng/ml IFN-γ, is depicted as the percentage of inhibition by 
IFN-α. IFN-γ induced expression was set at 100% and expression in untreated cells was set at 0%. The 
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Figure 2. Inhibition of TLR-ligand and IFN-γ induced cytokine production by IFN-α and IFN-β. 
CD14+ monocytes were stimulated with 1 ng/ml LPS and various concentrations of IFN-γ with or 
without 1000 U/ml IFN-α or IFN-β. After 24h the production of IL-12p40 (A), IL-1β (B) and TNF (C) 
were determined by ELISA. Four donors were tested, one representative experiment is shown. (D) The 
influence of 1000 U/ml of IFN-α/β on cytokine production, induced by LPS and 250 ng/ml IFN-γ, is 
depicted as the percentage of inhibition by IFN-α/β. LPS/IFN-γ induced production was set at 100% 
and LPS induced production was set at 0%. The effect of IFN-α/β on mycobacterial stimulation (E-
G) was determined by incubating CD14+ monocytes with 10 μg/ml MTB, with or without 2.5 ng/ml 
IFN-γ and with or without 1000 U/ml IFN-α or IFN-β. After 24h the production of IL-12p40 (E), IL-1β 
(F) and TNF (G) were determined by ELISA. Three donors were tested in triplo. One representative 























































































































































Figure 3. IFN-α elicits prolonged inhibitory effects on type I immune responses in vitro and in 
vivo. The duration of the inhibitory effects of IFN-α on type I immune response was studied in vitro 
(A, B). IFN-α was added to CD14+ monocytes 24 h, 4 h or 0 h prior to the addition of 2.5 ng/ml IFN-γ 
or medium. The cells were cultured for another 18 h before expression of CD64 (A) en CD54 (B) was 
analyzed. The results are displayed as the mean fluorescence +/- standard deviation of an experiment 
performed in triplo. One representative experiment out of three is shown. * significantly different from 
stimulation without IFN-α and ** significantly different pairs , p<0.05 (two-way ANOVA). To study 
the inhibitory effects of IFN-α in vivo (C), PBMCs from melanoma patients were obtained before and 
during treatment with IFN-α and cultured for 18 h with various concentrations of IFN-γ. Afterwards, 
CD54 expression of the CD14+ cells was analyzed by FACS, the relative mean fluorescence +/- standard 
deviation of four patients are shown (C). In addition, PBMCs from four patients and five controls 
were stimulated for 24 h with 10 ng/ml LPS or medium (D). IL-12p40 production in supernatants was 
analyzed by ELISA (D). For C * p<0.01 by one-way ANOVA and for D * p<0.05 (paired student t-test, 
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3.3. IFN-α elicits prolonged inhibition of type I immune responses in vitro and in vivo
IFN-α inhibits the IFN-γ responses when both cytokines are given together to the monocytes. 
It is not known how long the inhibitory effect of IFN-α lasts. We investigated whether IFN-α 
could still effectively inhibit type I immune responses until 24h after IFN-α stimulation. 
Therefore CD14+ monocytes were pre-cultured in the presence of IFN-α and subsequently 
stimulated with IFN-γ. IFN-α inhibited the IFN-γ induced CD64 expression when given 
together with IFN-γ and when given 4 h prior to IFN-γ to a similar extent (Fig. 3A). When 
IFN-α was given 24 h prior to the addition of IFN-γ the inhibition of CD64 expression was 
even stronger. IFN-α also displayed strong inhibitory effects on the induction of CD54 
expression when given 4 h or 24 h prior to IFN-γ (Fig. 3B).
To study whether IFN-α also inhibits monocytes in vivo we analyzed the PBMCs of 
melanoma patients before and during IFN-α treatment. Before and after at least one week of 
daily IFN-α injections we determined the basal and IFN-γ inducible expression of CD54 and 
the LPS-induced IL-12p40 production. Basal expression of CD54 was significantly reduced 
during IFN-α treatment (Fig. 3C). IFN-γ could not enhance the CD54 expression to maximum 
levels when the patients received IFN-α treatment. At all IFN-γ concentrations the CD54 
expression was significantly lower during IFN-α treatment. Due to the IFN-α treatment, the 
capacity of the PBMCs to produce IL-12p40 upon LPS stimulation was reduced (Fig. 3D). 
Unstimulated PBMCs did not produce any detectable IL-12p40 (data not shown). The IFN-
γR1 expression of the PBMCs, before and during IFN-α treatment, was comparable (data not 
shown).
3.4. Downregulation of IFN-γR1 expression by IFN-α and IFN-β
IFN-γ binding to its receptor complex, consisting of two IFN-γR1 and two IFN–γR2 chains, 
results in signal transduction and subsequent downregulation of the cell surface expression of 
IFN-γR1. Little is known about the kinetics of IFN-γR downregulation in human monocytes. 
We investigated the kinetics of IFN-γR1 downregulation on CD14+ monocytes by IFN-γ 
in more detail and whether IFN-α and IFN-β could also induce IFN-γR1 downregulation, 
independent from IFN-γ. The cell surface expression of the IFN-γR1 receptor was, after a 
delay of 2 h, gradually downregulated by IFN-γ, was strongly reduced after 4 h (up to 77%), 
and was still remarkably reduced after 18 h of stimulation (Fig. 4A). The IFN-γR1 expression 
was gradually reduced at all IFN-α concentrations, also with a delay of 2 h after stimulation, 
and was most strongly reduced after 4 h (up to 75%). The IFN-γR1 expression was partly 
restored after 18 h of stimulation with IFN-α (Fig. 4A). 
We next analyzed the effects of simultaneous stimulation with IFN-α and IFN-γ and 
whether a 4h or 24h pre-stimulation with IFN-α had an additive or synergistic effect on the 
IFN-γR1 downregulation induced by IFN-γ. We did not observe any additive effect of IFN-α 










































γR1 downregulation by IFN-γ (Fig. 4B). IFN-β downregulated the IFN-γR1 expression in a 
similar manner (data not shown). As previously reported, cell surface expression of IFN-γR2 
on monocytes could not be detected by FACS [25].
3.5. IFN-α signalling interferes with IFN-γ induced STAT1 phosphorylation
IFN-γ signalling occurs via the formation of STAT1 homodimers, while IFN-α signals via 
STAT1- STAT2 heterodimer complexes. The signalling of both interferons may influence 
each other through competition for STAT1. We examined the kinetics of STAT1 and STAT2 
phosphorylation in CD14+ monocytes after addition of IFN-α and IFN-γ alone or together. 
STAT1 phosphorylation was quantified by FACS (Fig. 4C). There was only a very small 
additive effect in STAT1 phosphorylation after stimulation for 5 or 10 minutes with 0.25 ng/
ml of IFN-γ and 100 U/ml of IFN-α, although maximum STAT1 phosphorylation was not 
reached, as illustrated by the use of a higher concentration of IFN-γ or by longer stimulation 
(15 minutes). The additive effect at 5 and 10 minutes was smaller than expected of a full 
additive effect (which can be calculated as the sum of the response induced by IFN-α and the 
response induced by IFN-γ). After 5, 10 and 15 minutes of stimulation with 2.5 ng/ml IFN-γ 
and 100 U/ml of IFN-α, no additive effects were observed (Fig. 4C).
Because no antibodies are available to quantify tyrosine phosphorylated STAT2 by 
FACS, we determined the STAT2 phosphorylation by western blot analysis. No STAT2 
phosphorylation was observed in unstimulated cells. As expected, IFN-γ did not induce any 
detectable STAT2 phosphorylation. IFN-α clearly induced STAT2 phosphorylation, which 
was not changed in the presence of IFN-γ (Fig. 4D).
Surprisingly, hardly any additive effects of IFN-α and IFN-γ were observed for the 
STAT1 phosphorylation, and IFN-α induced the same STAT2 phosphorylation in the 
presence or absence of IFN-γ. We argue that there may be a considerable reduction of IFN-γ 
induced STAT1 homodimer formation due to competition between STAT2 and STAT1 for 
dimer formation with STAT1. To estimate the reduction of STAT1 homodimer formation 
we compared the amount of STAT1 phosphorylated by IFN-γ alone with the amount of 
STAT1 phosphorylated by the costimulation of IFN-γ and IFN-α minus the amount of STAT1 
phosphorylated by IFN-α alone. In this way, we estimate that there may be a reduction in 
STAT1 homodimer formation of up to 17 %, 44 % and 58 % after respectively 5, 10 and 15 
minutes of stimulation. These calculated reductions are probably overestimated, because we 
presumed that all phosphorylated STAT1 dimerizes and because we cannot fully exclude that 
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Figure 4. IFN-α downregulates IFN-γR1 expression and interferes in the IFN-γ induced signal 
transduction. IFN-γR1 expression on CD14+ monocytes was measured by FACS after stimulation 
with medium, with 2.5 ng/ml IFN-γ or with various concentrations of IFN-α (A). Mean fluorescence 
of unlabeled monocytes was set at 0 % and mean fluorescence of labelled untreated monocytes was set 
at 100%. IFN-γR1 expression was calculated as percentage of the controls. The mean +/- the standard 
deviation of three donors is shown. * significantly different from the untreated control p<0.05 (two-way 
ANOVA). The effect of costimulation with 1000 U/ml IFN-α and the effect of prestimulation with 1000 
U/ml IFN-α on the IFN-γ induced IFN-γR1 downregulation was tested in triplo for two donors (B). The 
measured IFN-γR1 expression at 0 h was set at 100%. The mean +/- the standard deviation is shown. 
* significantly different from the expression measured at 0 h p<0.05 (two way ANOVA). The signal 
transduction was determined by measuring the STAT1 and STAT2 phosphorylation (C and D). CD14+ 
monocytes were stimulated with 0.25 ng/ml (C, D) or 2.5 ng/ml (A) IFN-γ and 100 U/ml of IFN-α 
(A, B). At various time points the STAT1 tyrosine phosphorylation was determined by FACS (A). The 
mean fluorescence +/- the standard deviation of three individual measurements is shown. The amount 
of tyrosine phosphorylated STAT2 and GAPDH was determined by western blot (B), one representative 
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Figure 5. Basal expression of PRMT1 and interferon inducible PIAS1 expression. The expression 
of PRMT1, PIAS1 and GAPDH in CD14+ monocytes was analyzed by western blot after 18 h of 
stimulation with medium, 1000 U/ml IFN-α, 25 ng/ml IFN-γ, 1 ng/ml of LPS or with combinations of 
the stimuli (A). The kinetics of PIAS1 expression was determined after stimulation with 1000 U/ml 
IFN-α or 25 ng/ml IFN-γ (B).
3.6. Monocytes show basal PRMT1 expression and inducible PIAS1 expression 
IFN-α could potentially inhibit IFN-γ responses via activation of PRMT1 and/or via 
induction of factors that negatively influence the JAK/STAT pathway, such as PIAS1. To 
establish whether these factors play a role in the inhibitory effects of IFN-α we investigated 
the basal and inducible expression of PRMT1 and PIAS1 in monocytes. CD14+ monocytes 
were stimulated for 18 h with combinations of IFN-α, IFN-γ and LPS. Monocytes showed 
basal expression of PRMT1 which was not further enhanced by the stimuli (Fig. 5A). A 
small amount of PIAS1 was expressed in unstimulated monocytes and could be enhanced 
by either IFN-α, IFN-γ or LPS alone or by combinations of these stimuli (Fig. 5A). Next, we 
determined the kinetics of PIAS1 upregulation by IFN-α or IFN-γ. Both interferons induced 
PIAS1 expression, relatively late, after more than 8 h of stimulation (Fig. 5B).
3.7. Inhibition of PRMTs reduces the inhibitory effects of IFN-α
IFN-α could potentially activate PRMT1, which in turn can influence the expression of 
immune genes via methylation of various regulatory proteins. With the use of a competitive 
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First, we determined the role of PRMTs in the regulation of CD54 and CD64 expression. 
CD14+ monocytes were pre-incubated with AMI1 and cultured in the presence of IFN-γ and 
various concentrations of IFN-α. IFN-α reduced the IFN-γ upregulated CD54 expression 
(Fig. 6A). Pre-incubation with AMI1 resulted in a significantly smaller reduction (Fig. 6C). 
In contrast, IFN-γ induced expression of CD64 was already somewhat reduced by AMI1 
itself (Fig. 6B), while AMI1 had no influence on the inhibitory effect of IFN-α on CD64 
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Figure 6. Inhibition of PRMTs reduces the IFN-α effect on IFN-γ induced CD54 and CD64 
expression. The PRMT inhibitor AMI1 was added in a concentration of 200 µM to CD14+ monocytes 
cultures 1 h before the addition of 2.5 ng/ml IFN-γ and various concentrations of IFN-α. The induction 
of CD54 (A) and CD64 (B) was measured by FACS. The fluorescence of unlabelled cells was set at 
0% and the fluorescence of the IFN-γ stimulated and CD54 or CD64 labelled cells was set at 100%. 
The results of one donor tested in triplo is shown, error bars represent the standard deviation (A, B). 
To indicate significant effects of IFN-α, the results of three donors were sampled (C, D). Therefore, the 
inhibition of IFN-α on the IFN-γ mediated CD54 (C) and CD64 (D) expression was calculated as the 
percentage of inhibition: IFN-γ induced expression was set at 0% and the basal expression was set at 
100%. The mean and standard deviation of three donors, each tested in triplo, is shown (C,D). p<0.05 


































































































































































































Figure 7. Inhibition of PRMTs reduces the effect of IFN-α on IFN-γ induced cytokine production. 
CD14+ monocytes were pre-incubated for 1 h with or without 200 μM of the PRMT inhibitor AMI1. 
Subsequently the cells were stimulated for 24 h with 1 ng/ml LPS with or without 2.5 ng/ml IFN-γ and 
various concentrations of IFN-α. After 24 h the production of IL-12p40 (A, D), IL-1β (B, E) and TNF 
(C, F) were measured by ELISA. The results of one out of three donors are shown (A, B, C). To indicate 
significant effects of IFN-α, the results of three donors were sampled (D, E, F). The inhibition by IFN-α 
on the LPS/IFN-γ induced cytokine production was calculated as percentage of inhibition (D, E, F). 
The LPS/ IFN-γ induced cytokine production was set at 0% and the LPS-induced production was set 
at 100%. The mean and the standard deviation of three donors is shown (D, E, F). AMI1 alone did not 
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Next, we analysed the influence of AMI1 on LPS and IFN-γ induced cytokine production. 
CD14+ monocytes were pre-incubated with AMI1 and then stimulated with IFN-γ and various 
concentrations of IFN-α in the presence of LPS. AMI1 alone did not induce any cytokine 
production (data not shown). AMI1 pre-incubation already resulted in a 2 fold enhanced 
LPS/IFN-γ-induced IL-12p40 production, without IFN-α (Fig. 7A). AMI1 had little influence 
on the effects of IFN-α on the LPS and IFN-γ induced IL-12p40 production (Fig. 7A, D). 
IFN-α reduced the LPS/IFN-γ induced IL-12p40 production. Pre-incubation with AMI1 
resulted in a similar reduction of IL-12p40 by IFN-α (Fig. 7D). IFN-α reduced the LPS/
IFN-γ induced IL-1β and TNF production, which was for both cytokines significantly less 
after pre-incubation with AMI1 (Fig. 7B, C, E, F). 
4. Discussion
This report demonstrates that IFN-α/β strongly inhibit the type I cytokine production and the 
IFN-γ responsiveness of human monocytes, probably via various mechanisms. Previously, we 
and others reported that exposure of monocytes to IFN-α/β leads to a reduction of IL-12p40 
production and IFN-γ responsiveness [12, 13]. We now demonstrate that IFN-α and IFN-β 
have comparable strong inhibiting effects on human monocytes and that exposure to high 
concentrations of IFN-γ could not counterbalance the inhibitory effects of either IFN-α or 
IFN-β. Furthermore, our results indicate that IFN-α interferes with the IFN-γ responsiveness, 
early and late after stimulation. To explore the mechanisms of inhibition we studied the 
kinetics of the IFN-α induced IFN-γR1 downregulation showed that the downregulation was 
transient and occurred with two hours delay after IFN-α stimulation, indicating that other 
mechanisms are involved in the direct and late inhibitory effects. Indeed, we found some 
additional evidence that IFN-α directly interferes with the IFN-γ mediated signalling and 
that IFN-α may, at least in part, inhibit the production of IL-1β and TNF via activation of 
a PRMT, probably PRMT1. Furthermore, we show that IFN-α induces PIAS1, a negative 
regulator of STAT1 mediated transcription, which indicates that a PRMT1/PIAS1 pathway 
may be involved as well.
Both IFN-α and IFN-β reduced the IFN-γ induced CD64 and CD54 expression as well as 
the LPS and IFN-γ induced IL-12p40, IL-1β and TNF production. IFN-α and IFN-β showed 
the strongest inhibition on the LPS and MTB induced production of IL-12p40, the shared 
subunit of IL-12 and IL-23. Both IL-12 and IL-23 play an important role in the mounting of 
type I immune responses. IL-12 is known to stimulate IFN-γ production, Th1 polarization 
and expansion of T-cells subsets. IL-23 stimulates NK-like T cells to produce IFN-γ [27]. 










































antagonized by IFN-α. These inhibitory effects on monocytes occurred in vitro for at least 24 
h after IFN-α stimulation and endured in vivo in IFN-α treated patients. The severe impact of 
IFN-α on type I immunity, the importance of IFN-γ in the control of mycobacterial diseases, 
the ability of virulent mycobacterial strains to induce IFN-α [5] and the finding of a typical 
IFN-α transcript signature in the blood cells of TB patients [2, 3] suggest an important role of 
IFN-α/β in the immunopathogenesis of Mycobacterium tuberculosis infections.
One mechanism through which IFN-α/β inhibits IFN-γ signalling may be downregulation 
of IFN-γR1 cell surface expression. IFN-γR downregulation by IFN-α/β was observed in 
mice after Listeria monocytogenes infection. Receptor down-regulation was found to be 
responsible for the IFN-γ unresponsiveness of monocytes after Listeria encounter [28]. In 
human macrophages, IFN-γR1 expression was also found to be reduced after incubation 
with IFN-α [29]. Our kinetic studies show that IFN-γR1 downregulation occurred only 
after two hours of stimulation with IFN-α and appeared to be transient. Hence, the IFN-γR1 
downregulation can not explain the inhibitory effects of IFN-α we observed when IFN-α was 
given together with or 24 h before IFN-γ in vitro or when given to patients in vivo. Thus, 
our results indicate that other mechanisms are also involved to achieve direct and enduring 
opposing effects on the type I immune responses of monocytes.
The fact that IFN-α/β can inhibit IFN-γ mediated responses when given to monocytes 
simultaneous with IFN-γ indicates that these interferons can also interfere directly with IFN-γ 
mediated signalling. Indeed, by studying the kinetics of STAT1 and STAT2 phosphorylation 
we found some evidence that there is a direct negative effect of IFN-α on IFN-γ signalling. 
The amount of phosphorylated STAT1 induced by IFN-γ signalling is reduced in the presence 
of IFN-α. We reason that this reduction in STAT1 phosphorylation may result in a reduction 
of STAT1 homodimer formation of maximal 58% and could thereby account for a severe 
loss of IFN-γ responsiveness. Previous investigations with human fetal astrocytes [30] 
and murine macrophages [31], indicate also that IFN-β is involved in IFN-γ signalling by 
reducing the amount of STAT 1 homodimers bound to DNA [30] and influencing the STAT1 
dephosphorylation [31]. It would be interesting to perform similar investigations with human 
monocytes and other phagocytes with ChIP analysis, using DNA probes coding for different 
GAS sites, in order to quantify the exact amounts of STAT1 homodimers, ISGF3 complexes 
and bioactive PIAS1 in the nucleus.
Another mechanism whereby IFN-α may oppose type I immune modulation is the 
activation of PRMTs. PRMT1 can associate with the intracellular part of IFN-αR1 and 
can be activated by IFN-α [19]. We show that PRMT1 is expressed in unstimulated human 
monocytes. And with the use of an inhibitor of PRMTs we revealed that only some of the 
inhibitory effects of IFN-α could be ascribed to a PRMT pathway. This was most prominent 
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Further extensive investigation is needed to reveal which PRMT and which PRMT targets 
are involved. 
PRMT1 is, for instance, able to methylate PIAS1, a negative regulator of the transcriptional 
activity of STAT1 [22, 23]. We show that expression of PIAS1 is induced relatively late 
after stimulation with IFN-γ, apparently as a negative feedback on IFN-γ signalling. IFN-α 
also induces PIAS1, with similar kinetics. The relatively late induction of PIAS1 may partly 
explain the fact that 24 h of pre-stimulation of monocytes with IFN-α results in a strong 
inhibition of the IFN-γ responsiveness in vitro, and why a lasting inhibitory effect on type I 
immunity could be observed in IFN-α treated patients.
Other mechanisms could also be involved. Gene transcription may be indirectly regulated 
by transcription factors other than STAT1 and STAT2. For example, the induction of the 
transcription factor IRF-8 by IFN-γ can be antagonized by IFN-α [18]. Furthermore, we 
speculate that there could be negative interference of ISGF3 with transcriptional activity. 
This may be the case with CD64 transcription. Despite the fact that the promoter of CD64 
contains an ISRE-like element, which is a putative ISGF3 binding site, we showed that IFN-α 
does not induce CD64 expression. In fact, IFN-γ induced CD64 expression was inhibited by 
IFN-α. This suggests that the inhibitory effects of IFN-α may be due to a partial or complete 
block of transcriptional activity as a result of binding of ISGF3 to the promoter of CD64. 
Taken together, IFN-α stimulation of monocytes results in a broad range of opposing 
effects on type I immunity, which may be established by various mechanisms. Some of these 
effects sustain for at least 24 h after IFN-α stimulation, in vitro as well as in vivo, indicating 
that IFN-α is an important negative regulator of the type I immune response. These effects 
may explain the enhanced susceptibility to bacterial pneumonia just after influenza infection 
[32]. Similarly, IFN-α/β induced by intracellular pathogens, such as Listeria monocytogenes 
[28] or virulent Mycobacterium tuberculosis [5] strains, can dampen the formation of an 
effective type I immune response. The benefit of the inhibitory effects of IFN-α for the host 
is not really understood. We speculate that a type I immune response during the early phase 
of viral infections may otherwise easily escalate in hyperinflammatory reactions.
Because IFN-α induces strong opposing effects on type I immune responses this should 
be taken into account in the treatment of certain patients. First, we recently reported that 
IFN-α treatment of IFN-γR1 deficient patients is not advisable [13]. Our present data further 
strengthen the advice not to use IFN-α in patients lacking Th1 immunity. Second, when 
considering IFN-α treatment in other types of patients, clinicians should be aware of the 
type I immune inhibiting effects. Several case reports of hepatitis patients who developed 
Tuberculosis during IFN-α treatment [33-35] indicate that perhaps patients from countries 
with high Tuberculosis prevalence should be screened for latent Tuberculosis prior to 
IFN-α treatment. Third, although cancer patients receiving IFN-α treatment to support T 










































immune responses hampers the therapy to some extent. Fourth, in the development of M. 
tuberculosis infections IFN-α/β appear to play an important role [2], the source of this IFN-
α/β is however still unclear. IFN-α/β may be produced by infected monocytes and/or during 
viral infection, allowing M. tuberculosis to take advantage of the situation and develop into 
an active infection. Thus, co-infections of M. tuberculosis with common types of viruses 
may aggravate the course of M. tuberculosis infections (R.A. de Paus et al, submitted for 
publication).
 
In conclusion, IFN-α and IFN-β both strongly inhibit monocytes in their capacity to 
produce type I cytokines and to respond to IFN-γ. The impact of IFN-α and IFN-β may 
indicate a major role of these interferons in the pathogenesis of infections with M. tuberculosis 
and other intracellular bacterial pathogens which are able to induce IFN-α/β. Our data 
provide novel insights into the mechanisms of the inhibitory effects. These effects may be 
achieved via various mechanisms, such as, a decreased IFN-γ signalling, a transient decrease 
in IFN-γR1 expression, activation of PRMTs and the induction of PIAS1. Further detailed 
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Recently, it was shown that interferon-γ mediated immune responses, which play a major 
role in the control of infection with Mycobacterium tuberculosis (Mtb), can be inhibited by 
type I interferons. Since type I interferons are abundantly induced during viral infections, we 
hypothesized that infections with influenza viruses might play a role in the development of 
active tuberculosis (TB) disease either directly after exposure to Mtb or through reactivation 
of latent Mtb-infection. To explore this hypothesis we investigated in a retrospective 
study whether newly diagnosed adult TB patients from Indonesia had had recent influenza 
infection. Plasma samples from TB patients and controls were assayed for antibodies against 
two subtypes of at that time relevant, seasonal influenza A viruses. Overall, no correlation 
was observed with the presence of antibodies and manifest tuberculosis. Still, antibody titers 
against circulating A/H3N2 influenza virus were slightly enhanced in tuberculosis patients 
as compared to controls, and highest in cases of advanced tuberculosis. This suggests that 
tuberculosis patients were recently infected with influenza, before clinical manifestation of 
the disease. Alternatively, the production of antibodies and susceptibility to tuberculosis may 
be influenced by a common confounding factor, for example the ability of patients to induce 
interferon-α. We conclude that in an endemic country like Indonesia, an influenza virus 












































Tuberculosis (TB) is a severe disease caused by Mycobacterium tuberculosis (Mtb). Up to 
10% of the Mtb infected individuals develop active tuberculosis, while the majority of those 
infected develop a latent state of infection for years [1, 2]. During latency, Mtb may stay 
quiescent, but when the immune system fails to control the bacteria, reactivation may occur 
and precipitate development of active disease [3, 4], in most cases pulmonary TB disease.
Several risk factors that influence the susceptibility to TB have been described, such 
as host genetic factors [5], malnutrition [6], smoking [7], diabetes [8] and infection with 
HIV [9]. Besides these factors also the Mtb strain virulence may influence the course of 
TB, since virulent Mtb can inhibit the host immune system in various ways [10]. Recently, 
IFN-α has been described as a putative factor, which may be induced by highly virulent Mtb 
strains [11, 12] and can inhibit an effective IFN-γ mediated immune response [13-15]. Mouse 
studies revealed that during Mtb infection IFN-α is induced and that IFN-γ mediated immune 
responses can be impaired by IFN-α [12, 16]. In humans, a typical IFN-α/β transcript signature 
was found in the blood cells from TB patients [11, 17, 18]. However, it is not clear whether 
Mtb infection in humans leads to the production of type I interferons or whether production 
of type I interferons leads to TB. It is possible that in TB patients type I interferons are more 
abundantly induced due to infections with viruses, such as pneumotropic influenza viruses. 
After influenza virus infection a period of enhanced susceptibility to bacterial infections 
is commonly seen in humans [19]. In mice, Toll like receptor-induced responses of alveolar 
macrophages to bacterial ligands remain desensitized for months after an influenza virus 
infection [20]. This explains why mice are highly susceptible to bacterial pneumonia for 
several weeks after influenza virus infection [21]. In humans, post-influenza bacterial 
pneumonia is a major cause of morbidity [19], with Streptococcus pneumonia as the main 
pathogen associated with post-influenza pneumonia [22]. TB is usually not diagnosed shortly 
after influenza infections and although some anecdotal reports suggest that the occurrence 
of TB was also high during influenza pandemics [23-25], a causal relationship between the 
epidemics of the two infectious diseases has not been investigated. 
If indeed an influenza virus infection leads to the (re)-activation of a latent Mtb infection, 
this may remain unnoticed, because the period between (re)-activation of the bacteria and 
the first presentation of the clinical symptoms of TB is long. TB develops slowly, due to the 
slow metabolism and replication rate of Mtb. Thus it may be that within the latency period 
of TB, during the primary infection or after re-infection, a transient inhibitory effect on the 
anti-bacterial responses by an influenza virus infection influences the course of TB and leads 
to active disease, possibly in conjunction with other risk factors. In mice, co-infections of 
influenza viruses with Mtb enhanced the development of TB in the lungs [26]. In humans, it 










































We hypothesized that influenza virus infections may promote the development of active 
disease after exposure to Mtb, or might play a role in the reactivation of latent Mtb-infection. 
To explore this hypothesis we investigated in a retrospective study whether patients with 
clinically-manifest TB had an influenza virus infection recently. Plasma samples collected 
from TB patients at time of diagnosis and from controls were screened for the presence of 
antibodies against influenza viruses in order to investigate a putative association between TB 
and influenza virus infections. 
2. Patients, materials and methods
2.1. Study subjects
Patients and controls (Table 1) were recruited between March 2001 and December 2004 from 
the TB clinic “Perkumpulan Pemberantasan Tuberkulosis Indonesia” in Jakarta [8, 27, 28]. 
Patients newly diagnosed with active pulmonary TB, between the age of 15 and 70, were 
included. TB diagnosis was based on WHO definitions including the presence of clinical 
symptoms, a chest X-ray examination (CXR), microscopic detection of acid-fast bacilli in 
sputum and a positive culture of Mtb. Based on the CXR examinations TB patients were 
classified into two groups; patients with mild to moderate TB and patients with advanced 
TB. Patients seropositive for HIV were excluded. Community control subjects were recruited 
from neighboring houses and matched for age, sex and socio-economic class. Controls with 
a history of TB or with positive TB finding in the CXR were excluded. The control subjects 
underwent the same examinations as the patients, but were not tested for HIV, since the 
prevalence of HIV in the Indonesian population was low, as evidenced by the low prevalence 
of HIV amongst the TB patients in this cohort (1.8%) [29]. The influenza vaccination status of 
our study cohort is unknown. However, at the time of our study, vaccination against influenza 
viruses in Indonesia was only rarely applied and based on the low socio-economic status of 
our patients and matched controls these individuals are extremely unlikely to have received 
such vaccinations. For this study, the patients and controls were matched for the date of 
inclusion. Patients and matched controls were only included if the dates of inclusion were not 
more than 14 days apart. Written informed consent was obtained from all subjects. The study 
was approved by the Ethical Committee of the Medical Faculty, University of Indonesia.
Table 1. Description of the study population.
TB patients (n=111) Controls (n=111) p-value
age in years (median) 18-67 (31) 17-69 (35) 0.153a
gender; males 72 (65%) 60 (54%) 0.132b
diabetes mellitus 24 (22%) 8 (8%) <0.001b
individuals with BCG scar 39 (35%) 45 (41%) 0.489b
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2.2. Detection of antibodies against influenza viruses
Heparinized plasma samples were obtained from the patients and controls and stored at 
–80°C. Thawed plasmas were analyzed for the presence of total IgG and IgM antibodies 
against two subtypes of influenza A virus, a H3N2 virus (A/Moscow/10/99, vaccine strain 
ResVir-17) and a H1N1 virus (A/New Caledonia/20/99, vaccine strain IVR-116), using 
the hemagglutinating inhibition (HI) test. These strains were chosen because of their high 
antigenic similarity to the specific H3N2 and H1N1 viruses circulating during the sample 
period. For use in the HI test, the influenza virus strains were propagated in 11-day old 
embryonated chicken eggs. The HI test was performed in duplicate according to standard 
methods [30] with turkey erythrocytes and four hemagglutinating units of virus. Ferret sera 
raised against the test antigens were used as positive controls. All plasma samples of all study 
subjects were tested simultaneously, in duplicate, and were only regarded positive when both 
analyses gave positive results. The threshold of detection was an HI titer ≥ 10.
2.3. Statistical analysis
Data were analyzed using SPSS software. The Pearson χ2 test and the paired samples t-test 
were regarded significant when p <0.05.
3. Results
3.1. No correlation between the incidence of tuberculosis and the seroprevalence of antibodies 
against influenza viruses
To study the effect of influenza virus infections on TB we examined the plasma samples of 
controls and newly identified TB patients for the presence or absence of antibodies against 
two subtypes of influenza A virus, H1N1 and H3N2 (Table 2). The threshold of detection was 
an HI titer ≥10. Both influenza strains circulated in the population during the time of plasma 
sampling: 46% of the TB patients and 41% of the controls had antibodies against H1N1, 
while 82% of the TB patients and 82% of the controls had antibodies against H3N2 (Table 
2). No significant differences in the number of individuals with antibodies against influenza 
viruses were thus observed between the control group and the group of TB cases.
Table 2. Seroprevalence of antibodies to A/H1N1 and A/H3N2 influenza viruses. 
Group H1N1 positive H3N2 positive
TB patients (n=111) 51 (46%) 91 (82%)
controls (n=111) 46 (41%) 91 (82%)
Total (n=222) 97 (44%) 182 (82%)
χ2 test; p-value p=0.499 p=1.000










































3.2. Titers of antibodies to influenza viruses correlated with the manifestation of tuberculosis
Because yearly influenza infection rates are estimated to be 5-10% [31] the high percentage 
of individuals with H1N1 and H3N2 antibodies indicate that many of these individuals 
were already exposed to these viruses in the past. Therefore, the magnitude of the antibody 
responses might be a better indication of recent exposure as IgG antibody levels will be 
boosted upon reinfection and will only wane partially. Hence, we examined the titers of 
antibodies against H1N1 and H3N2 influenza viruses in the TB and control group. The 
results are displayed in Table 3 and Figure 1. The geometric means of the titers of antibodies 
against the H3N2 and the H1N1 influenza viruses were higher (respectively 1.7 and 1.4 
times) for the total group of pulmonary TB patients, as compared to the titers of the control 
group. Statistical analysis using the paired sample t test showed that only for the titers of 
antibodies against H3N2 this difference was significant. We next determined whether there 
is a correlation between the severity of the disease and the antibody titers against H3N2. 
The cases of advanced pulmonary TB showed a higher geometric mean titer for H3N2 (1.8 
times), while the group of cases with mild and moderate TB showed a smaller increase (1.4 
times) in the geometric mean titer, as compared to the matched controls.
The difference in these titers was significant between the cases with advanced TB and 
their matched controls but not between the cases of mild to moderate TB and their matched 
controls. The geometric mean titer of antibodies against H3N2 influenza viruses for the 
extrapulmonary TB patients was even higher (2.0 times as compared to the matched controls). 
However, the latter patient group was small (n=10) and the antibody titers of the cases with 
extrapulmonary TB were not significantly different from the titers of their matched controls.
Table 3. Number of positive cases and mean antibody titers against A/H3N2 and A/H1N1 influenza 
viruses for the different groups of TB patients and their matched controls. 
H3N2 H1N1
n meana p-valueb n meana p-valueb
 total TB patients 72 244 0.002 25 72 0.330
 matched controls 72 145 25 51
 mild and moderate TB 33 211 0.152 11 52 0.995
 matched controls 33 147 11 52
 advanced TB 33 262 0.021 14 93 0.222
 matched controls 33 142 14 50
 only pulmonary TB 62 234 0.004 21 69 0.267
 matched controls 62 143 21 45
 extrapulmonary TB 10 319 0.289 4 92 0.986
 matched controls 10 157 4 94
TB patients without DM 55 271 0.030 20 70 0.496
matched controls without DM 55 148 20 54
a geometric mean.
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Figure 1. Antibody titer against A/H3N2 in the different groups from the Indonesian TB cohort. 
The antibody titers against A/H3N2 were determined for the groups of TB cases and their matched 
controls. The data of the TB cases and the paired controls, matched for the date of inclusion, that 
were both found positive for the presence of antibodies are displayed. The group of total TB cases 
(A) was divided into a group with mild to moderate pulmonary TB (B) and a group of cases with 
advanced pulmonary (C) according to CXR examinations. In a separate analysis the group of total TB 
cases was divided in a group of cases with only pulmonary TB (D) and a group of cases with signs of 
extrapulmonary TB (E). In addition, the TB cases without diabetes mellitus (DM) were compared with 
their matched controls without DM (F). The geometric mean of the antibody titers is indicated with 
a line. Cases were compared with their matched controls and statistical analysis was performed on 










































3.3. The influence of diabetes mellitus on tuberculosis and the titers of antibodies to influenza 
viruses
In a previous study from our group, with the large cohort of patients and controls from 
Indonesia, Diabetes mellitus (DM) was identified as a risk factor for TB [8]. Since having 
DM is correlated with the incidence of TB in this study (Table 1) we investigated whether 
having DM could be a factor of influence on influenza virus specific antibody levels. Hence, 
we compared the influenza virus specific antibody titers between the TB cases and their 
matched controls, while excluding individuals with DM from both groups. 
The group of patients with pulmonary TB and without DM showed still significantly 
higher amounts of antibodies against H3N2 as compared to their matched controls, (paired 
sample t test, Table 3 and Figure 1F). The mean titer of antibodies against H3N2 of the 
TB cases with DM was on the other hand significantly lower (student t test, p=0.049) as 
compared with the mean titer of the TB cases without DM (data not shown).
4. Discussion 
The main finding of this report is that there is no correlation between the seroprevalence 
of antibodies against influenza A viruses and the development of clinically active TB in an 
Indonesian cohort. However, we observed an association between the level of antibody titers 
against influenza A/H3N2 virus and the stage of active TB lung disease. Compared to the 
control group the mean antibody titer of the group of TB patients was slightly enhanced, 
which may indicate that the TB patients were recently re-infected with an influenza virus 
strain, suggesting that an influenza virus infection precedes and influences the clinical 
manifestation of TB. However, such an epidemiological association may not be causal, and 
be confounded. 
Previously, it was suggested that an association existed between the 20th century influenza 
pandemics and the incidence of TB [23-25]. The existence of this correlation can however 
be questioned because diagnoses in the early 20th century were based solely on clinical 
symptoms. In addition, an increased incidence of both diseases may also be explained by 
common susceptibility factors, such as malnutrition. Here, we tested the hypothesis that 
influenza virus infections enhance the susceptibility to develop active TB. Although we 
did not find an association between the number of people with antibodies against influenza 
viruses and the development of TB, the difference in influenza A/H3N2 virus specific 
antibody titers between TB cases and controls may suggest that more TB cases than controls 
were recently re-infected, or have been exposed more often, with these seasonal influenza 
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against H3N2. Detection of antibodies against specific epitopes of the most recent influenza 
subtypes was unfortunately not possible, due to the low antigenic drift between the latest 
seasonal influenza viruses.
Within the group of TB patients the cases with extrapulmonary manifestation of the disease 
showed the highest mean antibody titers against A/H3N2 viruses. This association suggests 
that the clinical manifestation of extrapulmonary infections occurs in TB patients with 
stronger antibody responses after influenza virus infections. Dissemination of mycobacterial 
infections are more common in hosts with impaired immunity, for example in MSMD 
patients with impaired IFN-γ mediated immune responses [32] or in HIV patients [33]. In 
patients with extrapulmonary TB the plasma concentrations of IFN-γ are also reduced, as 
compared to patients with pulmonary TB [34]. Therefore, we speculated that viruses other 
than HIV, like influenza viruses, affect the Th1 immunity against mycobacteria and in this 
way influence the course of TB. In mice it was indeed found that influenza virus infection 
aggravates the course of TB [26]. It is unclear whether this is also the case in humans. Our 
cohort was too small to assess whether the risk of extrapulmonary manifestation is increased 
due to influenza virus infections. 
The finding that TB patients had slightly higher plasma antibody levels to A/H3N2 
influenza virus than the control group suggests a relation exists between influenza virus 
infections and the clinical manifestation of tuberculosis. However, the association may very 
well be confounded. One possible confounding factor is that a co-infection with an influenza 
virus in patients with TB may be more severe or lasts longer due to lung damage by Mtb, 
and as a result more antibodies against the virus are generated. Another possible confounding 
factor is that Mtb infection may result in the polyclonal activation of B cells, as was observed 
in mice after infection with various microorganisms [35]. Human memory B cells were also 
found, in response to a strong stimulus, to polyclonally produce small amounts of antibodies 
in the absence of specific antigens [36]. Whether such non-specific antibody production also 
occurs during Mtb infection and results in a detectable rise in anti-influenza antibodies is yet 
unknown. Since plasma of TB patients before the manifestation of the disease is unavailable 
we were unable to determine whether the anti-influenza antibodies rise upon development 
of TB. The ability to produce high amounts of IFN-α may also be a confounding factor. 
Some individuals are relatively strong producers of type I interferons [37] and because of 
this they may produce both higher amounts of antibodies against viral pathogens and may be 
more susceptible to developing TB. In addition, TB may be aggravated if Mtb induced type 
I interferons are also more abundant in these individuals, as they may impair an effective 
IFN-γ mediated immune response [11]. Another potential confounding factor may be diabetes 
mellitus (DM) since DM was previously found to be a risk factor for developing TB [8]. We 
investigated whether DM cases had higher antibody titers against the viruses. Based on our 










































Our findings are based on a retrospective study with TB cases in Jakarta (Indonesia) in 
the period from March 2001 till December 2004. This is the first study which investigates 
a potential role for viral infections in the development of TB by determining the presence 
of antibodies against influenza viruses in plasmas of TB patients and matched controls. In 
order to determine whether the observed association between TB and higher virus-specific 
antibody titers indeed indicates an increased risk for TB after influenza virus infection and 
to exclude that confounding factors cause the increase in the antibody response to influenza 
viruses, a prospective study is needed. Although such a study would be difficult to set up, this 
should preferably investigate the influence of primary viral infections on the manifestation 
of TB in childhood. In such a cohort it would be possible to prove new, primary influenza 
virus infections.
A prospective study for adult TB is also possible, but because many adults already have 
antibodies against previous seasonal viruses (that may cross-react with contemporary viruses) 
novel infections will have to be identified by demonstrating antibody titers rises against a new 
seasonal strain. The current study was cross sectional and identified a high seroprevalence 
of antibodies against two subsubtypes (44% and 82% for H1N1 and H3N2 respectively) 
indicating that a large proportion of study subjects were infected during previous epidemics, 
as normally about 5 to 10% of the population are affected during annual influenza epidemics 
[31]. Studies of larger cohorts and screening for strain-specific antibodies may provide more 
insights into the effects of co-infections with influenza viruses on the occurrence and severity 
of TB. 
Based on our results we conclude that influenza virus infections are not a major 
determinant in the development of clinically active TB in adults, either through reactivation 
of latent disease or directly after exposure to the bacillus, nor of more severe manifestation 
of the disease. The identified correlation between the titers of antibodies against influenza 
viruses and the manifestation of TB, is still in line with the suggestion that type I interferons 
may play a role in the immunopathogenesis of TB. 
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Type I cytokine responses play an essential role in the control of mycobacterial infections. 
Mutations in genes involved in the type I cytokine pathway were found in patients with 
Mendelian susceptibility to mycobacterial disease (MSMD) [1]. These patients are highly 
susceptible to infections with non-tuberculous mycobacteria (NTM). NTM are usually 
poorly pathogenic, but can cause severe disseminated infections in MSMD patients. MSMD 
causing mutations have been found in genes of the type I cytokine pathway, for example in 
IL12B, IL12RB1, IFNGR1 and IFNGR2. The role of genetic host factors in the susceptibility 
to virulent Mycobacterium tuberculosis complex strains is less evident. Likely, other host-
factors, but also environmental factors and virulence factors of the mycobacterium, play an 
important role in the susceptibility to tuberculosis. Suppression of type I immune response 
by medication enhances also the susceptibility. For instance, patients treated with TNF 
blocking antibodies such as infliximab, effectively abrogating the effector arm of the type-I 
immune response including macrophage activation, and cell recruitment to and formation of 
granulomas, are exquisitely susceptible to mycobacterial infection. This thesis focuses on 
the relation between genotype and phenotype in the cause of an impaired type-I immunity, 
leading to the susceptibility to non-tuberculous and tuberculous mycobacterial diseases. 
1. Functional consequences of amino acid substitutions in IL-12Rβ1
MSMD patients develop severe disseminated infections with NTM and sometimes 
non-typhoid Salmonella, usually in but certainly not confined to early childhood. The 
susceptibility of MSMD patients to these intracellular bacteria is strongly enhanced due to 
mutations in genes involved in the type-I cytokine pathway, for example in IL12RB1. Many 
harmless polymorphisms and MSMD causing mutations in IL12RB1 are reported, but also 
variations with an unknown impact on gene and protein function. Amongst them several 
single nucleotide substitutions leading to amino acid substitutions are described. 
Chapter 2 describes the case of an adult patient with a severe disseminated infection of 
the NTM M. genavense. Immunological screenings indicated a severe defect in IL-12Rβ1 
function. Subsequent genetic screening revealed the presence of two variations, -2C>T and 
R521G, with unknown impact on the immunological phenotype. Using a cellular model, 
with retroviral expression of IL-12Rβ1 variants in cells from a complete IL-12Rβ1 deficient 
patient, the R521G variation was confirmed to be the mutation leading to impaired IL-12 and 
IL-23 responses. Remarkably, the patient developed the infection at the age of 43 and had no 
history of severe infections in the past. Usually, infections in MSMD patients occur in early 
childhood for the first time, at a mean age of 2.4 years [2], although it has also been reported 
that individuals, homozygous for an IL-12Rβ1 mutation, have remained asymptomatic for 
many years [1]. The IL-12Rβ1 deficient individuals may remain free of symptoms due to 
infection for several reasons. Firstly, before an infection to develop, individuals must be 










































these low virulent pathogens are ubiquitous and hard to escape; still the level of exposure 
may vary according to habits and local environment. Moreover, immunological mechanisms 
compensating for the defect may be active that preclude a clinical manifestation for years. 
Later in life, subtle, innate reductions in host defense may now become manifest as the 
function of organs and compensatory immunological mechanisms become compromised 
due to aging and the cumulative effect of bad habits like smoking, drinking, or nutritional 
deficiencies. Consequently, clinicians should be aware that a severe disseminated NTM 
infection due to MSMD may manifest for the first time later in life, even at middle age. 
With the use of the same cellular model, with which the R521G mutation was characterized, 
also other subtle variations in the IL12RB1 gene were investigated. In the addendum to 
chapter 2 a summary is given of the impact to immunological phenotype of all currently 
known variations resulting in amino acid substitutions. Several variations were confirmed to 
be deleterious mutations causing MSMD, while other variations were proven to be harmless 
polymorphisms without impact on immunological phenotype. Thus far, all known mutations 
in IL12RB1 show a complete or an almost complete dysfunction of the receptor. The two 
mutations leading to a partial deficiency, i.e., C198R and R521G, reduced the cell surface 
expression of IL-12Rβ1 by 250 or 450 times, respectively. This suggests that the IL-12Rβ1 
function has to be strongly reduced to impair the formation of sufficient immunity against 
intracellular bacteria. 
Most amino acid substitutions in IL-12Rβ1 characterized as mutations, lead to absent or 
severely reduced cell surface expression of IL-12Rβ1. This indicates that determining the IL-
12Rβ1 expression of cells from a putative MSMD patient can already give a first indication 
of a deleterious mutation in the receptor. Still, it is necessary to complete the genetic analysis 
and perform an immunological phenotypic test to determine the IL-12 responsiveness, 
because mutations in the intracellular part may affect receptor function but not the cell 
surface expression, as was proven to be the case with an artificial mutation leading to a 
truncated receptor which lacks the intracellular domain.
The two major haplotypes of IL12RB1, designated as RTR and QMG, are formed by three 
linked amino acid changes, known as R214Q, T365M and R378G [3]. The protein product 
of the QMG haplotype, the QMG variant, is slightly higher expressed and is slightly more 
responsive to IL-12 stimulation as compared to the RTR variant [4]. The IL-23 responses of 
both variants were similar (chapter 3). Thus, analyzing these functional haplotypes in genetic 
association studies may give information about a putative role for IL-12 in the protection or 
development of type-I cytokine immune diseases. Such an association was found in a study 
with a Japanese cohort of tuberculosis patients, in which the RTR allele appears to contribute 
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2. The direct biological effects of IL-23 and variations in the IL-23R
Thus far, all reported patients with a defect in IL-12 or the IL-12R function carry a mutation 
in respectively IL-12p40 or IL-12Rβ1, while no mutations are found in the IL-12Rβ2 and the 
IL-23R chains, or in the IL-12p35 and IL-23p19 cytokine subunits of the heterodimers IL-12 
and IL-23, respectively. Since IL-12p40 is also a subunit of the IL-23 cytokine and IL-12Rβ1 
is the IL-12p40 -binding subunit of the IL-23R complex, this suggests that both IL-12 and 
IL-23 mediated immunity are impaired in enhanced susceptibility to NTM infections. Thus, 
only a defect in both cytokines or both receptors results in a MSMD phenotype. Probably, 
both cytokines complement each others actions, with subtle differences in function, e.g., in 
the induction of IFN-γ production by T-cells.
IL-12 is known to play a pivotal role in the type-I immune responses of various subsets of 
T cells. In contrast, the role of IL-23 in the establishment of a type-I immune response is less 
clear, because little is known about the expression pattern of the specific IL-23R chain. More 
insight in the role of IL-23 may give clues for novel therapeutic interventions. In chapter 3 
the effects of IL-23 on human T cell blasts (TCB), which were retrovirally transduced with 
the wild type IL-23R or a variant of the receptor, were investigated. With the use of these 
TCB a comparison was made between the effects of IL-12 and IL-23 within the same type 
of cell. Both cytokines are only able to induce effects in the TCB after TCR stimulation 
and differ in their elicited signal transduction via STAT modules. IL-12 signals with the 
use of STAT4, while IL-23 signals via its own receptor with the use of STAT1, STAT3 and 
STAT4. These data confirm the previous data on IL-23 signaling in the human Kit225 cell 
line, derived from a T cell leukemia [5]. However, in this cell line also a slight signaling via 
STAT5 was observed, which was not observed in the TCB cells. In primary CD3+ CD56+ 
T cells IL-23 induced only STAT3 and STAT4 phosphorylation, while STAT1 and STAT5 
phosphorylation was not observed. Thus, the effects of IL-23 may depend on the type of T 
cell, and may depend on co-stimulations with other factors.
Remarkably, IL-23 elicited an IL-12 like response in the TCB cell lines without the 
retroviral expression of the IL-23R. In these cells, IL-23 elicited only STAT4 signaling, 
resulting in a slight IFN-γ production, which was about 50 times less as compared to IL-
12 stimulation. This may indicate that IL-23 also signals via another receptor, possibly IL-
12Rβ2, although with lower efficiency as compared to the IL-12 responses via the IL-12R 
complex. 
Another interesting finding is that both IL-23 and IL-12 were shown to be able to induce 
the production of IFN-γ as well as the production of the anti-inflammatory cytokine IL-10, 
albeit with different efficiency. IL-23 induced less IFN-γ and relatively more IL-10. Probably, 
there is a differential binding of STAT modules on the promoters of IFN-γ and IL-10 upon 
IL-23 stimulation, as compared to IL-12 stimulation. These data are in line with the results of 










































T cells [6]. Apparently, both IL-12 and IL-23 have the capacity to regulate the establishment 
of a type-I immune response but in addition have anti-inflammatory capacity. Thus, the 
influence of IL-23 on the establishment of a type-I immune response is also regulated by the 
presence of IL-10 producing T cells. The finding that IL-23, compared to IL-12, induces less 
IFN-γ and relatively more IL-10 and the fact that IL-23 can be rapidly produced in the early 
stage of the immune response [7, 8], followed by the production of IL-12 in later stages may 
indicate that the type-I immune responses are gradually upregulated, e.g., ‘pre-amplified’ by 
IL-23. 
In the cellular model with retroviral IL-23R expression, the function of the wild type 
IL-23R is compared with other IL-23R variants; Y173H, P310L and R381Q. The Y173H 
variant was found in a patient with intracranial abscesses and with sepsis due to a Salmonella 
infection. Although the Y173H variation was predicted to be a severe mutation, the functional 
characterization of the variation revealed that it does not affect the IL-23 response, and 
therefore is unlikely to be the cause of disease in the patient. The P310L and R381Q are 
common variations, which were previously found to be associated with other immune related 
diseases. Neither of these variations in the IL-23R had an impact on the IL-23 responses. 
Thus, these variations are considered to be harmless polymorphisms in the setting of NTM 
or Salmonella infections. 
Recently, an antibody against the human IL-23R was generated [9]. This antibody 
recognizes both the wild type and the R381Q variant. The R381Q variation was reported to 
be associated with a decreased number of IL-23R positive cells, not with a reduced capacity 
of these cells to respond to IL-23 [9]. This is in line with our observation, that the R381Q 
variant of the receptor is fully functional. Still, it remains unclear why the R381Q variation 
is correlated with a decreased number of IL-23 responsive cells. It was reported that the 
R381Q polymorphism is strongly associated with protection against Inflammatory Bowel 
Disease [10]. The 381Q allele is correlated with protection against IBD. Taken together this 
indicates that the IL-23 responsive cells may play a role in the establishment of an auto-
immune response. Thus, a reduced number of these IL-23 responsive cells may prevent the 
formation of a type-I immune response. It would be interesting to investigate in large cohorts 
whether the R381Q polymorphism is also associated with the susceptibility to tuberculosis.
After assessment of the effect of IL-23 on the TCB cell lines, we investigated the effects 
of IL-23 on primary cells. Because at the time of our investigations, no suitable antibody to 
detect the IL-23R was available, the presence of the IL-23R was determined by analyzing 
the IL-23 induced STAT3 phosphorylation directly after stimulation of T cell subsets with 
IL-23. Chapter 4 reports the investigation of the direct biological effects of IL-23 on the 
type-I immune responses in cultures of CD56+ cells, a mixture of CD3- CD56+ NK cells 
and CD3+ CD56+ NK-like T cells. IL-23 elicited without any pre-stimulation STAT3 and 
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production, independent of TCR triggering, but dependent on IL-18. In contrast to IL-12, 
which is able to induce IFN-γ production in NK and NK-like T cells, IL-23 is only able to 
induce IFN-γ production in NK-like T cells, whereas both cytokines are able to induce the 
proliferation of NK and NK-like T cells. Since IL-23 can be rapidly produced by monocytes 
after stimulation with various TLR ligands [8] this indicates that IL-23 and NK-like T cells 
play an important role in the early phase of the immune response against pathogens, and 
that the production of initial, small amounts of IFN-γ boosts and amplifies the subsequent 
production and responses to IL-12. 
Recent IL-23 research has focused on the IL-23/IL-17 axis. So far, there is a no evidence 
that IL-23 stimulates the IL-17 production directly, though IL-23 influences the proliferation 
and survival of IL-17 producing T cells [11]. In our IL-23 studies, we similarly could not 
detect an influence of IL-23 on production of IL-17, though we could detect other IL-23-
induced responses. We showed direct effects of IL-23 on NK-like T cells, such as the IL-23 
specific STAT3 phosphorylation and the IL-23 induced IFN-γ production. In contrast, IL-23 
induces proliferation, but no IFN-γ production in NK cells. Taken together, this suggests that 
the proliferation of various subsets of T cells, such as the IL-17 producing T cells and NK 
cells, can be stimulated by IL-23, indirectly via NK-like T cells. 
3. Functional consequences of amino acid substitutions in the IFN-γR
IFN-γ is the central effector cytokine in type-I immune responses, with pleiotropic effects 
on many cell types. By consequence, mutations in the IFN-γR have a major impact on the 
establishment of a type-I immune response. In the course of years, we and others have 
detected several amino acid substitutions in both chains of the IFN-γR. In order to investigate 
the functional consequences of these variations we developed two cellular models. Cell lines 
lacking IFN-γR1 or IFN-γR2 expression were retrovirally transduced with IFN-γR1 and 
IFN-γR2 variants, respectively. In this way the function of the receptor variants could be 
compared within the same genetic background.
Chapter 5 describes the functional characterization of amino acid variations in IFN-γR1, 
in order to make a distinction between polymorphisms and deleterious mutations. The amino 
acid substitutions V14M, V61I, S149L, H335P, I352M and L467P in IFN-γR1 appeared to 
be fully functional polymorphisms, with no major impact on receptor function. Interestingly, 
the S149L and I352M variations were heterozygously present in patients suspected to have 
MSMD, from which the blood cells showed a reduction in IFN-γ responsiveness. Since these 
variations were found to be functional polymorphisms, the reduced IFN-γ responsiveness 
of these patients cannot be explained by these variations in the receptor, but may be due 
to impaired signalling via STAT1 or due to other yet unknown factors. The amino acid 
substitutions V61E, V61Q, Y66C, C77F, C77Y and C85Y were deleterious mutations leading 











































Chapter 6 describes the evaluation of amino acid variations in IFN-γR2. The amino 
acid substitutions T58R, Q64R, E147K and K182E in IFN-γR2 were fully functional 
polymorphisms of IFN-γR2. On the other hand, the R114C, T168N and G227R variations 
were deleterious mutations with T168N leading to complete IFN-γR2 deficiency, while 
R114C and G227R lead to partial IFN-γR2 deficiency. 
The partial deficiencies in IFN-γR1, due to the V63G and I87T mutations, are nearly 
complete deficiencies. For the V63G and I87T variants up to 10,000 times more IFN-γ was 
needed to obtain a similar effect on STAT1 phosphorylation of upregulation of CD64 or 
HLA-receptor expression, as compared with the wild type variant of IFN-γR1 [12]. This 
explains why the patients, homozygous for these mutations, had very severe mycobacterial 
infections [13, 14]. In contrast, patients heterozygous for the dominant 818delTTAA mutation 
in IFN-γR1, show relatively mild clinical symptoms. The 818delTTAA mutation leads to 
a truncated IFN-γR1 product, unable to signal, which is overexpressed at the cell surface. 
As a consequence, only 1-4% of the IFN-γR complexes are fully functional resulting in a 
dominant negative phenotype [15]. 
The partial deficiencies in IFN-γR2 due to the R114C [16] and the G227R mutation [17] 
resulted in a strong reduction of the IFN-γ responsiveness. In both cases, up to 100 times 
more IFN-γ was needed for the patient cells to produce similar responses as produced by the 
cells from healthy controls. The latter patients had, because of the strongly reduced IFN-γ 
responsiveness, severe disseminated NTM infections. Taken together, a deficiency in the 
IFN-γR2 leads to MSMD only when the receptor expression is reduced by a factor 100 or 
more. 
The cellular models were used with success to investigate the impact of mutations and 
thus to reveal the nature of the IFN-γR deficiencies. However, the cellular models were less 
suitable to differentiate between more subtle variations with a small impact on receptor 
function. For example the V14M polymorphism in the IFN-γR1 showed normal function but 
was significantly less expressed on the cell surface. Due to the overexpression by the retroviral 
system, no differences in the IFN-γ responses were detected between cells expressing 
the wild type IFN-γR1 and the cells expressing the V14M variant. In this way, retroviral 
overexpression may mask subtle differences. In human subjects the V14M polymorphism 
was shown to correlate with an altered Th1/Th2 balance [18, 19]. This suggests that the 
influence of the V14M polymorphism on IFN-γR1 expression affects the IFN-γ responses in 
natural situations, where the IFN-γR1 expression is limited. Although it cannot be excluded 
that other polymorphisms linked to V14M are involved in the altered Th1/Th2 balance.
Both the V14M polymorphism in IFN-γR1 and the Q64R polymorphism in IFN-γR2 
influenced the cell surface expression of the receptor chains remarkably. Consequently, these 
polymorphisms may have a significant impact on the Th1/Th2 balance, since the regulation 
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role in the fate of T cells during the differentiation of Th0 cells [20, 21]. Therefore these 
two polymorphisms would be interesting to analyse in genetic association studies in order 
to investigate a putative role for IFN-γ or a lack of IFN-γ control in infection and immune 
related diseases. This was found to be the case for systemic lupus erythematosus [18, 19], but 
may also be true for infectious diseases such as tuberculosis. 
4. Towards novel therapies to treat MSMD
MSMD patients with NTM infections are usually treated with antituberculous drugs, based 
on findings concerning the in vitro sensitivity of the mycobacterium. Unfortunately, in vitro 
susceptibility determinations of such pathogens is complex, and findings may not correlate 
with clinical response and outcome to treatment. Some patients with severe defects in IFN-γ 
signalling received haematopoietic stem cell transplantation (HSCT). However, HSCT is 
not without problems in patients with active NTM or Salmonella infections and also graft 
failures have been reported [22]. In some cases, the deficient type-I immune responses can 
be bypassed. For example, MSMD patients with a complete defect in IL-12p40, TYK2, IL-
12Rβ1 or a partial defect in STAT1, IFN-γR1 or IFN-γR2 may benefit from treatment with high 
doses of IFN-γ in addition to antituberculous medication. Thus, rapid diagnosis of MSMD 
and investigation of the nature of the genetic defect as described in the chapters 2, 5, 6 may 
help in the choice for this additional treatment. Several case reports describe the use of high 
doses of IFN-γ to treat MSMD patients. For example, a patient with a complete defect in IL-
12Rβ1, who developed a severe disseminated M. bovis BCG infection, was treated with high 
doses of IFN-γ and showed remarkable clinical improvement without adverse effects [23]. 
During therapy, the mycobactericidal activity of the serum and the number of lymphocytes 
in the blood increased [23]. Another patient with a partial defect in IFN-γR2, who presented 
with a disseminated M. abscessus infection, showed no improvement on antituberculous 
therapy alone, but improved on adjunct IFN-γ therapy [16]. IFN-γ treatment is however not 
always successful. A report of two similar cases with disseminated M. bovis BCG infections, 
due to IL-12Rβ1 deficiency, shows successful remission after IFN-γ treatment in one case, 
while the other patient died despite IFN-γ treatment [16]. Still, the adjunct treatment with 
IFN-γ holds promise in the management of MSMD, especially in the early phase of the 
disease. Hence, early diagnosis may be necessary for the success of this treatment. Studying 
more MSMD patients in a multi-centre study would give valuable information about the 
effectiveness of high doses IFN-γ treatment. 
Besides IFN-γ treatment, treatment with IFN-α was advocated by some and applied in 
a few cases. Additional IFN-α treatment was given to MSMD patients with manifestations 
of disseminated M. avium infections, although the benefit of this treatment was not clear. 
In the first reported case, of a patient with a complete IFN-γR1 deficiency, a reduction of 










































mycobacteraemia did not ablate [24]. The latter can be explained by the fact that IFN-α 
in fact inhibits the type-I immune responses of monocytes [25]. The inhibitory effect of 
IFN-α on monocytes was further studied in detail in chapter 7. IFN-α was found to be a 
strong inhibitor of the type-I immune responses of monocytes. Thus, it could be that the 
residual type-I immune response in this patient was further impaired by IFN-α and that 
mycobacteraemia still occurred or was even aggravated. In another case report of a patient 
with complete IFN-γR2 deficiency, who developed a disseminated M. avium infection, the 
IFN-α therapy improved granuloma formation. Still the patient developed liver and bone 
lesions, and eventually succumbed to the infection [26]. This indicates that the outcome of 
the treatment may be counter effective and thus, the use of IFN-α in the treatment of MSMD 
is not adviced. 
Next to the treatment with cytokines also cellular therapies, such as adoptive T cell 
therapies, may be possible. The investigations in chapter 3 and 4 show that IL-23 may have 
an important role in the establishment of a type-I immune response, via the CD3+CD56+ 
NK-like T cells. This indicates that these cells, or certain subsets of this group of T cells, can 
potentially be used in cellular therapies. For example, CD1 restricted T cells are CD3+CD56+ 
and are able to produce IFN-γ and exhibit effector and memory functions [27]. Perhaps 
those cells can be expanded ex vivo in response to, e.g., mycobacterial ceramide glycolipids. 
Expanded CD1 T cells may than be transferred back to the patient in order to combat 
infections. Such therapy may be combined with gene therapy strategies. For example, the 
CD1 restricted T cells from IL-12Rβ1 deficient patients may be genetically modified with 
a vector carrying the coding sequence of IL12RB1. The safety and efficacy of these kinds 
of therapeutic strategies need to be tested in animal models, since IL-23 is also involved 
in various auto-immune diseases, such as inflammatory bowel disease [10]. This is further 
illustrated by mice studies. For example, IL-23p19-/- mice are relatively protected against 
the development of experimental autoimmune encephalomyelitis [28], while mice with IL-
23 overexpression showed development of arthritis [29]. The effectiveness and the possible 
adverse auto immune effects should be evaluated in the choice of putative T cell therapies. It 
would be interesting to determine which IL-23 responsive T cells, amongst the CD3+CD56+ 
T cells have the best potentials in such cellular therapies. 
5. Factors involved in impaired type I immunity in tuberculosis patients
Several studies provide evidence that the type-I immune responses of monocytes and 
dendritic cells can be inhibited by type-I interferons [25, 30, 31]. Recently in the blood cells 
of tuberculosis patients a typical type-I interferon transcript signature was found, which 
coincided with repressed IFN-γ signaling [32, 33]. Thus, the signaling of IFN-γ (a type II 
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In chapter 7 the impact of IFN-α and IFN-β on the TLR-ligand and IFN-γ responsiveness 
of monocytes was investigated. The experiments showed that IFN-α and IFN-β strongly 
inhibit the LPS-induced IL-12p40 production, while high concentrations of IFN-γ could not 
counterbalance the inhibition. Furthermore, the IFN-γ responsiveness was strongly reduced. 
For example, for the induction of CD64 and CD54, 10 to 100 times more IFN-γ is needed in 
the presence of IFN-α/β to obtain similar effects as obtained in the absence of IFN-α/β. This 
indicates that type-I interferons may play a significant role in the repressed IFN-γ signaling, 
as observed in tuberculosis patients. 
IFN-α inhibits the type-I immune responses of monocytes in vitro as well as in vivo, in 
melanoma patients who received IFN-α treatment prior to T cell therapy. The inhibition is 
probably achieved via various mechanisms (chapter 7): IFN-α may interfere directly with 
the IFN-γ mediated signaling via STAT1, IFN-α gradually downregulates the expression of 
IFN-γR1 after 2 h of stimulation, and IFN-α induces the production of the protein inhibitor 
of activated STAT1 (PIAS1) 8 h after stimulation. In addition, IFN-α may activate protein 
arginine methyltransferases (PRMTs), which influence the activity of various transcription 
factors and regulate via HuR antigens the stability of transcripts [34]. Further studies are 
needed to dissect the contributions of each of these mechanisms. 
The finding that an arginine methyltransferase inhibitor was able to enhance the production 
of IL-12p40, IL-1β and TNF indicates that PRMTs have a certain suppressive role in the 
regulation of type I immune responses. Because of this, PRMTs may be putative targets 
for therapeutic interventions. In addition, PRMTs as well as PIAS1, which is regulated by 
PRMT1 [35, 36], can also be regarded as putative factors influencing the susceptibility to 
tuberculosis.
Our study in chapter 7, together with previous studies [32, 37, 38] that show impaired 
IFN-γ-mediated immune responses in tuberculosis patients, indicate that type-I interferons 
may play a role in the immunopathogenesis of tuberculosis. However, it is not clear whether 
type-I interferons such as IFN-α, are induced by mycobacteria in tuberculosis patients. Thus 
far, there is no direct evidence that M. tuberculosis can induce IFN-α or IFN-β in human cells. 
Other intracellular bacteria, for example Bordetella pertussis [39] and Francisella tularensis 
[30], were found to be able to induce IFN-β in human cells and may take advantage of the 
IFN-β induced inhibiting effects on dendritic cells. It may be the case that another type-I 
interferon is induced by M. tuberculosis, since the class of interferons consists of 13 IFN-α 
subtypes and 7 other types [40]. Next to the type-I interferons, type-III interferons could also 
be involved, since both types of interferons signal via ISGF3 modules, albeit via another 
receptor. These classes of interferons can be induced via special pathogen recognition 
receptors, such as TLR8 and RIG-I. Interestingly, the TLR8 polymorphism M1V was found 
to be associated with tuberculosis disease [41]. Furthermore, the TLR8 protein is present 










































together, there are some indirect indications that M. tuberculosis infections result in the 
induction of type-I interferons.
Type-I interferons can be abundantly produced in response to viral infections. It may 
be that mycobacteria take advantage of an IFN-α/β mediated repression of type-I immune 
responses during viral infection. This suggestion leads to the following hypothesis: viral 
infections promote the development of active disease either after reactivation of latent M. 
tuberculosis or after first or re-exposure to the pathogen. In chapter 8 we tested the latter 
hypothesis for influenza infections. Influenza viruses may induce IFN-α/β in the respiratory 
tract and could locally suppress antigen presenting cells. As a consequence the mycobacterial 
infected host may develop active M. tuberculosis infection in the lung. 
To explore this hypothesis we investigated, in a retrospective study, plasma of tuberculosis 
patients and controls. The plasma samples, previously collected in Jakarta in Indonesia [38], 
were tested for the presence and titer of antibodies against influenza viruses that circulated 
during the sampling period. If the hypothesis would be correct, in the group of tuberculosis 
patients more cases of recent past influenza infections were expected. However, in the case-
control study the data showed no correlation between the presence of antibodies against 
influenza A viruses and manifest tuberculosis, which indicates that the risk of developing 
tuberculosis is not increased due to influenza A virus infections. Noteworthy, tuberculosis 
patients did have, at time of diagnosis, on average higher antibody titers against the H3N2 
influenza A virus as compared to controls. In addition, we found an association between 
the mean antibody titer against H3N2 and the manifestation of tuberculosis. Patients with 
extrapulmonary manifestation of tuberculosis and patients with advanced tuberculosis at time 
of diagnosis had the highest antibody titers against H3N2. The association may indicate that 
these tuberculosis cases had had more recent influenza infections than controls. However, the 
association is most probably confounded by one or more factors (chapter 8). For example, 
the association may be explained by the fact that individuals vary greatly in their capacity to 
induce type-I interferons upon viral stimulation [43]. Individuals which have a high capacity 
to produce type-I interferons, develop more antibodies against influenza viruses and may also 
be more susceptible to develop tuberculosis, presuming that type-I interferons play a role in 
the pathogenesis of tuberculosis. Thus, it would be interesting to test the capacity of patients 
to produce type I interferons in relation to the susceptibility to tuberculosis and the severity 
of the disease. Besides these immunological hypotheses, another plausible explanation may 
simply be that patients developing tuberculosis and influenza infections are more sociable 












































Until recently, the clinical management of NTM and TB infections was based on the 
eradication of the bacteria with antituberculous drugs. Because both the slowly replicating 
bacteria as well as the latently present, dormant bacteria have to be eliminated, such treatments 
often last for more than six months. Treatments require great compliance of the patients and 
are not in all cases accomplished successfully. Thus, there is an urgent need to improve 
current therapies and come up with additional therapeutic strategies that would shorten the 
antituberculous drugs regimens.  
A better understanding of the interactions between the host and the mycobacterial 
pathogen, will generate ideas for novel therapies, tailor made and individualized for the 
susceptible host. More knowledge of the biology of the different mycobacterial species may 
yield ideas for the development of new antituberculous drugs. In addition, improvement of the 
immunity of the patient may also help to limit dissemination and combat the mycobacterial 
infection, especially in the immunocompromised host. An intrinsic lack of type-I immune 
responses or otherwise impaired immunity should be restored, at least partially, in order to 
support and strengthen the immune response of the host. Such therapy may reduce the need 
of extensive or prolonged medical treatments. 
Currently, there are different therapeutic approaches at the various medical centers to 
treat disseminated NTM infections in MSMD patients. Since MSMD patients are rare, it is 
difficult to conduct clinical trials. Still, such trials could reveal more about the status of the 
infection at first presentation, the consequences of the genetic defect on the cellular immune 
response and the success of current therapies in relation to the genetic defect. 
In order to find a genetic deficiency, the blood cells from putative MSMD patients should 
be screened for IL-12 and IFN-γ responsiveness. Informative data can also be directly obtained 
by sequencing the patient’s genomic DNA or cDNA, in the search for known mutations in 
IL12B, IL12RB1, TYK2, IFNGR1, IFNGR2 and STAT1. Our data, provided with the cellular 
models to evaluate the effects of genetic variations, will help in revealing the nature of a 
genetic defect and establish the genotype – immunological phenotype relationship. Rapid 
determination of the genetic deficiency will help guide the physician in a choice for additional 
treatment, e.g., supplementing deficient or inadequate levels of IFN-γ. Patients with IL-12 
and IL-12R deficiency may respond to antituberculous drugs, but still may benefit from this 
additional treatment. So far, many patients were given extensive antituberculous medication 
and recovered, whereas some patients did not respond adequately and eventually died despite 
treatment. In some of these cases, clinicians should consider adding IFN-γ to their medical 
treatment, especially in IL-12p40 and IL-12Rβ1 deficient patients, and those with a partial 










































Additional treatment options for complete IFN-γR deficient patients are currently not 
available. Intervention with cytokines, other than IFN-γ, and cellular therapies may be 
possible. IL-27, which also signals via STAT1, is a putative candidate to achieve sufficient 
type-I immune responses against mycobacterial infections but clearly more experimental data 
supporting such usage in humans is needed. IL-27 may enhance the type-I immune response 
of monocytes and macrophages [44]. However, IL-27 is also able to signal via STAT3. 
For instance, regulatory T cells can be activated by IL-27, via STAT3 phosphorylation. By 
consequence, the cellular immune responses can be down regulated instead of stimulated. 
More knowledge about IL-27, in particular the factors that influence the activation of STAT1 
and STAT3 by IL-27, may give clues for novel therapeutic approaches with this cytokine. 
Possible therapeutic interventions with ex vivo treated cells should also be considered. Ex 
vivo treatment may circumvent the adverse effects of the use of cytokines in vivo. Therefore, 
it would be interesting to determine which subsets of T cells are underrepresented in the 
blood from MSMD patients, and to which extent the type-I immune modulating functions of 
these T cells are impaired. For example, NK-like T cells are underrepresented in IL-12Rβ1 
deficient patients [45]. Novel therapies may be based on the gain of functions of these T cells. 
For example, infusion of ex vivo expanded and differentiated T cells may help to boost the 
immune responses of the patient. Because of the wide range of opportunities to modulate the 
type I immune responses, and the uncertainty of the outcome of such treatments, it would be 
helpful to explore these opportunities in animal models. 
Mycobacterium tuberculosis evades host immunity via several mechanisms. Likely, an 
important mechanism is the blocking of the phagolysosome fusion and maturation. Next to 
this, virulent mycobacteria actively suppress the IFN-γ-mediated immune responses. This 
may be achieved via the induction of type-I interferons. Hence, it would be interesting to 
investigate whether virulent Mycobacteria are able to induce type I interferons in cultured 
human phagocytes. However, it is also possible that IFN-γ responses are inhibited by 
different, other factors. For instance, PRMT1 and PIAS1, which are thought to play a role 
in the repression of IFN-γ responses, may very well be induced and activated. Thus, these 
factors should be assessed in the blood cells of tuberculosis patients and if elevated, it should 
be determined how they are activated. Such exploratory studies will contribute greatly to the 
understanding of the mechanisms whereby the IFN-γ responses are repressed in tuberculosis 
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Het afweersysteem, ook wel aangeduid als het immuunsysteem, is voor elk individu van 
cruciaal belang om infecties met micro-organismen, ziekteverwekkende microscopisch-kleine 
organismen, binnen de perken te houden. Veel infecties verlopen zonder dat de betreffende 
persoon ziek wordt. Als er ziekteverschijnselen optreden zoekt het lichaam naar een balans 
tussen de noodzaak micro-organismen uit de weefsels te verwijderen en het ontstaan van 
weefselbeschadiging. Deze complexe taak is opgedragen aan het afweersysteem. Het lichaam 
bestrijdt infecties met verschillende micro-organismen met verschillende afweerreacties op 
heel diverse wijze. Bij een afweerreactie is er vaak rechtstreeks contact tussen afweercellen, 
zodat signalen van de ene op de andere cel kunnen worden doorgegeven. Deze communicatie 
tussen de afweercellen verloopt mede door specifieke boodschappermoleculen, de 
zogenaamde interleukines (ILs) en interferonen (IFNs), gezamenlijk ook wel aangeduid 
als cytokines. Deze boodschappermoleculen binden aan specifieke oppervlaktemoleculen, 
receptoren genaamd, op de buitenkant van afweercellen, zoals een sleutel in een deurslot 
past. Deze binding initieert een reeks van signalen binnen de afweercel. De afweercel wordt 
daardoor geactiveerd om taken die voorgeprogrammeerd liggen in het erfelijk materiaal uit 
te voeren. Zo spelen het IFN-α en IFN-β een belangrijke rol in de afweer tegen virussen. 
Bij infecties door parasieten is een geheel ander type afweerreactie van belang, waarbij het 
cytokine IL-4 een regulerende rol heeft. In dit onderzoek beperk ik mij tot de afweer tegen 
mycobacteriën. Bij afwikkeling van een infectie met mycobacteriën is de ontwikkeling 
van een type I immuunreactie essentieel, waarbij de cytokines IL-12 en IFN-γ een centrale 
regulerende rol spelen.
Mycobacteriën komen in vele gedaanten voor. Zo zijn er virulente en minder virulente 
mycobacteriën. De bekendste virulente mycobacterie is ongetwijfeld Mycobacterium 
tuberculosis, de veroorzaker van de besmettelijke longziekte tuberculose. Naast deze 
tuberculeuze mycobacterie zijn er vele niet-tuberculeuze mycobacteriën (NTM) die normaal 
gesproken geen ziekte veroorzaken. Deze minder virulente NTM veroorzaken echter 
bij patiënten met een verstoorde afweer lokale of gedissemineerde infecties, waarbij de 
bacterie zich door het lichaam verspreid. Dit laatste wordt vaak gezien bij patiënten met een 
erfelijk bepaalde verhoogde vatbaarheid voor infecties met mycobacteriën. De verhoogde 
vatbaarheid komt door een afwijking in het erfelijke materiaal (DNA) dat codeert voor een 
van de belangrijke componenten van een type I immuunreactie. Deze patiënten worden 
MSMD (Mendelian Susceptibility to Mycobacterial Disease) patiënten genoemd.
Een type I immuunreactie wordt in gang gezet nadat bepaalde afweercellen, zoals de 
monocyten uit het bloed, macrofagen of dendritische cellen in de weefsels, met mycobacteriën 
in contact komen. In de meeste gevallen zal opname van bacteriën door deze cellen ertoe 










































echter binnenin deze cellen overleven. Pas na activatie zijn deze afweercellen in staat de 
mycobacteriën in hun uitgroei te beteugelen. Bij deze activatie spelen verscheidene cytokines 
en andere typen afweercellen een rol. De opname van de mycobacteriën in deze afweercellen 
heeft afgifte van type I cytokines tot gevolg, zoals IL-23, IL-12 en IL-1β. In reactie op IL-
23 en IL-12 produceren weer andere witte bloedcellen, de NK cellen en de T cellen, het 
IFN-γ. Deze cytokines oefenen via hun specifieke receptoren effecten uit op verschillende 
lichaamscellen welke er op gericht zijn de bacteriële uitgroei te bestrijden. Het is dus ook 
niet verwonderlijk dat afwijkingen in het genetisch materiaal dat codeert voor IL-12, de IL-
12 receptor (IL-12R) en de IFN-γ receptor (IFN-γR) grote gevolgen kunnen hebben voor 
het bewerkstelligen van een afdoende immuunreactie tegen mycobacteriën. Anders gezegd: 
dergelijke genetische “afwijkingen”, aangeduid als mutaties, spelen een voorname rol in een 
verhoogde vatbaarheid voor NTM infecties.
Het is interessant te constateren dat mutaties die zo’n essentiële rol spelen in de afweer 
tegen NTM geen rol lijken te spelen in de vatbaarheid voor tuberculose. Wel is in verscheidene 
onderzoeken aangetoond dat de IFN-γ-gemedieerde type I immuunrespons bij patiënten 
met actieve tuberculose onderdrukt is, terwijl reactiviteit op IFN-γ weer toeneemt tijdens 
een effectieve behandeling met tuberculostatica. Hoe het komt dat de type I immuunreactie 
onderdrukt wordt in tuberculose patiënten is nog onduidelijk.
Het eerste gedeelte van dit proefschrift (hoofdstuk 2-6) richt zich op genetische factoren 
die ten grondslag liggen aan een verhoogde vatbaarheid voor infecties met NTM. In het 
tweede gedeelte (hoofdstuk 7 en 8) worden mogelijke mechanismen onderzocht die een rol 
spelen bij een verminderde type I immuunrespons bij tuberculose.
Genetische factoren bij MSMD
MSMD-patiënten kunnen op jonge leeftijd ernstige NTM infecties ontwikkelen, waarbij 
de bacterie zich door het lichaam verspreidt en meerdere organen betrokken raken bij de 
infectie. Naast een verhoogde vatbaarheid voor NTM infecties zijn MSMD patiënten soms 
vatbaar voor ernstige infecties met veelvoorkomende Salmonella soorten, bacteriën die voor 
de meeste mensen niet of zelden ziekmakend zijn. De vatbaarheid voor infecties is bij MSMD 
verhoogd door afwijkingen in genen die coderen voor eiwitten die betrokken zijn bij de 
regulatie van de type I immuunreactie, bijvoorbeeld mutaties in de genen IL12B, IL12RB1, 
IFNGR1 en IFNGR2. Vele MSMD-veroorzakende mutaties zijn inmiddels beschreven, maar 
in veel gevallen is niet onderzocht of een vastgestelde genetische variatie eigenlijk wel 
samengaat met een afwijkende functie van het desbetreffende eiwit. Van veel variaties in 
genen betrokken bij de type I immuunreactie weten we niet of het slechts polymorfismen, 











































mutaties zijn. In de studies van dit proefschrift (Hoofdstuk 2, 3, 5 en 6) is de invloed van 
aminozuurveranderingen in de receptoren van IL-12, IL-23 en IFN-γ op het functioneren van 
deze receptoren onderzocht. 
Functionele consequenties van aminozuurveranderingen in IL-12Rβ1
In hoofdstuk 2 beschrijven we de ziektegeschiedenis van een patiënt met een uitzonderlijk 
verlopende NTM infectie. Op grond van immunologisch onderzoek werd vermoed dat de 
patiënt een IL-12Rβ1 deficiëntie had, waarna met genetische analyse werd vastgesteld dat 
de patiënt twee afzonderlijke genetische variaties in IL-12Rβ1 droeg, te weten R521G en 
-2C>T. Met behulp van een in vitro onderzoeksmodel werd bevestigd dat de R521G variatie 
de genetische verandering is die leidt tot een gedeeltelijk defecte functie van IL-12Rβ1. 
De R521G is in dit geval de ziekteveroorzakende mutatie, terwijl de andere variatie een 
onschuldig polymorfisme bleek te zijn. Opmerkelijk in dit geval was dat de patiënt pas op 
middelbare leeftijd (43 jaar) voor het eerst een NTM infectie ontwikkelde, terwijl de meeste 
MSMD patiënten met een IL-12Rβ1 defect al op jeugdige leeftijd een eerste NTM infectie 
doormaken. Naast deze jeugdige MSMD patiënten zijn er ook familieleden van deze patiënten 
beschreven bij wie genetisch onderzoek een MSMD mutatie blootlegde maar die nog nooit 
klachten of tekenen van een NTM infectie gehad hadden. Dit kan natuurlijk het gevolg zijn 
van een verminderde blootstelling aan mycobacteriën ten opzichte van de gevallen die wel 
NTM infecties doormaken of door een compenserend afweermechanisme. Ook leeftijd kan 
hierop van invloed zijn. 
Met behulp van hetzelfde in vitro onderzoeksmodel zijn de functionele consequenties 
van meerdere aminozuurveranderingen in IL-12Rβ1 onderzocht. In het addendum bij 
hoofdstuk 2 staat een korte samenvatting van de invloed van alle tot dusver bekende 
aminozuurveranderingen op de type I immuunreactie van T cellen. Sommige variaties 
zijn definitief getypeerd als MSMD veroorzakende mutaties, anderen bleken onschuldige 
polymorfismen. Alle nu bekende MSMD mutaties leiden tot een compleet of bijna compleet 
defect in de expressie van IL-12Rβ1. Twee mutaties leiden tot een partieel functioneel defect, 
te weten C198R en R521G, en hebben tot gevolg dat het receptoreiwit sterk verminderd op 
T cellen aanwezig is. Deze bevindingen suggereren dat pas als de IL-12Rβ1 functie sterk 
verminderd is, een effectieve immuunreactie tegen NTM uitblijft. 
De twee meest voorkomende varianten van IL-12Rβ1, te weten RTR en QMG, worden 
feitelijk gevormd door drie polymorfismen, te weten R214Q, T365M en R378G, welke als 
één blok overerven. De QMG variant is in hogere aantallen aanwezig op het celoppervlak 
van T cellen en reageert intensiever op stimulatie met IL-12 dan de RTR variant. Dit verschil 
maakt deze twee genvarianten zeer geschikt in genetische associatiestudies naar een rol voor 
IL-12 bij een bepaald ziektebeeld. Zo is bijvoorbeeld gebleken dat het dragen van een RTR 











































De biologische effecten van IL-23 en variaties in de IL-23R
Tot dusver hebben alle gerapporteerde MSMD patiënten met een functioneel gekarakteriseerd 
defect in de functie van IL-12 of het IL-12R complex, een gen mutatie in respectievelijk 
IL-12p40 of IL-12Rβ1. Aangezien IL-12p40 ook een onderdeel is van het eiwit IL-23, dat 
evenals IL-12 een heterodimeer is waarvan IL-12p40 onderdeel uitmaakt, en IL-12Rβ1 ook 
een keten is van het IL-23R complex, hebben deze patiënten ook een defect in de functies 
van IL-23 of het IL-23R complex. Het is opmerkelijk dat er geen defecten beschreven zijn 
in de specifieke componenten van IL-12 en IL-23 of van hun specifieke receptorketens, IL-
12Rβ2 en IL-23R. Dit suggereert dat zowel de IL-12 als de IL-23-gemedieerde immuniteit 
verminderd moet zijn wil dit leiden tot een verhoogde vatbaarheid voor NTM infecties. 
Mogelijk complementeren beide cytokines elkaars effecten. 
Het belang van IL-12 in de type I immuunreactie is evident. De rol van IL-23 is minder 
duidelijk, onder andere omdat maar weinig bekend is over welke afweercellen een IL-23R op 
hun celoppervlak hebben. In hoofdstuk 3 beschrijven wij het effect van IL-23 op geactiveerde 
T cellen, waarin tevoren op artificiële wijze de IL-23R ingebracht is. Het onderzoek toonde 
verschillende, maar ook overlappende, gemeenschappelijke effecten van IL-12 en IL-23 op 
deze cellen. IL-12 stimulatie leidt in de cel tot activatie van het eiwit STAT4, wat resulteert 
in een sterke productie van IFN-γ en een geringe productie van het remmende cytokine 
IL-10. Dit staat in contrast met de uitwerking van IL-23, dat na stimulatie van het IL-23R 
complex leidt tot activatie van STAT1, STAT3 en STAT4 en resulteert in een geringere IFN-γ 
productie dan IL-12 en relatief meer IL-10 productie. Deze bevinding en het gegeven dat IL-
23 voornamelijk in de eerste fase van de immuunreactie geproduceerd wordt en IL-12 in een 
latere fase, is een aanwijzing voor een stapsgewijze versterking van een type I immuunreactie.
In de situatie dat er geen IL-23R tot expressie gebracht wordt kan IL-23 toch STAT4 
activeren, wat resulteert in een bescheiden IFN-γ productie, veel minder dan de hoeveelheid 
die vrijkomt na IL-12 stimulatie. Deze bevinding suggereert dat IL-23 de afweercellen ook 
activeert via een andere receptor dan de IL-23R, mogelijk het IL-12 receptor complex. 
In het in vitro model zijn de IL-23R varianten Y173H, P310L en R381Q wat betreft 
functionaliteit vergeleken met de wild type IL-23R (de meest voorkomende natuurlijke 
variant). Deze receptor varianten en de wild type receptor blijken vergelijkbaar te 
functioneren. De variaties zijn dus onschuldige polymorfismen en geen mutaties. De Y173H 
was gevonden in een patiënt met een Salmonella infectie en is mogelijk een mutatie met 
ernstige gevolgen voor de functie van IL-23R. Echter, de functionele karakterisering toont 
aan dat Y173H een volkomen onschuldig polymorfisme is zonder enige invloed op de IL-23 
respons; het gevonden polymorfisme kan dus niet verantwoordelijk gehouden worden voor 
de beschreven infectie. 
De R381Q variant is een polymorfisme geassocieerd met bescherming tegen de ziekte 











































een andere studie werd beschreven dat het R381Q polymorfisme is geassocieerd met een 
verminderde aanwezigheid van IL-23R positieve afweercellen. Bij elkaar genomen, past dit 
in het beeld dat IL-23 waarschijnlijk een belangrijke rol speelt in het opstarten van een type 
I immuunrespons.
Omdat tijdens dit onderzoek geen methode beschikbaar was om de aanwezigheid van de 
IL-23R op cellen aan te tonen, hebben wij onderzocht of IL-23R-geïnduceerde activatie van 
STAT3 te bepalen was direct na toevoeging van IL-23 aan afweercellen, als een indirecte 
maat voor IL-23 reactiviteit. Hoofdstuk 4 beschrijft onderzoek waaruit blijkt dat zogenaamde 
‘NK-achtige’ T cellen reageren op IL-23. De IL-12 en IL-23-geïnduceerde IFN-γ productie 
door deze NK-T cellen is onafhankelijk van T-cel-receptor-activatie, maar bleek wel 
afhankelijk van de aanwezigheid van IL-18. Het onderzoek toonde ook aan dat IL-23 indirect 
de celdeling, maar niet de IFN-γ productie, van NK-cellen stimuleert. Eerder was aangetoond 
dat IL-23 ook de celdeling en de overleving van IL-17-producerende T cellen stimuleert. 
Dit wijst erop dat IL-23 stimulatie mogelijk resulteert in de productie van een factor, die 
essentieel is voor celdeling en overleving van NK-cellen en van T cellen.
Functionele consequenties van aminozuur veranderingen in de IFN-γR
IFN-γ is hét centrale cytokine in de type I immuunreactie met een veelheid aan effecten 
op meerdere celtypen. Mutaties in de genen die coderen voor elk van de twee eiwitketens 
van de IFN-γ receptor, IFN-γR1 of IFN-γR2, hebben grote gevolgen voor de afwikkeling 
van een type I immuunreactie. Door meerdere onderzoekers zijn aminozuurveranderingen 
beschreven in beide receptorketens. Om de functionele consequenties van deze variaties te 
bepalen zijn twee onderzoeksmodellen ontwikkeld, die beschreven zijn in hoofdstuk 5 en 6. 
In cellijnen die zelf geen IFN-γR1 of IFN-γR2 tot expressie brengen, werd met behulp van 
een gemodificeerd virus de genen ingebracht van één van de varianten van IFN-γR1 of IFN-
γR2, of van de wild type receptoren (de meest voorkomende varianten van de receptorketens). 
Op deze wijze kan de functie van de receptorvarianten vergeleken worden met de wild 
type receptor tegen één en dezelfde genetische achtergrond. Hiermee kon een onderscheid 
gemaakt worden tussen onschuldige polymorfismen en ziekteveroorzakende mutaties.
De aminozuurvariaties V14M, V61I, S149L, H335P, I352M en L467P in IFN-γR1 blijken 
polymorfismen te zijn, welke nauwelijks invloed hebben op de receptor functie. De variaties 
S149L en I352M waren beschreven in patiënten van wie men vermoedde dat ze MSMD 
hadden, omdat de bloedcellen van deze personen vermindert reageerden op stimulatie met 
IFN-γ dan bloedcellen van controles. Uit ons onderzoek volgt dat dit fenotype van verminderde 
IFN-γ reactiviteit niet verklaard kan worden door de aanwezige variatie in IFN-γR1 en dus 
zeer waarschijnlijk toegeschreven moet worden aan een ander defect, bijvoorbeeld in STAT1, 
een eiwit dat door de IFN-γ receptor geactiveerd wordt en diverse antibacteriële processen 










































De aminozuurvariaties V61E, V61Q, Y66C, C77F, C77Y en C85Y konden aangemerkt 
worden als mutaties die tot een complete IFN-γR1 deficiëntie leiden, terwijl de V63G en I87T 
mutaties een partiële, bijna complete deficiëntie, veroorzaken. De functie van de laatste twee 
receptorvarianten bleek sterk gereduceerd te zijn, maar niet geheel afwezig. In vergelijking 
met de wild type receptor is bij deze varianten echter wel veel meer IFN-γ nodig om hetzelfde 
biologisch effect tot gevolg te hebben. Dit kan een verklaring vormen voor de bevinding dat 
MSMD patiënten met deze partiële mutaties ook ernstige infecties ontwikkelen.
In het IFN-γR2 gen zijn DNA variaties beschreven die de aminozuurvariaties T58R, 
Q64R, E147K en K182E tot gevolg hebben; allen zijn gekarakteriseerd als onschuldige 
polymorfismen. De beschreven variaties R114C, T168N en G227R bleken echter mutaties, 
waarvan R114C en G227R leiden tot een gedeeltelijk defect in de expressie van IFN-
γR2. Bloedcellen van patiënten die homozygoot zijn voor een van deze mutaties, hebben 
inderdaad een sterk afgenomen reactie op stimulatie met IFN-γ. In vergelijking met cellen 
van een gezonde controle blijkt een circa 100 keer hogere concentratie van IFN-γ nodig om 
een vergelijkbare respons te geven. Deze gedeeltelijke, bijna complete deficiënties in IFN-
γR1 en IFN-γR2 wijzen erop dat een IFN-γ deficiëntie pas tot MSMD leidt als de reactiviteit 
op IFN-γ sterk gereduceerd is.
Het V14M polymorfisme in IFN-γR1 en het Q64R polymorfisme in IFN-γR2 beïnvloeden 
de expressie van de receptorketens op de buitenkant van de afweercel aanzienlijk, maar 
blijken toch niet geassocieerd met MSMD. Deze polymorfismen hebben niettemin enige 
invloed op de ontwikkeling van een T cel reactie tot een type I of een type II immuunrespons. 
Daarom zijn deze twee polymorfismen interessant als markers in genetische associatiestudies 
om te bepalen of IFN-γ een factor is in de aanleg voor infectieziekten waartegen een type I 
respons gewenst is, en of IFN-γ een rol speelt in auto-immuunziekten. Ziekte-associatie met 
deze polymorfismen is bijvoorbeeld eerder beschreven voor systemische lupus erythematosus 
(SLE). Voor infectieziekten zoals longtuberculose is hiernaar nog onvoldoende onderzoek 
verricht. 
Op zoek naar nieuwe therapieën om MSMD te behandelen
MSMD patiënten met NTM infecties moeten vaak langdurig behandeld worden met 
antibiotische middelen, en zelfs dan is deze therapie niet altijd succesvol. Een langdurige 
preventieve therapie kan mogelijk antibioticaresistentie in de hand werken. Verschillende 
alternatieve therapieën zijn daarom overwogen en toegepast. 
Zo hebben patiënten met een ernstig IFN-γR1 defect stamceltransplantatie ondergaan. Dit 
bleek lang niet altijd succesvol, bijvoorbeeld omdat patiënten tijdens de transplantatie nog 
een actieve infectie hadden, die in de fase van ernstig gestoorde afweer na de transplantatie 
niet langer onder controle te houden was. Ook bleek het gebruik van donorstamcellen niet 











































Voor patiënten met een defect in IL-12p40 of IL-12Rβ1 of met een gedeeltelijk defect 
in IFN-γR1 of IFN-γR2, is een aanvullende behandeling met IFN-γ toegepast in een poging 
de gevolgen van de deficiëntie in de type I immuunreactie te omzeilen. Dit toont eens te 
meer het belang aan van een volledige karakterisering van het immunologische fenotype 
en de achterliggende genetische mutatie bij MSMD, waarbij de onderzoeken beschreven in 
hoofdstuk 2, 5 en 6 kunnen helpen bij de keuze voor een additionele behandeling. 
Naast het toedienen van IFN-γ is er ook gepleit (en gekozen) voor een behandeling met 
IFN-α. Uit de spaarzame beschrijvingen is het succes van deze behandeling echter niet 
duidelijk. In een MSMD patiënt met een compleet IFN-γR1 defect nam de vergroting van 
lever, milt en lymfeklieren af als gevolg van de IFN-α behandeling, echter de verspreiding 
van de NTM via het bloed nam niet af, en de patiënt overleed uiteindelijk als gevolg van de 
gedissemineerde infectie. Een mogelijke verklaring hiervoor kan zijn dat IFN-α de type I 
immuunreactie juist sterk blijkt te kunnen remmen (hoofdstuk 7). Het is niet uit te sluiten 
dat de systemische verspreiding van NTM in de beschreven patiënt mede is toe te schrijven 
aan de IFN-α behandeling. In een andere patiënt met een compleet IFN-γR2 defect werden 
infecties in de organen schijnbaar beter ingeperkt, door de vorming van weefselgranulomen 
tijdens IFN-α behandeling. Niettemin ontwikkelde de patiënt een niet te stuiten uitbreiding 
van infectiehaarden in lever en botten, en bezweek ook deze patiënt aan een gedissemineerde 
NTM infectie. Mede gezien onze bevindingen beschreven in hoofdstuk 7 zou de behandeling 
met IFN-α dus zelfs contra-effectief kunnen zijn en ligt het niet langer voor de hand het 
gebruik ervan bij MSMD aan te bevelen.
Naast behandeling met cytokines zijn ook cellulaire therapieën overwogen. De 
onderzoeken beschreven in hoofdstuk 3 en 4 tonen aan dat IL-23 een potentiële rol speelt in 
de totstandkoming van een type I immuunreactie, via een subgroep van T cellen, de NK-T 
cellen. Het zou interessant zijn na te gaan of deze NK-T cellen gebruikt kunnen worden in een 
cellulaire therapie. Bijvoorbeeld T cellen die specifiek een mycobacterieel product herkennen 
zijn een bron van IFN-γ, het cytokine dat zij na stimulatie aanmaken. Het is in principe 
mogelijk deze cellen buiten het lichaam te stimuleren en te vermeerderen. Hierna kunnen de 
T cellen aan de patiënt teruggegeven worden, in de hoop dat de T cellen het afweersysteem 
helpen bij het bestrijden en afwikkelen van de mycobacteriële infectie. Eventueel zou deze 
vorm van therapie gecombineerd kunnen worden met gentherapie. Bijvoorbeeld, T cellen 
van een IL-12Rβ1 deficiënte patiënt kunnen genetisch gemodificeerd worden door het gen 
coderend voor IL-12Rβ1 in de cellen te brengen, waarna de receptor weer tot expressie komt 
aan het celoppervlak en de cellen weer kunnen reageren op IL-12. Voor het tot dergelijke 
behandelingen komt moet nagegaan worden welke typen T cellen het best te gebruiken zijn 










































Factoren die betrokken zijn bij een verminderde type I immuniteit in 
tuberculose patiënten
Er zijn aanwijzingen dat de IFN-γ-gemedieerde immuniteit onderdrukt is bij patiënten met 
actieve tuberculose. Recentelijk is gebleken dat, naast een onderdrukte IFN-γ reactiviteit, 
de bloedcellen van tuberculose patiënten een cytokine profiel tonen dat past bij een IFN-α 
gemedieerde afweerreactie. Zoals boven beschreven kan IFN-α de type I immuunreactiviteit 
van monocyten remmen. Mogelijk wordt de type I immuniteit in tuberculose patiënten 
onderdrukt door lokaal geproduceerde interferonen, zoals IFN-α, en het daarop gelijkende 
IFN-β.
In hoofdstuk 7 is de invloed die IFN-α/β kunnen hebben op de vorming van een type I 
immuunreactie door monocyten beschreven. De experimenten tonen dat de (door bacteriële 
producten aangestuurde) aanmaak van IL-12p40 sterk geremd wordt door IFN-α/β, terwijl 
IFN-γ dit effect niet kan opheffen. Verscheidene effecten van IFN-γ werden sterk onderdrukt 
door IFN-α/β. Deze bevindingen zijn bewijs dat IFN-α/β een belangrijke rol kan spelen in het 
onderdrukken van IFN-γ reactiviteit zoals beschreven in tuberculose patiënten. De remmende 
effecten van IFN-α worden bewerkstelligd via meerdere mechanismen. Zo bleek IFN-α niet 
alleen de expressie van de receptor voor IFN-γ te kunnen verlagen, maar IFN-α beïnvloedt 
ook de activatie van STAT1 door IFN-γ. Daarnaast stimuleert IFN-α ook remmende factoren, 
zoals de eiwitremmer van STAT1 (PIAS1) en methylerende eiwitten (PRMTs). PRMTs en 
PIAS1 kunnen daarmee beschouwd worden als factoren die de vatbaarheid voor tuberculose 
negatief beïnvloeden, en zijn dus potentiële aangrijpingspunten voor immuuntherapie.
Het lijkt erop dat antivirale interferonen zoals IFN-α en IFN-β, een rol spelen in de 
immuunpathogenese van tuberculose, maar het is niet duidelijk of deze interferonen in 
de patiënt daadwerkelijk aangemaakt worden tijdens een infectie met Mycobacterium 
tuberculosis. Het is ook mogelijk dat deze interferonen door een geheel andere reden 
aangemaakt worden, bijvoorbeeld door een gelijktijdig optredende virus infectie. Kortom, 
mycobacteriën zouden voordeel kunnen hebben van het feit dat antivirale interferonen, die 
aangemaakt zijn tijdens een virus infectie, de type I immuunreacties tegen intracellulaire 
bacteriën (tijdelijk) onderdrukken. Dit leidt tot de volgende hypothese: Virale infecties 
bevorderen de klinische openbaring van een tuberculose. In hoofdstuk 8 is deze hypothese 
getoetst voor tuberculose na een recente influenza virus infectie (ofwel griep). Influenza 
virussen kunnen door de aanmaak van IFN-α of IFN-β in de ademhalingswegen lokaal de 
vorming van type I immuunreacties remmen. Mogelijk zal hierdoor de gastheer, indien besmet 
met Mycobacterium tuberculosis, eerder dan anders een klinisch-actieve longtuberculose 
ontwikkelen. 
Om deze hypothese te testen is plasma van tuberculose patiënten en van controles 











































Deze type virussen circuleerden ten tijde van het verzamelen van de plasmamonsters in de 
bevolking. Indien de hypothese juist is, zouden naar verwachting meer tuberculose patiënten 
dan controle personen antilichamen tegen deze virussen in hun plasma aantoonbaar hebben. 
Hoewel er geen correlatie is gevonden tussen het aantal personen met antilichamen tegen 
influenza en de klinische openbaring van tuberculose, werd er wel een verband gevonden 
tussen de concentratie van antilichamen in het bloedplasma en het hebben van klinisch 
actieve longtuberculose. Patiënten met tuberculose hadden ten opzichte van de gezonde 
controle groep een hogere concentratie van antilichamen tegen het H3N2 influenza virus in 
hun bloedplasma. Daarnaast hadden patiënten met extrapulmonaire tuberculose en patiënten 
met tuberculose in een vergevorderd stadium, de hoogste concentratie aan antilichamen. Ook 
de sero-immuniteit voor het H3N2 virus was hoog (rond de 82%), wat suggereert dat er meer 
tuberculose patiënten dan controles recentelijk opnieuw geïnfecteerd zijn met het influenza 
virus. Maar conclusies kunnen hieruit niet getrokken worden, want veel factoren kunnen dit 
verband vertroebelen. Zo kan de associatie mogelijk verklaard worden doordat individuen 
verschillen in de mate van IFN-α productie. Individuen die meer dan gemiddeld IFN-α 
produceren na een virale infectie, produceren mogelijk ook meer antilichamen tegen het virus. 
Dezelfde personen produceren mogelijk ook meer IFN-α tijdens een mycobacteriële infectie. 
En zo zijn er andere mogelijke verklaringen. Kortom, de resultaten beschreven in hoofdstuk 
8 geven vooralsnog onvoldoende bewijs om de hypothese te bevestigen of ontkrachten.
Toekomstperspectieven
Tot nu toe is de behandeling van NTM infecties en tuberculose gebaseerd op het doden 
van de bacteriën door anti-mycobacteriële middelen. Omdat naast de al langzaam delende 
mycobacteriën ook de ‘slapende’ nauwelijks delende mycobacteriën gedood moeten worden, 
duurt een dergelijke behandeling langer dan 6 maanden, welke zeer belastend is voor de 
patiënt. Er is dus een sterke behoefte aan aanvullende behandelmethodes. Inzichten in de 
interactie tussen mycobacteriën en gastheer zullen ongetwijfeld nieuwe ideeën opleveren 
voor behandelmethodes. Nieuwe en krachtige tuberculostatica moeten ontwikkeld worden. 
Antimicrobiële middelen zijn echter niet meer dan hulpmiddelen van de afweer. De aanpak 
moet zich dus ook richten op ondersteuning van de afweer van de patiënt. Dit laatste kan 
mogelijk de tijdsduur van de behandeling met tuberculostatica bekorten.
 
Voor MSMD patiënten geldt dat een snelle diagnose geboden is, al was het maar omdat 
een deel van deze patiënten baat heeft bij een additionele behandeling met IFN-γ. Voor 
patiënten met een complete IFN-γR deficiëntie is momenteel geen andere behandeling 










































I immuunrespons kunnen versterken, zoals bijvoorbeeld IL-27, hier in de toekomst uitkomst 
bieden.
De mogelijkheid van interventies met afweercellen, die na oogsten buiten het lichaam 
geselecteerd en geactiveerd worden, dient nader onderzocht te worden. Kandidaten voor een 
dergelijke aanpak zijn NK-achtige T cellen, welke overigens verminderd aanwezig zijn in het 
bloed van IL-12Rβ1-deficiënte patiënten.
 
Mycobacterium tuberculosis heeft verschillende mechanismen om het afweersysteem te 
omzeilen. Een belangrijk mechanisme is het tegenwerken van bacteriedodende mechanismen 
in witte bloedcellen, zoals in monocyten en weefselmacrofagen. Daarnaast onderdrukt de 
mycobacterie ook de IFN-γ gemedieerde immuunrespons, mogelijk door de effecten van 
een IFN-α gemedieerde afweerreactie. De IFN-γ respons in tuberculose patiënten kan echter 
ook door andere factoren geremd zijn, zoals de eerder beschreven activatie van PRMT1 
en PIAS1. Het is duidelijk dat er nog veel onderzoek nodig is voordat we daadwerkelijk 
begrijpen waarom de ene persoon na blootstelling aan deze bacterie wel en de andere geen 
tuberculose ontwikkelt. Zulk onderzoek zal bijdragen aan verdere kennis over de rol van 
een verminderde IFN-γ-gemedieerde immuniteit bij mycobacteriële infecties en zal hopelijk 
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